EX-99.1

EX-99.1 2 d850358dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

DISTRICT OF DELAWARE


	:
In re	:	Chapter 11
	:
DENDREON CORPORATION, et al.,	:	Case No. 14-12515 (LSS)
	:
Debtors.¹	:
	:	Jointly Administered
	:

SCHEDULE OF ASSETS AND LIABILITIES FOR

DENDREON CORPORATION (CASE NO. 14-12515 (LSS))

The Debtors and the last four digits of their respective taxpayer identification numbers are as follows: Dendreon Corporation (3193), Dendreon Holdings, LLC (8047), Dendreon Distribution, LLC (8598) and Dendreon Manufacturing, LLC (7123). The address of the Debtors’ corporate headquarters is 1301 2nd Avenue, Seattle, Washington 98101.

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE


	x
	:
In re:	:	Chapter 11
	:
DENDREON CORPORATION, et al.,	:	Case No. 14-12515 (LSS)
	:
Debtors.¹	:	Jointly Administered
	:
	:
	x

GLOBAL NOTES, METHODOLOGY AND SPECIFIC

DISCLOSURES REGARDING THE DEBTORS’ SCHEDULES OF

ASSETS AND LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS

Introduction

Dendreon Corporation, Dendreon Holdings, LLC, Dendreon Distribution, LLC, and Dendreon Manufacturing, LLC, the debtors and debtors-in-possession in the above-captioned cases (together, the “Debtors,” and the Debtors together with their non-debtor subsidiaries and affiliates, the “Company”), with the assistance of their advisors, have filed their respective Schedules of Assets and Liabilities (the “Schedules”) and Statements of Financial Affairs (the “Statements” and, together with the Schedules, the “Schedules and Statements”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), pursuant to section 521 of title 11 of the United States Code (the “Bankruptcy Code”) and Rule 1007 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”).

These Global Notes, Methodology and Specific Disclosures Regarding the Debtors’ Schedules and Statements (the “Global Notes”) pertain to, are incorporated by reference in, and comprise an integral part of all the Schedules and Statements. The Global Notes should be referred to, considered and reviewed in connection with any review of the Schedules and Statements.²

The Schedules and Statements do not purport to represent financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), nor

These Global Notes are in addition to any specific notes contained in each Debtor’s Schedules or Statement. The fact that the Debtors have prepared a “General Note” with respect to any of the Schedules and Statements and not to others should not be interpreted as a decision by the Debtors to exclude the applicability of such General Note to any of the Debtors’ remaining Schedules and Statements, as appropriate.

are they intended to be fully reconciled with the financial statements of the Debtors. Additionally, the Schedules and Statements contain unaudited information that is subject to further review and potential adjustment.

In preparing the Schedules and Statements, the Debtors relied upon information derived from its books and records that was available at the time of such preparation. Although the Debtors have made reasonable efforts to ensure the accuracy and completeness of such financial information, inadvertent errors, or omissions, as well as the discovery of conflicting, revised, or subsequent information, may cause a material change to the Schedules and Statements. Accordingly, the Debtors reserve all of their rights to amend, supplement, or otherwise modify the Schedules and Statements as is necessary and appropriate. Notwithstanding the foregoing, the Debtors shall not be required to update the Schedules and Statements.

Mr. Gregory R. Cox has signed the Schedules and Statements. Mr. Cox is Interim Chief Financial Officer of Dendreon Corporation, and an authorized signatory for the Debtors. In reviewing and signing the Schedules and Statements, Mr. Cox necessarily has relied upon the efforts, statements and representations of the Debtors’ advisors and various personnel employed by the Debtors. Mr. Cox has not (and could not have) personally verified the accuracy of each statement and representation contained in the Schedules and Statements, including statements and representations concerning amounts owed to creditors, classification of such amounts and creditor addresses.

Global Notes and Overview of Methodology

1. Reservation of Rights. Although reasonable efforts have been made to prepare and file complete and accurate Schedules and Statements, inadvertent errors or omissions may exist. The Debtors reserve all rights to amend, supplement or otherwise modify the Schedules and Statements from time to time, in all respects, as may be necessary or appropriate, including, without limitation, the right to amend the Schedules and Statements with respect to a claim (including, but not limited to, amending the description or designation of any claim; disputing or otherwise asserting offsets or defenses to any claim reflected in the Schedules and Statements as to amount, liability, priority, status or classification; subsequently designating any claim as “disputed,” “contingent” or “unliquidated”; or objecting to the extent, validity, enforceability, priority or avoidability of any claim). Any failure to designate a claim in the Schedules and Statements as “disputed,” “contingent,” or “unliquidated” does not constitute an admission by the Debtors that such claim or amount is not “disputed,” “contingent,” or “unliquidated.” Listing a claim does not constitute an admission of liability by the Debtors. Notwithstanding the foregoing, the Debtors shall not be required to update the Schedules and Statements.

Further, nothing contained in the Schedules and Statements shall constitute a waiver of rights or an admission with respect to the Chapter 11 Cases (as defined below), including, without limitation, matters involving objections to claims, substantive consolidation, equitable subordination, defenses, characterization or re-characterization of contracts, assumption or rejection of contracts under the provisions of chapter 3 of the Bankruptcy Code and/or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code or any other relevant applicable laws to recover assets or avoid transfers. Any specific reservation of rights contained

elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this or the preceding paragraph.

2. Description of Cases and “as of” Information Date. On November 10, 2014 (the “Petition Date”), the Debtors filed voluntary petitions for relief under chapter 11 of the Bankruptcy Code (the “Chapter 11 Cases”). The Debtors are operating their business and managing their properties as debtors-in-possession pursuant to Bankruptcy Code sections 1107(a) and 1108. On November 12, 2014, the Bankruptcy Court entered an order (Docket No. 49) providing for the joint administration of these cases pursuant to Bankruptcy Rule 1015(b).

On November 19, 2014, the United States Trustee for the District of Delaware appointed a statutory committee of unsecured creditors pursuant to Bankruptcy Code section 1102(a)(1). (Docket No. 92).

The asset information provided herein, except as otherwise noted, represents the asset data of the Debtors as of October 31, 2014, and the liability information provided herein, except as otherwise noted, represents the liability data of the Debtors as of the Petition Date.

3. Basis of Presentation. As set forth in the Declaration of Robert L. Crotty in Support of Chapter 11 Petitions and First Day Pleadings (Docket No. 3) (the “First Day Declaration”), the Debtors operate as a single entity with all operations conducted through the parent entity, Dendreon Corporation. In 2010, the Company began a process to realign its corporate structure to better allow it to support significant anticipated growth. This involved separating the Company’s distribution, manufacturing and management functions. In connection therewith, certain assets were transferred on the Company’s books and records, and contracts were assigned to various subsidiaries. It is unclear however, whether all the contract assignments were effective, and asset accounting was never maintained at the various subsidiaries, because the change in corporate structure was never completed from an accounting and operational perspective when it became clear that the Company would not grow as anticipated. Thus, the Company continued (and continues) to operate as a single entity, with Dendreon Corporation conducting all operations. The Schedules and Statements therefore reflect the assets and liabilities of the Debtors on a consolidated basis, and such assets and liabilities are solely reflected in the Schedules and Statements for Dendreon Corporation.

The totals listed in the Schedules and Statements may not be comparable to the Company’s consolidated financial reports prepared for public reporting purposes or otherwise as these reports include Dendreon Corporation and each of its subsidiaries, some of which are not Debtors in these proceedings. Although these Schedules and Statements may, at times, incorporate information prepared in accordance with GAAP, the Schedules and Statements neither purport to represent nor reconcile to financial statements otherwise prepared and/or distributed by the Debtors in accordance with GAAP or otherwise. Additionally, the Schedules and Statements contain unaudited information that is subject to further review and potential adjustment. The Debtors reserve all rights to amend these Schedules and Statements.

4. Confidentiality. Due to concerns of confidentiality or concerns for the privacy of an individual, the Debtors have deemed it appropriate and necessary to avoid listing certain names,

addresses and amounts in the Schedules and Statements. Accordingly, there are instances within the Schedules and Statements where names, addresses or amounts have been redacted.

5. Recharacterization. Notwithstanding the Debtors’ reasonable efforts to properly characterize, classify, categorize and designate certain claims, assets, executory contracts, unexpired leases and other items reported in the Schedules and Statements, the Debtors may nevertheless seek to recharacterize, reclassify, recategorize, redesignate, add or delete items. Accordingly, the Debtors reserve all of their rights to recharacterize, reclassify, recategorize, redesignate, add or delete items reported in the Schedules and Statements at a later time as is necessary or appropriate as additional information becomes available, including, without limitation, whether contracts or leases listed in the Schedules and Statements were deemed executory or unexpired as of the Petition Date and remain executory and unexpired postpetition.

6. Liabilities. The Debtors have sought to allocate liabilities between the prepetition and postpetition periods based on the information and research conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available and further research is conducted, the allocation of liabilities between the prepetition and postpetition periods may change. Accordingly, the Debtors reserve all of their rights to amend, supplement or otherwise modify the Schedules and Statements as is necessary or appropriate.

The liabilities listed on the Schedules do not reflect any analysis of claims under Bankruptcy Code section 503(b)(9). Accordingly, the Debtors reserve all of their rights to dispute or challenge the validity of any asserted claims under Bankruptcy Code section 503(b)(9) or the characterization of the structure of any such transaction or any document or instrument related to any creditor’s claim.

7. Excluded Assets and Liabilities. The Debtors have excluded certain categories of assets, tax accruals and liabilities from the Schedules and Statements, including, without limitation, goodwill, accrued salaries, certain employee benefit accruals, accrued accounts payable and deferred gains. The Debtors also have excluded rejection damage claims of counterparties to executory contracts and unexpired leases that may be rejected, to the extent such damage claims exist. In addition, certain immaterial assets and liabilities may have been excluded.

8. Insiders. Solely for purposes of the Schedules and Statements, the Debtors define “insiders” to include the following: (a) members of the board of directors; (b) employees who hold a position on the Executive Committee; (c) shareholders holding in excess of 5% of the voting shares of the Debtors (whether directly or indirectly); (d) relatives of (a) – (c) (to the extent known by the Debtors); and (e) non-Debtor affiliates.

Persons listed as “insiders” have been included for informational purposes only. The Debtors do not take any position with respect to: (a) such person’s influence over the control of the Debtors; (b) the management responsibilities or functions of such individual; (c) the decision-making or corporate authority of such individual; or (d) whether such individual could successfully argue that he or she is not an “insider” under applicable law, including the federal securities laws, or with respect to any theories of liability or for any other purpose.

9. Leases. In the ordinary course of business, the Debtors lease certain fixtures and equipment from certain third party lessors for use in the daily operation of the Debtors’ business. The Debtors’ obligations pursuant to such leases appear on Schedule F, and the underlying lease agreements are listed on Schedule G. Nothing in the Schedules and Statements is or shall be construed as an admission as to the determination of the legal status of any lease (including whether any lease is a true lease or a financing arrangement), and the Debtors reserve all rights with respect to such issues.

10. Classifications. Listing a claim on Schedule E as “priority” or Schedule F as “unsecured”; or listing a contract on Schedule G as “executory” or “unexpired,” does not constitute an admission by the Debtors of the legal rights of the claimant or a waiver of the Debtors’ rights to recharacterize or reclassify such claims or contracts.

11. Claims Description. Schedules E and F permit the Debtors to designate a claim as “disputed,” “contingent” and/or “unliquidated.” Any failure to designate a claim on a given Schedule as “disputed,” “contingent” or “unliquidated” does not constitute an admission by the Debtors that such amount is not “disputed,” “contingent” or “unliquidated,” or that such claim is not subject to objection. The Debtors reserve all of their rights to dispute, or assert offsets or defenses to, any claim reflected on their Schedules on any grounds, including, but not limited to amount, liability, validity, priority or classification. Additionally, the Debtors expressly reserve all of their rights to subsequently designate such claims as “disputed,” “contingent” or “unliquidated.” Moreover, listing a claim does not constitute an admission of liability by the Debtors.

12. Causes of Action. Despite their reasonable efforts to identify all known assets, the Debtors may not have identified and/or listed as assets in the Schedules and Statements all of their causes of action or potential causes of action against third-parties (and in particular have not identified or listed causes of action arising under the provisions of chapter 5 of the Bankruptcy Code and any other relevant non-bankruptcy laws to recover assets or avoid transfers). The Debtors reserve all of their rights with respect to any cause of action (including avoidance actions), controversy, right of setoff, cross-claim, counterclaim or recoupment; any claim on a contract or for breach of duty imposed by law or in equity; and any demand, right, action, lien, indemnity, guaranty, suit, obligation, liability, damage, judgment, account, defense, power, privilege, license or franchise, in each case of any kind or character whatsoever, known or unknown, fixed or contingent, matured or unmatured, suspected or unsuspected, liquidated or unliquidated, disputed or undisputed, secured or unsecured, assertable directly or derivatively, whether arising before, on, or after the Petition Date, in contract or in tort, in law or in equity, or pursuant to any other theory of law (collectively, “Causes of Action”) they may have, and neither the Global Notes nor the Schedules and Statements shall be deemed a waiver of any claims or Causes of Action or in any way prejudice or impair the assertion of such claims or Causes of Action.

13. Summary of Significant Reporting Policies. The following is a summary of significant reporting policies:

Currency. Unless otherwise indicated, all amounts are reflected in U.S. dollars.

Undetermined Amounts. The description of an amount as “unknown,” “TBD” or “undetermined” is not intended to reflect upon the materiality of such amount.

Net Book Value of Assets. It would be prohibitively expensive, unduly burdensome and an inefficient use of estate assets for the Debtors to obtain current market valuations for all of their assets. Accordingly, unless otherwise indicated, the Debtors’ Schedules and Statements reflect net book values as of the Petition Date. Additionally, because the book values of assets such as patents, trademarks and copyrights may materially differ from their fair market values, they are listed as undetermined amounts as of the Petition Date. Furthermore, assets that have fully depreciated or were expensed for accounting purposes may not appear in the Schedules and Statements as they have no net book value, or may appear but be listed as undetermined amounts or at zero.

Totals. All totals that are included in the Schedules and Statements represent totals of all known amounts. To the extent there are unknown or undetermined amounts, the actual total may be different than the listed total.

Paid Claims. The Debtors were authorized (but not directed) to pay certain outstanding prepetition claims pursuant to various orders entered by the Bankruptcy Court (collectively, the “First-Day Orders”). The Schedules and Statements generally reflect (and do not list) prepetition obligations that have been satisfied pursuant to such First-Day Orders. To the extent the Schedules and Statements fail to reflect any such payments or the Debtors pay in the future claims listed in the Schedules and Statements pursuant to orders entered by the Bankruptcy Court, the Debtors reserve all of their rights to amend or supplement the Schedules and Statements or take other action as is necessary or appropriate to avoid over-payment of or duplicate payments for any such liabilities.

Credits and Adjustments. The claims of individual creditors for, among other things, goods, products, services or taxes are listed as the amounts entered on the Debtors’ books and records and may not reflect credits, allowances or other adjustments due from such creditors to the Debtors. The Debtors reserve all of their rights with regard to such credits, allowances and other adjustments, including the right to assert objections and/or setoffs with respect to the same.

Accounts Receivable. The accounts receivable information listed on Schedule B includes net receivables from the Debtors’ customers which receivables are calculated net of any amounts that, as of the Petition Date, may be owed to such customers in the form of rebates, offsets or other price adjustments pursuant to the Debtors’ customer program policies and day-to-day operating policies. A claim is listed on Schedule F to the extent that a net payable remains to a given customer.

Liens. Property and equipment listed in the Schedules and Statements are presented without consideration of any liens that may attach (or have attached) to such property and equipment.

14. Estimates. To prepare and file the Schedules and Statements in accordance with the deadlines established in the Chapter 11 Cases, the Debtors were required to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and reported revenue and expenses. The Debtors reserve all rights to amend the reported amounts of assets, liabilities, revenue and expenses to reflect changes in those estimates and assumptions.

15. Setoffs. The Debtors periodically incur certain setoffs from customers and suppliers in the ordinary course of business. Setoffs in the ordinary course can result from various items including, but not limited to, pricing discrepancies, returns, refunds and other disputes between the Debtors and their customers and/or suppliers, as well as rebates, chargebacks, incentives and other obligations in connection with the Debtors’ customer programs. These normal setoffs are consistent with the ordinary course of business in the Debtors’ industry and can be voluminous, making it unduly burdensome and costly for the Debtors to list such ordinary course setoffs. Therefore, although such setoffs and other similar rights may have been accounted for when scheduling certain amounts, these ordinary course setoffs are not independently accounted for, and as such, are excluded from the Schedules and Statements.

16. Totals. The asset totals listed on Schedule B represent all known amounts included in the Debtors’ books and records as of October 31, 2014. The liability totals listed on Schedule F, however, reflect postpetition payments on prepetition claims made pursuant to First-Day Orders, as noted above. To the extent there are unknown or undetermined amounts, the actual total may be different than the listed total. Also as noted above, certain liabilities reflected in the books and records in accordance with GAAP, but which would not represent a claim against the Debtors, are not reflected on Schedule F.

17. Global Notes Control. In the event that the Schedules and Statements differ from the foregoing Global Notes, the Global Notes shall control.

Specific Disclosures with Respect to the Debtors’ Schedules

Schedule B2 Amounts listed in Schedule B2 reflect actual amounts in the respective accounts as of November 7, 2014, and may vary from the Debtors’ books and records amounts. Schedule B2 reflects a restricted account held at Wells Fargo Securities, LLC (“Wells Fargo”) relating to letters of credit required in connection with certain of the Debtors’ real property leases. The balance in the Wells Fargo account reflects these letters of credit. The letters of credit can be found on Schedule B3.

Schedule B9 Additional information regarding the insurance policies listed on Schedule B9 is available in the Debtors’ Motion for Order Pursuant to 11 U.S.C. §§ 105, 361, 362, 363, 364, 1107 and 1108, and Fed. R. Bankr. P. 6003 and 6004 Authorizing Debtors to (I) Maintain Existing Insurance Policies and Pay All Insurance Obligations Arising Thereunder and (II) Renew, Revise, Extend, Supplement, Change or Enter Into New Insurance Policies [Docket No. 9].

Schedule B13 Ownership interests in incorporated and unincorporated businesses, including subsidiaries, have been listed on Schedule B13 at net book value as of the Petition Date. The

fair market value of such ownership is dependent on numerous variables and factors and may differ significantly from the listed net book value.

Schedule B16 The Debtors have disclosed the net book value with respect to accounts receivable listed on Schedule B16, which represents the amount of the accounts receivable netted by any “doubtful accounts.” For purposes of Schedule B16, “doubtful accounts” are those accounts that the Debtors have identified as unlikely to be paid given the amount of time such accounts have been outstanding. Schedule B16 reflects the accounts receivable balance without netting against open accounts payable.

Schedule B21 In the ordinary course of their businesses, the Debtors may have accrued, or may subsequently accrue, certain rights to counter-claims, setoffs, refunds with their customers and suppliers, or potential warranty claims against their suppliers. Additionally, the Debtors may be a party to pending litigation in which the Debtors have asserted, or may assert, claims as plaintiffs or counter-claims as defendants. Because such claims are unknown to the Debtors and not quantifiable as of the Petition Date, they are not listed on Schedule B21.

Schedule B22 Exclusion of certain intellectual property shall not be construed as an admission that such intellectual property rights have been abandoned, terminated or assigned; have expired by their terms; or otherwise have been transferred pursuant to a sale, acquisition or other transaction. Conversely, inclusion of certain intellectual property shall not be construed as an admission that such intellectual property rights have not been abandoned, terminated or assigned; have not expired by their terms; or otherwise have not been transferred pursuant to a sale, acquisition or other transaction.

Finally, the Debtors have numerous pieces of unregistered intellectual property which have not been included on Schedule B22.

Schedule F The Debtors have used their reasonable best efforts to report all general unsecured claims against the Debtors on Schedule F based upon the Debtors’ existing books and records as of the Petition Date. The claims of individual creditors for, among other things, products, goods, or services are listed as either the lower of the amounts invoiced by such creditor or the amounts entered on the Debtors’ books and records and may not reflect credits or allowances due from such creditors to the Debtors. The Debtors reserve all of their rights with respect to any such credits and allowances including the right to assert objections and/or setoffs with respect to same. Schedule F does not include certain deferred charges, deferred liabilities, accruals, or general reserves. Such amounts are, however, reflected on the Debtors’ books and records as required in accordance with GAAP. Such accruals are general estimates of liabilities and do not represent specific claims as of the Petition Date. The Debtors have made every effort to include as a contingent, unliquidated, or disputed the claim of any vendor not included on the Debtors’ open accounts payable that is associated with an account that has an accrual or receipt not invoiced.

The claims listed in Schedule F arose or were incurred on various dates. In certain instances, the date on which a claim arose is an open issue of fact. Although reasonable efforts have been made to identify the date of incurrence of each claim, determining the date upon

which each claim in Schedule F was incurred or arose would be unduly burdensome and cost prohibitive and, therefore, the Debtors do not list a date for each claim listed on Schedule F.

Schedule F contains information regarding pending litigation involving the Debtors. The dollar amount of potential claims associated with any such pending litigation is listed as “undetermined” and marked as contingent, unliquidated, and disputed in the Schedules and Statements. Some of the litigation claims listed on Schedule F may be subject to subordination pursuant to Bankruptcy Code section 510.

Schedule F also includes potential or threatened legal disputes that are not formally recognized by an administrative, judicial, or other adjudicative forum due to certain procedural conditions that counterparties have yet to satisfy. Any information contained in Schedule F with respect to such potential litigation shall not be a binding representation of the Debtors’ liabilities with respect to any of the potential suits and proceedings included therein.

Schedule F reflects the prepetition amounts owing to counterparties to executory contracts and unexpired leases. Such prepetition amounts, however, may be paid in connection with the assumption or assumption and assignment of an executory contract or unexpired lease. Additionally, Schedule F does not include potential rejection damage claims, if any, of the counterparties to executory contracts and unexpired leases that may be rejected.

Schedule G Although reasonable efforts have been made to ensure the accuracy of Schedule G regarding executory contracts and unexpired leases (collectively, the “Agreements”), inadvertent errors, omissions or over-inclusion may have occurred. The Debtors may have entered into various other types of Agreements in the ordinary course of their business, such as indemnity agreements, supplemental agreements, amendments/letter agreements and confidentiality agreements, which may not be set forth on Schedule G. Omission of an Agreement from Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease, and Schedule G may be amended at any time to add any omitted Agreement. Likewise, the listing of an Agreement on Schedule G does not constitute an admission that such Agreement is an executory contract or unexpired lease or that such Agreement was in effect on the Petition Date or is valid or enforceable.

Certain confidentiality or nondisclosure agreements may not be listed on Schedule G. The Debtors reserve all of their rights with respect to such agreements.

Certain of the contracts and agreements listed on Schedule G may consist of several parts, including purchase orders, amendments, restatements, waivers, letters and other documents that may not be listed separately on Schedule G or that may be listed as a single entry. The Debtors expressly reserve their rights to challenge whether such related materials constitute an executory contract, a single contract or agreement or multiple, severable or separate contracts.

The contracts, agreements and leases listed on Schedule G may have expired or may have been modified, amended or supplemented from time to time by various amendments, restatements, waivers, estoppel certificates, letters, memoranda, and other documents,

instruments and agreements that may not be listed on Schedule G. Further, unless otherwise specified on Schedule G, each executory contract or unexpired lease listed thereon shall include all exhibits, schedules, riders, modifications, declarations, amendments, supplements, attachments, restatements or other agreements, instruments or other documents that in any manner affect such executory contract or unexpired lease, without respect to whether such agreement, instrument or other document is listed separately on Schedule G. In some cases, the same counterparty appears multiple times on Schedule G. This multiple listing is intended to reflect distinct agreements between the Debtors and such counterparty.

Any and all of the Debtors’ rights, claims and Causes of Action with respect to the Agreements listed on Schedule G are hereby reserved and preserved and, as such, the Debtors hereby reserve all of their rights to, among other things, (i) dispute the validity, status or enforceability of any Agreements set forth on Schedule G, (ii) dispute or challenge the characterization of the structure of any transaction, or any document or instrument related to a creditor’s claim, including, but not limited to, the Agreements listed on Schedule G, and (iii) amend or supplement such Schedule as necessary.

Certain of the Agreements may not have been memorialized and could be subject to dispute. Further, Agreements that are oral in nature have not been included on Schedule G.

Schedule H In the ordinary course of their businesses, the Debtors may be involved in pending or threatened litigation. These matters may involve multiple plaintiffs and defendants, some or all of whom may assert cross-claims and counter-claims against other parties. Because all such claims are contingent, disputed or unliquidated, such claims have not been set forth individually on Schedule H. Litigation matters can be found on each Debtor’s Schedule F and Statement 4a, as applicable.

Moreover, the Debtors reserve all of their rights to amend the Schedules to the extent that any guarantees associated with the Debtors’ executory contracts, unexpired leases, prepetition unsecured notes, debt instruments and other such agreements are identified.

Specific Disclosures with Respect to the Debtors’ Statements

Statement 3b Statement 3b includes any disbursement or other transfer made by the Debtors except for those made to bankruptcy professionals, employees and insiders (except to the extent that such employee or insider disbursements were made to Automatic Data Processing, Inc. (“ADP”) on account of payroll obligations). Transfers to insiders are included on Statement 3c. The amounts listed in Statement 3b reflect the Debtors’ disbursements netted against any check level detail; thus, to the extent a disbursement was made to pay for multiple invoices, only one entry has been listed on Statement 3b. All disbursements listed on Statement 3b are made through Dendreon Corporation.

ADP is the Debtors’ payroll administrator. Statement 3b reflects disbursements made to ADP on account of the Debtors’ payroll obligations, which ADP ultimately disburses to the Debtors’ employees.

Statement 4a Information provided in Statement 4a includes only those legal disputes and administrative proceedings that are formally recognized by an administrative, judicial, or other adjudicative forum. In the Debtor’s attempt to provide full disclosure, to the extent a legal dispute or administrative proceeding is not formally recognized by an administrative, judicial, or other adjudicative forum due to certain procedural conditions that counterparties have yet to satisfy, the Debtor has identified such matters on Schedule F. Additionally, any information contained in Statement 4a shall not be a binding representation of the Debtor’s liabilities with respect to any of the suits and proceedings identified therein.

Statement 7 In addition to the gifts noted in the Schedules and Statements, the Debtors may make de minimis gifts or gifts in kind from time to time.

Statement 8 The Debtors occasionally incur losses for a variety of reasons, including theft and property damage. The Debtors, however, may not have records of all such losses to the extent such losses do not have a material impact on the Debtors’ businesses or are not reported for insurance purposes.

Statement 9 Although all of the Debtors retained or paid the entities and individuals who provided consultation concerning debt consolidation, relief under the Bankruptcy Code or preparation of a petition in bankruptcy within one (1) year immediately preceding the Petition Date, all of the payments, or property transferred by or on behalf of a Debtor for such services, were made by Dendreon Corporation, and are therefore listed on that Debtor’s response to Statement 9.

Several of the professionals listed on Statement 9 were providing services to the debtors beyond debt consolidation, relief under the Bankruptcy Code or preparation of a petition in bankruptcy, as such the fees listed may include amounts not associated with the bankruptcy process.

Statement 19d The Debtors have provided financial statements in the ordinary course of their businesses to numerous financial institutions, creditors, and other parties within two years immediately before the Petition Date. Considering the number of such recipients and the possibility that such information may have been shared with parties without the Debtors’ knowledge or consent, the Debtors have not disclosed any parties that may have received such financial statements for the purposes of Statement 19d.

Statement 23 The Debtor has included a comprehensive response to Statement 23 in Statement 3c.

LOGO

B 6 Summary (Official Form 6 - Summary) (12/13)
United States Bankruptcy Court
District of Delaware
In re Dendreon Corporation, Case No. 14-12515 (LSS)
Debtor
Chapter 11
SUMMARY OF SCHEDULES
Indicate as to each schedule whether that schedule is attached and state the number of pages in each. Report the totals from Schedules A, B, D, E, F, I, and J in the boxes provided. Add the amounts from Schedules A and B to determine the total amount of the debtor’s assets. Add the amounts of all claims from Schedules D, E, and F to determine the total amount of the debtor’s liabilities. Individual debtors must also complete the “Statistical Summary of Certain Liabilities and Related Data” if they file a case under chapter 7, 11, or 13.
NAME OF SCHEDULE ATTACHED (YES/NO) NO. OF SHEETS ASSETS LIABILITIES OTHER
A - Real Property Yes 13 0.00
B - Personal Property Yes 36 320,697,757.49
C - Property Claimed as Exempt No 0
D - Creditors Holding Secured Claims Yes 1 0.00
E - Creditors Holding Unsecured Priority Claims (Total of Claims on Schedule E) Yes 1 0.00
F - Creditors Holding Unsecured Nonpriority Claims Yes 11 624,050,463.03
G - Executory Contracts and Unexpired Leases Yes 17
H - Codebtors Yes 1
I - Current Income of Individual Debtor(s) No 0 N/A
J - Current Expenditures of Individual Debtor(s) No 0 N/A
Total Number of Sheets of ALL Schedules 81
Total Assets 320,697,757.49
Total Liabilities 624,050,463.03

LOGO

B6A (Official Form 6A) (12/07)
In re Dendreon Corporation, Case No. 14-12515 (LSS)
Debtor
SCHEDULE A - REAL PROPERTY
Except as directed below, list all real property in which the debtor has any legal, equitable, or future interest, including all property owned as a cotenant, community property, or in which the debtor has a life estate. Include any property in which the debtor holds rights and powers exercisable for the debtor’s own benefit. If the debtor is married, state whether husband, wife, both, or the marital community own the property by placing an “H,” “W,” “J,” or “C” in the column labeled “Husband, Wife, Joint, or Community.” If the debtor holds no interest in real property, write “None” under “Description and Location of Property.”
Do not include interests in executory contracts and unexpired leases on this schedule. List them in Schedule G - Executory Contracts and Unexpired Leases.
If an entity claims to have a lien or hold a secured interest in any property, state the amount of the secured claim. See Schedule D. If no entity claims to hold a secured interest in the property, write “None” in the column labeled “Amount of Secured Claim.” If the debtor is an individual or if a joint petition is filed, state the amount of any exemption claimed in the property only in Schedule C - Property Claimed as Exempt.
Description and Location of Property Nature of Debtor’s Interest in Property Husband, Wife, Joint, or Community Current Value of Debtor’s Interest in Property, without Deducting any Secured Claim or Exemption Amount of Secured Claim
None
Sub-Total > 0.00 (Total of this page)
Total > 0.00
0 continuation sheets attached to the Schedule of Real Property
(Report also on Summary of Schedules)

LOGO

B6B (Official Form 6B) (12/07)
In re Dendreon Corporation, Case No. 14-12515 (LSS)
Debtor
SCHEDULE B - PERSONAL PROPERTY
Except as directed below, list all personal property of the debtor of whatever kind. If the debtor has no property in one or more of the categories, place an “x” in the appropriate position in the column labeled “None.” If additional space is needed in any category, attach a separate sheet properly identified with the case name, case number, and the number of the category. If the debtor is married, state whether husband, wife, both, or the marital community own the property by placing an “H,” “W,” “J,” or “C” in the column labeled “Husband, Wife, Joint, or Community.” If the debtor is an individual or a joint petition is filed, state the amount of any exemptions claimed only in Schedule C - Property Claimed as Exempt.
Do not list interests in executory contracts and unexpired leases on this schedule. List them in Schedule G - Executory Contracts and Unexpired Leases.
If the property is being held for the debtor by someone else, state that person’s name and address under “Description and Location of Property.” If the property is being held for a minor child, simply state the child’s initials and the name and address of the child’s parent or guardian, such as “A.B., a minor child, by John Doe, guardian.” Do not disclose the child’s name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).
Type of Property NONE Description and Location of Property Husband, Wife, Joint, or Community Current Value of Debtor’s Interest in Property, without Deducting any Secured Claim or Exemption
1. Cash on hand X
2. Checking, savings or other financial accounts, certificates of deposit, or shares in banks, savings and loan, thrift, building and loan, and homestead associations, or credit unions, brokerage houses, or cooperatives. See Schedule B2 Attachment - 97,454,007.48
3. Security deposits with public utilities, telephone companies, landlords, and others. See Schedule B3 Attachment - 338,294.00
4. Household goods and furnishings, including audio, video, and computer equipment. X
5. Books, pictures and other art objects, antiques, stamp, coin, record, tape, compact disc, and other collections or collectibles. X
6. Wearing apparel. X
7. Furs and jewelry. X
8. Firearms and sports, photographic, and other hobby equipment. X
9. Interests in insurance policies. Name insurance company of each policy and itemize surrender or refund value of each. X
10. Annuities. Itemize and name each issuer. X
Sub-Total > 97,792,301.48
(Total of this page)
4 continuation sheets attached to the Schedule of Personal Property

LOGO

B6B (Official Form 6B) (12/07) - Cont.
In re Dendreon Corporation , Case No. 14-12515 (LSS)
Debtor
SCHEDULE B - PERSONAL PROPERTY
(Continuation Sheet)
Type of Property
NONE
Description and Location of Property
Husband, Wife, Joint, or Community
Current Value of Debtor’s Interest in Property, without Deducting any Secured Claim or Exemption
11. Interests in an education IRA as defined in 26 U.S.C. § 530(b)(1) or under a qualified State tuition plan as defined in 26 U.S.C. § 529(b)(1). Give particulars. (File separately the record(s) of any such interest(s). 11 U.S.C. § 521(c).)
X
12. Interests in IRA, ERISA, Keogh, or other pension or profit sharing plans. Give particulars.
X
13. Stock and interests in incorporated and unincorporated businesses. Itemize.
Dendreon Holdings, LLC - 100% equity interest
Dendreon Holdings (Netherlands) B.V. - 100% equity interest
-
Unknown
14. Interests in partnerships or joint ventures. Itemize.
X
15. Government and corporate bonds and other negotiable and nonnegotiable instruments.
X
16. Accounts receivable.
Trade & Other Accounts Receivable
1301 2nd Avenue
Seattle, WA 98101
-
27,543,230.93
17. Alimony, maintenance, support, and property settlements to which the debtor is or may be entitled. Give particulars.
X
18. Other liquidated debts owed to debtor including tax refunds. Give particulars.
X
19. Equitable or future interests, life estates, and rights or powers exercisable for the benefit of the debtor other than those listed in Schedule A - Real Property.
X
20. Contingent and noncontingent interests in estate of a decedent, death benefit plan, life insurance policy, or trust.
X
Sub-Total >
27,543,230.93
(Total of this page)
Sheet 1 of 4 continuation sheets attached to the Schedule of Personal Property

LOGO

B6B (Official Form 6B) (12/07) - Cont.
In re Dendreon Corporation , Case No. 14-12515 (LSS)
Debtor
SCHEDULE B - PERSONAL PROPERTY
(Continuation Sheet)
Type of Property
NONE
Description and Location of Property
Husband, Wife, Joint, or Community
Current Value of Debtor’s Interest in Property, without Deducting any Secured Claim or Exemption
21. Other contingent and unliquidated claims of every nature, including tax refunds, counterclaims of the debtor, and rights to setoff claims. Give estimated value of each.
X
22. Patents, copyrights, and other intellectual property. Give particulars.
Copyright Registration No. TXu001204767, dated December 12, 2004, for a manuscript entitled Tumor immunotherapy with alternative reading frame peptide antigens.
-
Unknown
Copyright Registration No. TXu001222497, dated February 15, 2005, for a computer program entitled Patient Scheduling Center.
- Unknown
See Schedule B22 Attachment
- Unknown
23. Licenses, franchises, and other general intangibles. Give particulars.
X
24. Customer lists or other compilations containing personally identifiable information (as defined in 11 U.S.C. § 101(41A)) provided to the debtor by individuals in connection with obtaining a product or service from the debtor primarily for personal, family, or household purposes.
X
25. Automobiles, trucks, trailers, and other vehicles and accessories.
2005 Chevrolet Astro Minivan
1301 2nd Avenue
Seattle, WA 98101
-
0.00
26. Boats, motors, and accessories.
X
27. Aircraft and accessories.
X
28. Office equipment, furnishings, and supplies.
Furniture & Office Equipment
1301 2nd Avenue
Seattle, WA 98101
-
1,410,586.77
Lab Equipment
1301 2nd Avenue
Seattle, WA 98101
-
5,492,485.35
Computer Equipment & Software
1301 2nd Avenue
Seattle, WA 98101
-
8,107,039.88
Sub-Total >
15,010,112.00
(Total of this page)
Sheet 2 of 4 continuation sheets attached to the Schedule of Personal Property

LOGO

B6B (Official Form 6B) (12/07) - Cont.
In re Dendreon Corporation , Case No. 14-12515 (LSS)
Debtor
SCHEDULE B - PERSONAL PROPERTY
(Continuation Sheet)
Type of Property NONE
Description and Location of Property
Husband, Wife, Joint, or Community
Current Value of Debtor’s Interest in Property, without Deducting any Secured Claim or Exemption
29. Machinery, fixtures, equipment, and supplies used in business.
Manufacturing Equipment
1301 2nd Avenue
Seattle, WA 98101
-
5,299,349.45
30. Inventory.
Raw Materials
1301 2nd Avenue
Seattle, WA 98101
-
61,447,086.81
Work in Progress
1301 2nd Avenue
Seattle, WA 98101
-
98,673.49
Finished Product 1301
2nd Avenue
Seattle, WA 98101
-
3,841,948.33
31. Animals. X
32. Crops - growing or harvested. Give particulars. X
33. Farming equipment and implements. X
34. Farm supplies, chemicals, and feed. X
35. Other personal property of any kind not already listed. Itemize.
Prepaid Rent 1301 2nd Avenue Seattle, WA 98101
- 746,050.00
Other Prepaid Assets (Professional Retainers;
Compensation; Investigation Study Grants; FDA
Enhancement Fees)
1301 2nd Avenue
Seattle, WA 98101
- 5,279,380.00
Prepaid Maintenance
1301 2nd Avenue
Seattle, WA 98101
- 2,740,658.00
Prepaid Manufacturing Costs
1301 2nd Avenue
Seattle, WA 98101
- 198,895.00
Prepaid Antigen Costs
1301 2nd Avenue
Seattle, WA 98101
- 12,395,000.00
Sub-Total > 92,047,041.08
(Total of this page)
Sheet 3 of 4 continuation sheets attached to the Schedule of Personal Property

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule B2 - Checking, savings or other financial accounts
Description and Location of Property
Current Value of Debtor’s Interest in Property, Without Deducting Any Secured Claim or Exemption
US Bank, N.A. XXXX-XXXX-4656 $12,519,085.91
Operating Account
P.O. Box 1800
St. Paul, MN 55101-0800
US Bank, N.A. XXXX-XXXX-7365 $54,490.47
Deposit Account
P.O. Box 1800
St. Paul, MN 55101-0800
Morgan Stanley Smith Barney, LLC XXXX-XXXX-0516 $79,674,780.64
Investment Account
555 California St., 35th Floor
San Francisco, CA 94104
Wells Fargo Securities, LLC XX-XX-6872 $5,205,650.46
Letters of Credit
999 3rd Avenue, 11th Floor
Seattle, WA 98104
TOTAL: $97,454,007.48
1 of 1

LOGO

In re Dendreon Corporation Case No. 14-12515 Schedule B3 - Security deposits
Description and Location of Property Current Value of Debtor’s Interest in Property, Without Deducting Any Secured Claim or Exemption
Letter of Credit at Bridgwater NJ Lease $1,500,000 included in restricted cash listed under Wells Fargo Securities, LLC entry on Schedule B2
Letter of Credit at Seal Beach Lease $1,425,000 included in restricted cash listed under Wells Fargo Securities, LLC entry on Schedule B2
Letters of Credit at R&D Lease in Seattle $1,000,000 included in restricted cash listed under Wells Fargo Securities, LLC entry on Schedule B2
Letter of Credit at 5th Street Property building Lease in Seattle $1,004,000 included in restricted cash listed under Wells Fargo Securities, LLC entry on Schedule B2
Security Deposit at Union City Lease $52,715.00
Utility Deposit held at Georgia Power Co. $51,870.00
Utility Deposit held at Southern California Edison $218,135.00
Utility Deposit held at Puget Sound Energy $15,574.00
Letter of Credit held for Nebraska Department of Health and Human Services, Division of Public Health $100,000 included in restricted cash listed under Wells Fargo Securities, LLC entry on Schedule B2
Letters of Credit for Nevada State Board of Pharmacy $100,000 included in restricted cash listed under Wells Fargo Securities, LLC entry on Schedule B2
Letters of Credit for State of Wisconsin/Wisconsin Department of Regulation and Licensing $5,000 included in restricted cash listed under Wells Fargo Securities, LLC entry on Schedule B2
TOTAL: $338,294.00
1 of 1

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 1
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
PROVENGE Specific Patent Families Highlighted in Red
IMMUNOSTIMULATORY METHOD
AUSTRIA 14-122-005AT DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
AUSTRALIA 14-122-005AU DCA 12/23/1996 13380/97 6/22/2000 716783 ISSUED
BELGIUM 14-122-005BE DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
CANADA 14-122-005CA DCA 12/23/1996 2,241,373 4/9/2013 2,241,373 ISSUED
DENMARK 14-122-005DK DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
EUROPEAN PATENT 14-122-005EP DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
SPAIN 14-122-005ES DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
FINLAND 14-122-005FI DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
FRANCE 14-122-005FR DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
UNITED KINGDOM 14-122-005GB DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
GREECE 14-122-005GR DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
IRELAND 14-122-005IE DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
ITALY 14-122-005IT DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
JAPAN 14-122-005JP DCA 12/23/1996 9-524418 1/26/2007 3908277 ABANDONED
LUXEMBOURG 14-122-005LU DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
MONACO 14-122-005MC DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
NETHERLANDS 14-122-005NL DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
NEW ZEALAND 14-122-005NZ DCA 12/23/1996 326092 3/9/2000 326092 ISSUED
PORTUGAL 14-122-005PT DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
SWEDEN 14-122-005SE DCA 12/23/1996 96944879.4 2/7/2007 870022 ISSUED
WIPO 14-122-005WO CEQ 12/23/1996 PCT/US96/20241 7/10/1997 WO97/24438 NAT PHASE
UNITED STATES 14-122-005US NEW 12/28/1995 08/579,823 6/27/2000 6,080,409 ISSUED
UNITED STATES 14-122-005US DIV DIV 3/21/1997 08/823,008 ABANDONED
UNITED STATES 14-122-005US DIV1 DIV 9/3/1998 09/146,283 11/2/1999 5,976,546 ISSUED
UNITED STATES 14-122-005US CON CON 6/24/1999 09/344,195 4/3/2001 6,210,662 ISSUED
NEW ZEALAND 14-122-005NZ DIV DIV 10/28/1999 500665 10/6/2005 500665 ISSUED
SWITZERLAND 14-122-005CH DCA 10/6/2000 00968813.6 2/7/2007 870022 ISSUED
GERMANY 14-122-005DE DCA 12/23/2006 96944879.4 2/7/2007 870022 ISSUED
REAGENT FOR CELL SEPARATION
CANADA 14-123-002CA DCA 3/25/1987 534,167 7/30/1996 1,338,492 EXPIRED
JAPAN 14-123-002JP DCA 3/25/1987 62-502184 4/18/1997 2628509 EXPIRED
UNITED STATES 14-123-002US NEW 4/9/1986 06/849,819 5/22/1990 4,927,749 EXPIRED
UNITED STATES 14-123-002US CIP CIP 3/25/1987 07/049,863 5/22/1990 4,927,750 EXPIRED
WIPO 14-123-002WO CEQ 3/25/1987 PCT/US87/00628 NAT PHASE
METHOD FOR DETERMINING POTENCY OF ANTIGENIC PRESENTING CELL BASED VACCINES
UNITED STATES
14-123-007US
NEW 4/5/2002
10/118,392
8/19/2008 7,413,869
ISSUED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 2
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
CELL SEPARATION COMPOSITION, KIT AND METHOD
AUSTRIA 14-123-001AT DCA 8/31/1995 95931685 5/10/2000 0778944 ISSUED
AUSTRALIA 14-123-001AU DCA 8/31/1995 35025/95 3/22/1996 700743 ISSUED
CANADA 14-123-001CA DCA 8/31/1995 2,198,607 4/18/2000 2,198,607 ISSUED
SWITZERLAND 14-123-001CH DCA 8/31/1995 19950931685 2/2/2000 0778944 ISSUED
GERMANY 14-123-001DE DCA 8/31/1995 69513188.5 7/6/2000 DE69513188T2 ISSUED
DENMARK 14-123-001DK DCA 8/31/1995 EP19950931685 5/1/2000 DK/EP 0778944 ISSUED
EUROPEAN PATENT 14-123-001EP DCA 8/31/1995 EP19950931685 11/3/1999 EP0778944 ISSUED
SPAIN 14-123-001ES DCA 8/31/1995 95931685.2 3/1/2000 ES2140705T3 ISSUED
FRANCE 14-123-001FR DCA 8/31/1995 95931685.2 11/3/1999 0778944 ISSUED
UNITED KINGDOM 14-123-001GB DCA 8/31/1995 EP19950931685 11/3/1999 EP0778944 ISSUED
HONG KONG 14-123-001HK DCA 8/31/1995 98115108.0 10/15/2000 HK1013862 ISSUED
IRELAND 14-123-001IE DCA 8/31/1995 EP19950931685 11/3/1999 EP0778944 ISSUED
ITALY 14-123-001IT DCA 8/31/1995 EP19950931685 1/17/2000 67144BE/2000 ISSUED
JAPAN 14-123-001JP DCA 8/31/1995 8-508985 2/14/2003 3397795 ISSUED
NETHERLANDS 14-123-001NL DCA 8/31/1995 95931685.2 12/29/1999 0778944 ISSUED
NEW ZEALAND 14-123-001NZ DCA 8/31/1995 PCT/US95/11169 2/11/1999 292756 ISSUED
SWEDEN 14-123-001SE DCA 8/31/1995 95931685.2 11/3/1999 0778944 ISSUED
WIPO 14-123-001WO CEQ 8/31/1995 PCT/US95/11169 WO96/07097 NAT PHASE
UNITED STATES 14-123-001US NEW 8/31/1994 08/299,469 12/12/1995 5,474,687 EXPIRED
UNITED STATES 14-123-001US CIP CIP 12/11/1995 08/570,397 9/2/1997 5,663,051 EXPIRED
UNITED STATES 14-123-003US CIP CIP 12/11/1995 08/570,120 8/4/1998 5,789,148 EXPIRED
UNITED STATES 14-123-003US CON CON 8/4/1998 09/128,643 ABANDONED
AUSTRIA 14-123-003AT DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
AUSTRALIA 14-123-003AU DCA 12/11/1996 14150/97 11/4/1999 707878 ISSUED
BELGIUM 14-123-003BE DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
CANADA 14-123-003CA DCA 12/11/1996 2,239,729 10/31/2006 2,239,729 ISSUED
SWITZERLAND 14-123-003CH DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
CYPRUS 14-123-003CY DCA 12/11/1996 96944310.0 10/26/2011 958046 INACTIVE
GERMANY 14-123-003DE DCA 12/11/1996 96944310.0 10/26/2011 958046 /696 38 439.6 ISSUED
DENMARK 14-123-003DK DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
EUROPEAN PATENT 14-123-003EP DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
SPAIN 14-123-003ES DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
FINLAND 14-123-003FI DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
FRANCE 14-123-003FR DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
UNITED KINGDOM 14-123-003GB DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
GREECE 14-123-003GR DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
HONG KONG 14-123-003HK DCA 12/11/1996 96944310.0 3/23/2012 1023083 ISSUED
IRELAND 14-123-003IE DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
ITALY 14-123-003IT DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
JAPAN 14-123-003JP DIV DIV 2006-117292 ABANDONED
JAPAN 14-123-003JP DCA 12/11/1996 9-522180 8/3/2007 3993892 ABANDONED
LUXEMBOURG 14-123-003LU DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
MONACO 14-123-003MC DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
NETHERLANDS 14-123-003NL DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
PORTUGAL 14-123-003PT DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
SWEDEN 14-123-003SE DCA 12/11/1996 96944310.0 10/26/2011 958046 ISSUED
WIPO 14-123-003WO CEQ 12/11/1996 PCT/US96/19713 6/19/1997 WO 97/21488 NAT PHASE

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 3
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
CELL WASHING DEVICE AND METHOD
AUSTRIA 14-123-004AT DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
AUSTRALIA 14-123-004AU DCA 2/13/1998 61581/98 3/7/2002 741086 ISSUED
BELGIUM 14-123-004BE DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
CANADA 14-123-004CA DCA 2/13/1998 2,280,129 10/24/2006 2,280,129 ISSUED
SWITZERLAND 14-123-004CH DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
GERMANY 14-123-004DE DCA 2/13/1998 69819689.9-08 11/12/2003 0959989 ISSUED
DENMARK 14-123-004DK DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
EUROPEAN PATENT 14-123-004EP DCA 2/13/1998 98906333.4 11/12/2003 0959989 ISSUED
SPAIN 14-123-004ES DCA 2/13/1998 98906333.4 11/21/2003 0959989 ISSUED
FINLAND 14-123-004FI DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
FRANCE 14-123-004FR DCA 2/13/1998 98906333.4 11/21/2003 0959989 ISSUED
UNITED KINGDOM 14-123-004GB DCA 2/13/1998 98906333.4 11/21/2003 0959989 ISSUED
GREECE 14-123-004GR DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
IRELAND 14-123-004IE DCA 2/13/1998 98906333.4 11/21/2003 0959989 ISSUED
ITALY 14-123-004IT DCA 2/13/1998 98906333.4 11/21/2003 0959989 ISSUED
JAPAN 14-123-004JP DCA 2/13/1998 10-535874 11/12/2004 3615226 ISSUED
LUXEMBOURG 14-123-004LU DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
MONACO 14-123-004MC DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
NETHERLANDS 14-123-004NL DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
NEW ZEALAND 14-123-004NZ DCA 2/13/1998 337472 8/9/2001 337472 ISSUED
PORTUGAL 14-123-004PT DCA 2/13/1998 98906333.4 11/12/2003 EP 0959989 ABANDONED
SWEDEN 14-123-004SE DCA 2/13/1998 98906333.4 11/12/2003 0959989 ISSUED
WIPO 14-123-004WO CEQ 2/13/1998 PCT/US98/02661 WO 98/035758 NAT PHASE
UNITED STATES 14-123-004US NEW 2/14/1997 08/800,687 ABANDONED
UNITED STATES 14-123-004US CIP CIP 7/17/1998 09/118,326 3/6/2001 6,197,579 ISSUED
HONG KONG 14-123-004HK DCA 5/2/2000 00102655.2 ABANDONED
CENTRIFUGATION SYRINGE, SYSTEM AND METHOD
AUSTRIA 14-122-001AT DCA 8/31/1995 95931683.7 2/25/1999 0778794 ISSUED
AUSTRALIA 14-122-001AU DCA 8/31/1995 35023/95 11/13/1997 860383 ISSUED
BELGIUM 14-122-001BE DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
CANADA 14-122-001CA DCA 8/31/1995 2,198,606 10/17/2000 2,198,606 ISSUED
SWITZERLAND 14-122-001CH DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
GERMANY 14-122-001DE DCA 8/31/1995 69503512.6 7/15/1998 DE69503512T2 ISSUED
DENMARK 14-122-001DK DCA 8/31/1995 95931683.7 7/15/1998 DK/EP0778794 ISSUED
EUROPEAN PATENT 14-122-001EP DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
HONG KONG 14-122-001HK DCA 12/23/1998 98115107.1 6/23/2000 HK1013807 ISSUED
SPAIN 14-122-001ES DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
FRANCE 14-122-001FR DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
UNITED KINGDOM 14-122-001GB DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
GREECE 14-122-001GR DCA 8/31/1995 95931683.7 12/31/1998 3028114 ISSUED
IRELAND 14-122-001IE DCA 8/31/1995 95931683.7 1/15/1998 07789794 ISSUED
ITALY 14-122-001IT DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
JAPAN 14-122-001JP DCA 8/31/1995 8-508984 10/31/2003 3487604 ISSUED
LUXEMBOURG 14-122-001LU DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
MONACO 14-122-001MC DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
NETHERLANDS 14-122-001NL DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
NEW ZEALAND 14-122-001NZ DCA 8/31/1995 292754 5/12/1999 292754 ISSUED
PORTUGAL 14-122-001PT DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
SWEDEN 14-122-001SE DCA 8/31/1995 95931683.7 7/15/1998 0778794 ISSUED
WIPO 14-122-001WO CEQ 8/31/1995 PCT/US95/11162 3/7/1996 WO96/06679 NAT PHASE
UNITED STATES 14-122-001US NEW 8/31/1994 08/298,882 11/26/1996 5,577,513 EXPIRED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 6
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
TRPM8 Related and D-3263 Specific Patents and Applications Highlighted in Green
PROSTATE TUMOR POLYNUCLEOTIDE AND ANTIGEN COMPOSITION
UNITED STATES 14-126-001US PRV NEW 8/20/1997 60/056,110 INACTIVE
UNITED STATES 14-126-001US FCA 7/9/1998 09/112,096 2/27/2001 6,194,152 ISSUED
AUSTRALIA 14-126-001AU DCA 8/18/1998 90218/98 6/20/2002 744875 ISSUED
CANADA 14-126-001CA DCA 8/18/1998 2,300,364 PENDING
SWITZERLAND 14-126-001CH CEQ 8/18/1998 98942089.8 2/13/2008 1005549 ISSUED
GERMANY 14-126-001DE CEQ 8/18/1998 98942089.8 2/13/2008 1005549 ISSUED
EUROPEAN PATENT 14-126-001EP DCA 8/18/1998 98942089.8 1005549 ISSUED
SPAIN 14-126-001ES CEQ 8/18/1998 98942089.8 2/13/2008 98942089.8 ISSUED
FRANCE 14-126-001FR CEQ 8/18/1998 98942089.8 2/13/2008 1005549 ISSUED
UNITED KINGDOM 14-126-001GB CEQ 8/18/1998 98942089.8 2/13/2008 1005549 ISSUED
HONG KONG 14-126-001HK DCA 8/18/1998 00107762.1 9/26/2008 1029139 ISSUED
IRELAND 14-126-001IE CEQ 8/18/1998 98942089.8 2/13/2008 1005549 ISSUED
JAPAN 14-126-001JP DCA 8/18/1998 2000-509830 12/18/2008 4234319 ISSUED
LUXEMBOURG 14-126-001LU CEQ 8/18/1998 98942089.8 2/13/2008 1005549 ISSUED
NETHERLANDS 14-126-001NL CEQ 8/18/1998 98942089.8 2/13/2008 1005549 ISSUED
NEW ZEALAND 14-126-001NZ DCA 8/18/1998 503404 6/10/2002 503404 ISSUED
WIPO 14-126-001WO CEQ 8/19/1998 PCT/US98/17058 WO99/09166 NAT PHASE
ITALY 14-126-001IT CEQ 8/18/2008 98942089.8 2/13/2008 1005549 ISSUED
SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY
UNITED STATES 14-126-003US PRV NEW 2/15/2006 60/773,435 INACTIVE
AUSTRIA 14-126-003AT DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
BELGIUM 14-126-003BE DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
BULGARIA 14-126-003BG DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
SWITZERLAND 14-126-003CH DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
CYPRUS 14-126-003CY DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
CZECH REPUBLIC 14-126-003CZ DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
GERMANY 14-126-003DE DCA 1/15/2007 07750861.2 10/2/2013 602007033131.5 ISSUED
DENMARK 14-126-003DK DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
ESTONIA 14-126-003EE DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
EUROPEAN PATENT 14-126-003EP CEQ 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
SPAIN 14-126-003ES DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
FINLAND 14-126-003FI DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
FRANCE 14-126-003FR DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
UNITED KINGDOM 14-126-003GB DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
GREECE 14-126-003GR DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
HUNGARY 14-126-003HU DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
IRELAND 14-126-003IE DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
ICELAND 14-126-003IS DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
ITALY 14-126-003IT DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
LITHUANIA 14-126-003LT DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
LUXEMBOURG 14-126-003LU DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
LATVIA 14-126-003LV DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
MONACO 14-126-003MC DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
NETHERLANDS 14-126-003NL DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
POLAND 14-126-003PL DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
PORTUGAL 14-126-003PT DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
ROMANIA 14-126-003RO DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
SWEDEN 14-126-003SE DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
SLOVENIA 14-126-003SI DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 4/16/2014 Page 7
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY continued
SLOVAK REPUBLIC 14-126-003SK DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
TURKEY 14-126-003TR DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
AUSTRALIA 14-126-003AU DCA 2/15/2007 2007215015 PENDING
BRAZIL 14-126-003BR DCA 2/15/2007 PI0707821-8 PENDING
CANADA 14-126-003CA DCA 2/15/2007 2642297 PENDING
CHINA 14-126-003CN CEQ 2/15/2007 200780013155.7 PUBLISHED
EUROPEAN PATENT 14-126-003EP DIV DIV 2/15/2007 12001852.8 PENDING
INDIA 14-126-003IN DCA 2/15/2007 3560/KOLNP/2008 PENDING
JAPAN 14-126-003JP DCA 2/15/2007 2008-555361 10/4/2013 5376957 ISSUED
SOUTH KOREA 14-126-003KR CEQ 2/15/2007 10-2008-7022583 PUBLISHED
MEXICO 14-126-003MX DCA 2/15/2007 MX/a/2008/010434 2/15/2012 296249 ISSUED
RUSSIA 14-126-003RU DCA 2/15/2007 2008136859 PENDING
SINGAPORE 14-126-003SG DCA 2/15/2007 200806003-0 7/29/2011 145256 ISSUED
TAIWAN 14-126-003TW CEQ 2/15/2007 96105713 7/11/2013 I401248 ISSUED
UNITED STATES 14-126-003US FCA 2/15/2007 11/707,546 6/22/2010 7,741,355 ISSUED
WIPO 14-126-003WO CEQ 2/15/2007 PCT/US07/04053 NAT PHASE
UNITED STATES 14-126-003US CIP CIP 11/19/2007 11/942,660 8/10/2010 7,772,266 ISSUED
SOUTH AFRICA 14-126-003ZA DCA 9/5/2008 2008/07680 2/23/2011 2008/07680 ISSUED
CANADA 14-126-003CA CIP DCA 11/17/2008 2,706,102 PENDING
EUROPEAN PATENT 14-126-003EP CIP DCA 11/17/2008 08852382.4 PUBLISHED
WIPO 14-126-003WO CIP CEQ 11/17/2008 PCT/US08/083810 NAT PHASE
HONG KONG 14-126-003HK CEQ 5/5/2009 09104113.5 PENDING
UNITED STATES 14-126-003US CON CON 6/8/2010 12/796,587 12/24/2013 8,614,243 ISSUED
UNITED STATES 14-126-003US CIP DIV DIV 8/9/2010 12/853,202 12/31/2013 8,618,155 B2 ISSUED
JAPAN 14-126-003JP DIV DIV 1/17/2013 2013-6063 PENDING
SLOVENIA 14-126-003SI DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
SLOVAK REPUBLIC 14-126-003SK DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
TURKEY 14-126-003TR DCA 1/15/2007 07750861.2 10/2/2013 1986622 ISSUED
AUSTRALIA 14-126-003AU DCA 2/15/2007 2007215015 PENDING
BRAZIL 14-126-003BR DCA 2/15/2007 PI0707821-8 PENDING
CANADA 14-126-003CA DCA 2/15/2007 2642297 PENDING
CHINA 14-126-003CN CEQ 2/15/2007 200780013155.7 PUBLISHED
EUROPEAN PATENT 14-126-003EP DIV DIV 2/15/2007 12001852.8 PENDING
INDIA 14-126-003IN DCA 2/15/2007 3560/KOLNP/2008 PENDING
JAPAN 14-126-003JP DCA 2/15/2007 2008-555361 10/4/2013 5376957 ISSUED
SOUTH KOREA 14-126-003KR CEQ 2/15/2007 10-2008-7022583 PUBLISHED
MEXICO 14-126-003MX DCA 2/15/2007 MX/a/2008/010434 2/15/2012 296249 ISSUED
RUSSIA 14-126-003RU DCA 2/15/2007 2008136859 PENDING
SINGAPORE 14-126-003SG DCA 2/15/2007 200806003-0 7/29/2011 145256 ISSUED
TAIWAN 14-126-003TW CEQ 2/15/2007 96105713 7/11/2013 I401248 ISSUED
UNITED STATES 14-126-003US FCA 2/15/2007 11/707,546 6/22/2010 7,741,355 ISSUED
WIPO 14-126-003WO CEQ 2/15/2007 PCT/US07/04053 NAT PHASE
UNITED STATES 14-126-003US CIP CIP 11/19/2007 11/942,660 8/10/2010 7,772,266 ISSUED
SOUTH AFRICA 14-126-003ZA DCA 9/5/2008 2008/07680 2/23/2011 2008/07680 ISSUED
CANADA 14-126-003CA CIP DCA 11/17/2008 2,706,102 PENDING
EUROPEAN PATENT 14-126-003EP CIP DCA 11/17/2008 08852382.4 PUBLISHED
WIPO 14-126-003WO CIP CEQ 11/17/2008 PCT/US08/083810 NAT PHASE
HONG KONG 14-126-003HK CEQ 5/5/2009 09104113.5 PENDING
UNITED STATES 14-126-003US CON CON 6/8/2010 12/796,587 12/24/2013 8,614,243 ISSUED
UNITED STATES 14-126-003US CIP DIV DIV 8/9/2010 12/853,202 12/31/2013 8,618,155 B2 ISSUED
JAPAN 14-126-003JP DIV DIV 1/17/2013 2013-6063 PENDING

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 9
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
HCV Related Portfolio (Jointly owned with Schering and subject to Royalty Purchase by CPPIB)
Highlighted in Gray
NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
CANADA 10-105-001DCAA CEQ 2,473,032 PENDING
GERMANY 10-105-001DDE DCA MAILED
GERMANY 10-105-001DDE DIV DCA MAILED
UNITED STATES 10-105-P001D NEW 7/21/2000 60/220,108 ABANDONED
ALBANIA 10-105-001DAL DCA 7/19/2001 03731956.3 6/2/2010 1481000 ABANDONED
AUSTRIA 10-105-001DAT DCA 7/19/2001 PCT/US2001/022678 PENDING
AUSTRIA 10-105-001DAT DIV DCA 7/19/2001 03731956.3 ABANDONED
AUSTRALIA 10-105-001DAU DCA 7/19/2001 2001276988 5/11/2007 2001276988 ISSUED
BELGIUM 10-105-001DBE DCA 7/19/2001 01954764.5 PENDING
BELGIUM 10-105-001DBE DIV DCA 7/19/2001 03731956.3 PENDING
BULGARIA 10-105-001DBG DIV DCA 7/19/2001 03731956.3 ABANDONED
BRAZIL 10-105-001DBR DCA 7/19/2001 PI0112540-0 PENDING
CANADA 10-105-001DCA DCA 7/19/2001 2,410,662 9/18/2012 2,410,662 ISSUED
SWITZERLAND 10-105-001DCH DCA 7/19/2001 01954764.5 PENDING
SWITZERLAND 10-105-001DCH DIV DCA 7/19/2001 03731956.3 ABANDONED
COLOMBIA 10-105-001DCO DCA 7/19/2001 03.003.340 11/29/2010 683 ISSUED
CYPRUS 10-105-001DCY DCA 7/19/2001 01954764.5 PENDING
CYPRUS 10-105-001DCY DIV DCA 7/19/2001 03731956.3 ABANDONED
CZECH REPUBLIC 10-105-001DCZ DCA 7/19/2001 PV 2003-151 PUBLISHED
CZECH REPUBLIC 10-105-001DCZ DIV DCA 7/19/2001 03731956.3 ABANDONED
DENMARK 10-105-001DDK DCA 7/19/2001 01954764.5 PENDING
DENMARK 10-105-001DDK DIV DCA 7/19/2001 03731956.3 ABANDONED
ECUADOR 10-105-001DEC DCA 7/19/2001 SP03-4438 PCT PENDING
ESTONIA 10-105-001DEE DIV DCA 7/19/2001 03731956.3 ABANDONED
EUROPEAN PATENT 10-105-001DEP DCA 7/19/2001 01954764.5 3/17/2010 1385870 ISSUED
EUROPEAN PATENT 10-105-001DEP DIV DIV 7/19/2001 03731956.3 6/2/2010 1481000 ABANDONED
SPAIN 10-105-001DES DCA 7/19/2001 01954764.5 PENDING
SPAIN 10-105-001DES DIV DCA 7/19/2001 03731956.3 ABANDONED
FINLAND 10-105-001DFI DCA 7/19/2001 01954764.5 PENDING
FINLAND 10-105-001DFI DIV DCA 7/19/2001 03731956.3 ABANDONED
FRANCE 10-105-001DFR DCA 7/19/2001 01954764.5 PENDING
FRANCE 10-105-001DFR DIV DCA 7/19/2001 03731956.3 ABANDONED
UNITED KINGDOM 10-105-001DGB DCA 7/19/2001 01954764.5 PENDING
UNITED KINGDOM 10-105-001DGB DIV DCA 7/19/2001 03731956.3 ABANDONED
GREECE 10-105-001DGR DCA 7/19/2001 01954764.5 PENDING
GREECE 10-105-001DGR DIV DCA 7/19/2001 03731956.3 ABANDONED
HONG KONG 10-105-001DHK CEQ 7/19/2001 04100762.2 12/10/2010 HK1058047 ISSUED
HUNGARY 10-105-001DHU DCA 7/19/2001 P04 01730 PENDING
HUNGARY 10-105-001DHU DIV DCA 7/19/2001 03731956.3 ABANDONED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 10
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS continued
INDONESIA 10-105-001DID DCA 7/19/2001 W002003 00127 PENDING
IRELAND 10-105-001DIE DCA 7/19/2001 01954764.5 PENDING
IRELAND 10-105-001DIE DIV DCA 7/19/2001 03731956.3 ABANDONED
ISRAEL 10-105-001DIL DCA 7/19/2001 153,670 PENDING
INDIA 10-105-001DIN DCA 7/19/2001 00089/CHENP/2003 5/16/2007 206985 ISSUED
ITALY 10-105-001DIT DCA 7/19/2001 01954764.5 PENDING
ITALY 10-105-001DIT DIV DCA 7/19/2001 03731956.3 ABANDONED
SOUTH KOREA 10-105-001DKR DCA 7/19/2001 2003-7000784 6/19/2009 0904788 ISSUED
LIECHTENSTEIN 10-105-001DLI DCA 7/19/2001 01954764.5 PENDING
LIECHTENSTEIN 10-105-001DLI DIV DCA 7/19/2001 03731956.3 ABANDONED
LUXEMBOURG 10-105-001DLU DCA 7/19/2001 01954764.5 PENDING
LUXEMBOURG 10-105-001DLU DIV DCA 7/19/2001 03731956.3 ABANDONED
MONACO 10-105-001DMC DCA 7/19/2001 01954764.5 PENDING
MONACO 10-105-001DMC DIV DCA 7/19/2001 03731956.3 ABANDONED
MEXICO 10-105-001DMX DCA 7/19/2001 PA/A/2003/00627 5/2/2008 256832 ISSUED
MALAYSIA 10-105-001DMY CEQ 7/19/2001 PI20013436 8/28/2009 MY-139078A ISSUED
MALAYSIA 10-105-001DMY DIV DIV 7/19/2001 PI 2006-4737 4/15/2011 MY-143322A ISSUED
NETHERLANDS 10-105-001DNL DCA 7/19/2001 01954764.5 PENDING
NETHERLANDS 10-105-001DNL DIV DCA 7/19/2001 03731956.3 ABANDONED
NORWAY 10-105-001DNO DCA 7/19/2001 2003-0272 PENDING
NEW ZEALAND 10-105-001DNZ CEQ 7/19/2001 523782 2/9/2006 523782 ISSUED
PERU 10-105-001DPE CEQ 7/19/2001 732.2001 PENDING
PHILIPPINES 10-105-001DPH CEQ 7/19/2001 1-2001-001848 I-2001-001848 ISSUED
POLAND 10-105-001DPL DCA 7/19/2001 PCT/US01/22678 PENDING
PORTUGAL 10-105-001DPT DCA 7/19/2001 01954764.5 PENDING
PORTUGAL 10-105-001DPT DIV DCA 7/19/2001 03731956.3 ABANDONED
ROMANIA 10-105-001DRO DCA 7/19/2001 03731956.3 6/2/2010 1481000 ABANDONED
RUSSIA 10-105-001DRU DCA 7/19/2001 2003105217 PENDING
SWEDEN 10-105-001DSE DCA 7/19/2001 01954764.5 PENDING
SWEDEN 10-105-001DSE DIV DCA 7/19/2001 03731956.3 ABANDONED
SINGAPORE 10-105-001DSG DCA 7/19/2001 200300058-5 PENDING
SLOVENIA 10-105-001DSI DIV DCA 7/19/2001 03731956.3 ABANDONED
SLOVAK REPUBLIC 10-105-001DSK DCA 7/19/2001 PP 0075-2003 PUBLISHED
SLOVAK REPUBLIC 10-105-001DSK DIV DCA 7/19/2001 03731956.3 ABANDONED
THAILAND 10-105-001DTH CEQ 7/19/2001 067080 PENDING
TURKEY 10-105-001DTR DCA 7/19/2001 01954764.5 6/21/2010 TR 2010 03796 T4 ISSUED
TURKEY 10-105-001DTR DIV DCA 7/19/2001 03731956.3 ABANDONED
UNITED STATES 10-105-001DUS FCA 7/19/2001 09/908,955 3/14/2006 7,012,066 ISSUED
VENEZUELA 10-105-001DVE CEQ 7/19/2001 2001-001546 PENDING
WIPO 10-105-001DWO CEQ 7/19/2001 PCT/US01/22678 WO02/08244 NAT PHASE
SOUTH AFRICA 10-105-001DZA DCA 7/19/2001 2002/10312 PENDING
ARGENTINA 10-105-001DAR CEQ 7/20/2001 P010103450 PENDING
CHILE 10-105-001DCL CEQ 7/20/2001 1724-2001 PENDING
TAIWAN 10-105-001DTW CEQ 7/20/2001 090117804 5/11/2010 1324611 ISSUED
UNITED STATES 10-105-001DUSA CIP 1/18/2002 10/052,386 7/17/2007 7,244,721 ISSUED
TAIWAN 10-105-001DTWA CEQ 1/15/2003 092100868 12/21/2010 1334872 ISSUED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 11
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS continued
AUSTRALIA 10-105-001DAUA CEQ 1/16/2003 2003216064 ABANDONED
BRAZIL 10-105-001DBRA CEQ 1/16/2003 PI0306931-1 PENDING
CHILE 10-105-001DCLA CEQ 1/16/2003 2003-0067 PENDING
CHINA 10-105-001DCN DCA 1/16/2003 03805933.9 PUBLISHED
JAPAN 10-105-001DJP DCA 1/16/2003 2003-562142 PENDING
MALAYSIA 10-105-001DMYA CEQ 1/16/2003 PI 20030137 1/15/2010 MY-140710-A ABANDONED
NEW ZEALAND 10-105-001DNZA CEQ 1/16/2003 PCT/US03/01430 PENDING
NEW ZEALAND 10-105-001DNZ DIV DIV 1/16/2003 533662 ABANDONED
PERU 10-105-001DPEA CEQ 1/16/2003 49.2003 PENDING
THAILAND 10-105-001DTHA CEQ 1/16/2003 079465 PENDING
VENEZUELA 10-105-001DVEA CEQ 1/16/2003 2003-000037 PENDING
WIPO 10-105-001DWOA CEQ 1/16/2003 PCT/US03/01430 WO03/062265 NAT PHASE
ARGENTINA 10-105-001DARA CEQ 1/17/2003 P 03 01 00131 PENDING
UNITED STATES 10-105-001DUS DIV DIV 9/30/2005 11/241,656 ABANDONED
UNITED STATES 10-105-001DUSA DIV DIV 3/6/2007 11/714,457 9/22/2009 7,592,316 ISSUED
UNITED STATES 10-105-001DUS DIV COCON 12/20/2010 12/973,020 PUBLISHED
UNITED STATES 10-105-001DUS RI RIS 4/22/2011 13/068,159 PENDING
NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C
ARGENTINA 10-105-001 BAR DIV DIV PROPOSED
UNITED STATES 10-105-P001B NEW 7/21/2000 60/220,109 ABANDONED
ARGENTINA 10-105-001BAR CEQ 7/18/2001 P010103434 ABANDONED
CANADA 10-105-001BCA DCA 7/19/2001 2,418,204 ABANDONED
EUROPEAN PATENT 10-105-001BEP DCA 7/19/2001 01959046.2 ABANDONED
JAPAN 10-105-001BJP DCA 7/19/2001 2002-514160 ABANDONED
TAIWAN 10-105-001BTW CEQ 7/19/2001 90117694 ABANDONED
UNITED STATES 10-105-001BUS FCA 7/19/2001 09/909,062 10/5/2004 6,800,434 ISSUED
WIPO 10-105-001BWO CEQ 7/19/2001 PCT/US01/22826 WO01/08256 NAT PHASE
UNITED STATES 10-105-001BUS DIV DIV 9/3/2004 10/934,141 ABANDONED
NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C
UNITED STATES 10-105-P001E NEW 7/21/2000 60/220,101 ABANDONED
CANADA 10-105-001ECA DCA 7/19/2001 2,418,199 ABANDONED
EUROPEAN PATENT 10-105-001EEP DCA 7/19/2001 01955916.0 ABANDONED
JAPAN 10-105-001EJP DCA 7/19/2001 2002-514155 ABANDONED
UNITED STATES 10-105-001EUS FCA 7/19/2001 09/909,164 ABANDONED
WIPO 10-105-001EWO CEQ 7/19/2001 PCT/US01/23169 WO02/08251 NAT PHASE
NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITUS C VIRUS
NEW ZEALAND 10-105-001CNZ DIV II DIV PROPOSED
NEW ZEALAND 10-105-001CNZ DIV II CIP 571073 PENDING
UNITED STATES 10-105-P001C NEW 7/21/2000 60/220,107 ABANDONED
AUSTRALIA 10-105-001CAU DCA 7/19/2001 2001280637 ABANDONED
BRAZIL 10-105-001CBR DCA 7/19/2001 PI0112666-0 ABANDONED
CANADA 10-105-001CCA DCA 7/19/2001 2,410,682 ABANDONED
CHINA 10-105-001CCN DCA 7/19/2001 01813921.3 ABANDONED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 14
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
COMPOSITIONS AND METHODS EMPLOYING ALTERNATIVE READING FRAME POLYPEPTIDES FOR THE
TREATMENT OF CANCER AND INFECTIOUS DISEASE
EUROPEAN PATENT 14-127-001EP DCA 04749357.2 PENDING
UNITED STATES 14-127-001US PRV NEW 3/5/2003 60/453,131 INACTIVE
CANADA 14-127-001CA DCA 3/5/2004 2,514,288 PENDING
UNITED STATES 14-127-001US FCA 3/5/2004 10/794,514 10/6/2009 7,597,894 ISSUED
WIPO 14-127-001WO CEQ 3/5/2004 PCT/US2004/006979 NAT PHASE
UNITED STATES 14-127-001US DIV DIV 10/5/2009 12/573,685 PUBLISHED
EUROPEAN PATENT 14-127-001EP DIV DIV 12/16/2011 11194012.8 PENDING
COMPOSITIONS AND METHODS FOR ENHANCEMENT OF MAJOR HISTO-COMPATABILITY COMPLEX
CLASS I RESTRICTED ANTIGEN PRESENTATION
UNITED STATES 14-121-004US PRV NEW 12/14/1998 60/112,324 INACTIVE
AUSTRALIA 14-121-004AU DCA 12/14/1999 20538/00 11/25/2004 775767 ISSUED
CANADA 14-121-004CA DCA 12/14/1999 2,353,816 6/1/2010 2,353,816 ISSUED
GERMANY 14-121-004DE DCA 12/14/1999 99964259.8 5/15/2013 1141007 ISSUED
EUROPEAN PATENT 14-121-004EP DCA 12/14/1999 99964259.8 5/15/2013 1141007 ISSUED
FRANCE 14-121-004FR DCA 12/14/1999 99964259.8 5/15/2013 1141007 ISSUED
UNITED KINGDOM 14-121-004GB DCA 12/14/1999 99964259.8 5/15/2013 1141007 ISSUED
HONG KONG 14-121-004HK DCA 12/14/1999 02100178.2 ABANDONED
JAPAN 14-121-004JP DCA 12/14/1999 2000-588205 ABANDONED
NEW ZEALAND 14-121-004NZ DCA 12/14/1999 512807 2/9/2004 512807 ISSUED
UNITED STATES 14-121-004US FCA 12/14/1999 09/461,684 12/12/2006 7,148,324 ISSUED
WIPO 14-121-004WO CEQ 12/14/1999 PCT/US99/29724 6/22/2000 WO 00/35949 NAT PHASE
UNITED STATES 14-121-004US CON CON 6/16/2006 11/455,031 7/14/2009 7,560,104 ISSUED
BINDING PROTEINS SPECIFIC FOR HUMAN MATRIPTASE (Jointly-Owned with Amgen Fremont)
GERMANY 19-110-001DE DCA 12/16/2005 05854462.8 4/6/2011 1838737 ISSUED
WIPO 19-110-001WO CEQ 12/16/2005 PCT/US2005/045755 NAT PHASE
UNITED STATES 19-110-001US PRV NEW 12/20/2004 60/637,859 INACTIVE
UNITED STATES 19-110-001US PRV1 OTH 8/8/2005 60/706,467 INACTIVE
AUSTRALIA 19-110-001AU DCA 12/16/2005 2005319404 2/2/2012 2005319404 ISSUED
CANADA 19-110-001CA DCA 12/16/2005 2,592,249 7/29/2014 2,592,249 ISSUED
SWITZERLAND 19-110-001CH DCA 12/16/2005 05854462.8 4/6/2011 1838737 ISSUED
EUROPEAN PATENT 19-110-001EP DCA 12/16/2005 05854462.8 4/6/2011 1838737 ISSUED
FRANCE 19-110-001FR DCA 12/16/2005 05854462.8 4/6/2011 1838737 ISSUED
UNITED KINGDOM 19-110-001GB DCA 12/16/2005 05854462.8 4/6/2011 1838737 ISSUED
ITALY 19-110-001IT DCA 12/16/2005 05854462.8 4/6/2011 1838737 ISSUED
NETHERLANDS 19-110-001NL DCA 12/16/2005 05854462.8 4/6/2011 1838737 ISSUED
TAIWAN 19-110-001TW DCA 12/16/2005 094144958 ABANDONED
UNITED STATES 19-110-001US FCA 12/16/2005 11/303,608 8/11/2009 7,572,444 ISSUED
MATRIPTASE INHIBITORS AND METHODS OF USE
UNITED STATES 10-110-P002AUS NEW 12/23/2002 60/436,264 INACTIVE
UNITED STATES 10-110-002US FCA 12/18/2003 10/740,946 3/28/2006 7,019,019 ISSUED
WIPO 10-110-002WO CEQ 12/19/2003 PCT/US03/40927 7/15/2004 WO04/058688 ABANDONED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 15
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
GROWTH ARREST GENE COMPOSITIONS
UNITED STATES 14-130-001US PRV NEW 6/28/1996 60/021,874 INACTIVE
AUSTRALIA 14-130-001AU DCA 6/27/1997 35101/97 9/7/2000 720324 ISSUED
CANADA 14-130-001CA DCA 6/27/1997 2,259,337 ABANDONED
EUROPEAN PATENT 14-130-001EP DCA 6/27/1997 97931484.6 ABANDONED
JAPAN 14-130-001JP DCA 6/27/1997 10-504370 ABANDONED
NEW ZEALAND 14-130-001NZ DCA 6/27/1997 333563 12/7/2000 333563 ISSUED
UNITED STATES 14-130-001US FCA 6/27/1997 08/883,070 12/7/1999 5,998,599 ISSUED
WIPO 14-130-001WO CEQ 6/27/1997 PCT/US97/11341 WO98/00544 NAT PHASE
METHODS FOR INDUCING A NATURAL KILLER (NK) CELL-MEDIATED IMMUNE RESPONSE AND FOR
INCREASING NK CELL ACTIVITY
UNITED STATES 14-123-008US PRV NEW 3/22/2007 60/896,461 INACTIVE
CANADA 14-123-008CA DCA 3/21/2008 2,682,661 PUBLISHED
EUROPEAN PATENT 14-123-008EP DCA 3/21/2008 EP08727066.6 PUBLISHED
UNITED STATES 14-123-008US FCA 3/21/2008 12/077,823 4/10/2012 8,153,120 ISSUED
WIPO 14-123-008WO CEQ 3/21/2008 PCT/US2008/003755 NAT PHASE
UNITED STATES 14-123-008US DIV DIV 4/10/2012 13/443,703 PENDING
METHODS FOR ENRICHING BREAST TUMOR CELLS
UNITED STATES 14-122-004US NEW 8/31/1994 08/299,465 7/15/1997 5,648,223 ISSUED
METHODS FOR ENRICHING FETAL CELLS FROM MATERNAL BODY FLUIDS
UNITED STATES 14-122-002US NEW 8/31/1994 08/299,468 7/8/1997 5,646,004 ISSUED
METHODS FOR ENRICHING SPECIFIC CELL-TYPES BY DENSITY GRADIENT CENTRIFUGATION
UNITED STATES 14-122-003US NEW 8/31/1994 08/299,467 11/24/1998 5,840,502 ISSUED
INHIBITORS OF SERINE PROTEASE ACTIVITY OF MATRIPTASE (MTSP1)
UNITED STATES 10-110-001US NEW 9/8/2000 09/657,986 9/28/2004 6,797,504 ISSUED
AUSTRALIA 10-110-001AU DCA 9/7/2001 2001288922 ABANDONED
CANADA 10-110-001CA DCA 9/7/2001 2,422,157 ABANDONED
EUROPEAN PATENT 10-110-001EP DCA 9/7/2001 01968692.2 ABANDONED
JAPAN 10-110-001JP DCA 9/7/2001 2002-525098 ABANDONED
SOUTH KOREA 10-110-001KR DCA 9/7/2001 2003-7003459 ABANDONED
WIPO 10-110-001WO CEQ 9/7/2001 PCT/US01/28137 WO02/20475 NAT PHASE
UNITED STATES 10-110-001USA CIP 3/5/2002 10/092,004 1/2/2007 7,157,596 ISSUED
INHIBITORS OF UROKINASE
UNITED STATES 10-107-001US CIP 7/24/1998 09/121,921 6/10/2003 6,576,613 ABANDONED
AUSTRALIA 10-107-001AUA DCA 7/22/1999 50058/99 8/26/2004 772024 ABANDONED
CANADA 10-107-001CAA DCA 7/22/1999 2,338,524 1/22/2013 2,338,524 ISSUED
CHINA 10-107-001CNA DCA 7/22/1999 99810002.1 ABANDONED
CZECH REPUBLIC 10-107-001CZA DCA 7/22/1999 PV 2001-276 ABANDONED
EUROPEAN PATENT 10-107-001EPA DCA 7/22/1999 99934173.8 ABANDONED
ISRAEL 10-107-001ILA DCA 7/22/1999 140939 ABANDONED
JAPAN 10-107-001JPA DCA 7/22/1999 2000-561201 ABANDONED
SOUTH KOREA 10-107-001KRA DCA 7/22/1999 10-2001-7000985 ABANDONED
NEW ZEALAND 10-107-001NZA DCA 7/22/1999 509400 3/29/2004 509400 ISSUED
POLAND 10-107-001PLA DCA 7/22/1999 P345960 ABANDONED
UNITED STATES 10-107-001USA CIP 7/22/1999 09/359,929 8/13/2002 6,432,922 ABANDONED
WIPO 10-107-001WOA CEQ 7/22/1999 PCT/US99/16577 WO00/05245 NAT PHASE

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 16
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS
UNITED STATES 10-103-007US NEW 12/13/1994 08/356,833 8/19/2003 6,608,204 ISSUED
UNITED STATES 10-103-007USA CIP 6/7/1995 08/484,506 8/12/1997 5,656,645 ISSUED
UNITED STATES 10-103-007USB CIP 6/7/1995 08/481,660 8/19/1997 5,658,930 ISSUED
UNITED STATES 10-103-007USC CON 10/2/1995 08/480,476 ABANDONED
AUSTRALIA 10-103-007AUA DCA 12/13/1995 44248/96 11/5/1998 693636 ABANDONED
BRAZIL 10-103-007BRA DCA 12/13/1995 PI9509994-8 ABANDONED
CANADA 10-103-007CAA DCA 12/13/1995 2206400 ABANDONED
CHINA 10-103-007CNA DCA 12/13/1995 95196753.3 ABANDONED
GERMANY 10-103-007DEA DCA 12/13/1995 0804464 5/10/2002 69526677.2 ABANDONED
EUROPEAN PATENT 10-103-007EPA CEQ 12/13/1995 95943130.5 5/8/2002 0804464 ABANDONED
UNITED KINGDOM 10-103-007GBA DCA 12/13/1995 95943130.5 ABANDONED
HUNGARY 10-103-007HUA DCA 12/13/1995 P9801160 ABANDONED
JAPAN 10-103-007JPA DCA 12/13/1995 8-519290 ABANDONED
SOUTH KOREA 10-103-007KRA DCA 12/13/1995 703970/97 ABANDONED
MEXICO 10-103-007MXA DCA 12/13/1995 974439 ABANDONED
NEW ZEALAND 10-103-007NZA DCA 12/13/1995 298699 ABANDONED
RUSSIA 10-103-007RUA DCA 12/13/1995 97111793 ABANDONED
SINGAPORE 10-103-007SGA DCA 12/13/1995 9702286-7 5/23/2000 41176 ABANDONED
WIPO 10-103-007WOA DCA 12/13/1995 PCT/US95/16410 6/20/1996 WO96/18644 NAT PHASE
UNITED STATES 10-103-007USD CIP 12/18/1995 08/573,775 12/28/1999 6,008,351 ISSUED
UNITED STATES 10-103-007USE CIP 6/7/1996 08/659,983 1/4/2000 6,011,158 ISSUED
WIPO 10-103-007WOE DCA 6/9/1997 PCT/US97/09818 WO97/46207 NAT PHASE
UNITED STATES 10-103-007USEA CEQ 12/21/1999 09/194,855 1/29/2002 6,342,504 ABANDONED
ASP-PRO-ARG a-KETO-AMIDE ENZYME INHIBITORS
UNITED STATES 10-103-005US NEW 10/16/1992 07/962,301 12/6/1994 5,371,072 EXPIRED
AUSTRALIA 10-103-005AUB DCA 10/18/1993 54081/94 9/11/1997 678189 ABANDONED
CANADA 10-103-005CAB DCA 10/18/1993 2,146,446 ABANDONED
EUROPEAN PATENT 10-103-005EPB CEQ 10/18/1993 93924369.7 3/24/1999 EP0664786 EXPIRED
JAPAN 10-103-005JPB DCA 10/18/1993 510359/1994 ABANDONED
NETHERLANDS 10-103-005NLB DCA 10/18/1993 93924369.7 3/24/1999 EP0664786 ABANDONED
UNITED STATES 10-103-005USA CIP 10/18/1993 08/139,300 1/28/1997 5,597,804 EXPIRED
WIPO 10-103-005WOB DCA 10/18/1993 PCT/US93/10015 4/28/1994 WO94/09841 NAT PHASE
UNITED STATES 10-103-005USB CON 6/5/1995 08/462,899 2/9/1999 5,869,454 ISSUED
SELECTIVE APOPTOSIS OF NEOPLASTIC CELLS BY AN HLA-DR SPECIFIC MONOCLONAL ANTIBODY
UNITED STATES 14-125-001US PRV NEW 8/28/1998 60/098,292 INACTIVE
EUROPEAN PATENT 14-125-001EP DCA 8/26/1999 99942522.6 ABANDONED
UNITED STATES 14-125-001US FCA 8/26/1999 09/383,663 ABANDONED
WIPO 14-125-001WO CEQ 8/26/1999 PCT/US99/19628 WO 00/122560 ABANDONED
UNITED STATES 14-125-001US DIV DIV 8/13/2001 09/929,209 7/9/2002 6,416,958 ISSUED
HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
UNITED STATES 14-125-002US PRV NEW 12/15/2003 60/608,944 INACTIVE
CANADA 14-125-002CA DCA 12/15/2004 2,550,155 PUBLISHED
EUROPEAN PATENT 14-125-002EP DCA 12/15/2004 04814490.1-2402 ABANDONED
JAPAN 14-125-002JP DCA 12/15/2004 2006-544134 ABANDONED
UNITED STATES 14-125-002US FCA 12/15/2004 11/013,537 1/15/2013 8,354,507 ISSUED
WIPO 14-125-002WO CEQ 12/15/2004 PCT/US2004/042312 NAT PHASE

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 18
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
BLOOD COAGULATION PROTEIN ANTAGONISTS
UNITED STATES 10-111-001US NEW 10/22/1990 07/601,454 ABANDONED
UNITED STATES 10-111-001USA CIP 9/13/1991 07/759,443 4/9/1996 5,506,134 EXPIRED
AUSTRALIA 10-111-001AU DCA 10/17/1991 90298/91 3/14/1995 654311 ABANDONED
CANADA 10-111-001CA DCA 10/17/1991 2,094,372 ABANDONED
GERMANY 10-111-001DE DCA 10/17/1991 EP0554383 8/2/2000 69132352.6 ABANDONED
EUROPEAN PATENT 10-111-001EP CEQ 10/17/1991 91920567.4 8/2/2000 EP0554383 NAT PHASE
SPAIN 10-111-001ES DCA 10/17/1991 91920567.4 8/2/2000 EP0554383 ABANDONED
FRANCE 10-111-001FR DCA 10/17/1991 91920567.4 8/2/2000 EP0554383 ABANDONED
UNITED KINGDOM 10-111-001GB DCA 10/17/1991 91920567.4 8/2/2000 EP0554383 ABANDONED
ITALY 10-111-001IT DCA 10/17/1991 91920567.4 8/2/2000 EP0554383 ABANDONED
JAPAN 10-111-001JP DCA 10/17/1991 518610/1991 8/1/1997 2680192 ABANDONED
LUXEMBOURG 10-111-001LU DCA 10/17/1991 91920567.4 8/2/2000 EP0554383 ABANDONED
NETHERLANDS 10-111-001NL DCA 10/17/1991 91920567.4 8/2/2000 EP0554383 ABANDONED
WIPO 10-111-001WO DCA 10/17/1991 PCT/US91/07811 WO92/06711 NAT PHASE
UNITED STATES 10-111-001USAA R62 12/6/1993 08/163,576 ABANDONED
UNITED STATES 10-111-001USB CON 5/30/1995 08/453,047 12/1/1998 5,843,442 ISSUED
UNITED STATES 10-111-004USA R62 1/15/1998 09/008,121 4/24/2001 6,221,659 EXPIRED
BOVINE PANCREATIC TRYPSIN INHIBITOR DERIVED INHIBITORS OF FACTOR Xa
UNITED STATES 10-104-001US NEW 7/13/1992 07/913,232 ABANDONED
UNITED STATES 10-104-001USA CIP 11/3/1992 07/952,801 ABANDONED
CANADA 10-104-001CA DCA 7/1/1993 2139945 ABANDONED
EUROPEAN PATENT 10-104-001EP CEQ 7/1/1993 93917108.8 ABANDONED
JAPAN 10-104-001JP DCA 7/1/1993 503560/1994 ABANDONED
UNITED STATES 10-104-001USAA CIP 7/1/1993 08/086,328 9/15/1998 5,807,980 ISSUED
UNITED STATES 10-104-001USB CIP 7/1/1993 08/086,630 5/5/1998 5,747,449 ISSUED
WIPO 10-104-001WO DCA 7/1/1993 PCT/US93/06530 WO94/01461 NAT PHASE
UNITED STATES 10-104-001USAB CON 6/1/1995 08/456,754 ABANDONED
METHIONINE SULFONE AND S-SUBSTITUTED CYSTEINE SULFONE DERIVATIVES AS ENZYME INHIBITORS
UNITED STATES 10-104-006US NEW 4/18/1994 08/229,298 7/7/1998 5,776,927 ISSUED
UNITED STATES 10-104-006USA CIP 4/28/1994 08/234,811 10/28/1997 5,681,844 ISSUED
CANADA 10-104-006CAA DCA 4/18/1995 2188162 ABANDONED
EUROPEAN PATENT 10-104-006EP CEQ 4/18/1995 95917624.9 8/30/2000 EP0765340 ABANDONED
UNITED KINGDOM 10-104-006GB DCA 4/18/1995 95917624.9 8/30/2000 EP0765340 ABANDONED
JAPAN 10-104-006JPA DCA 4/18/1995 527181/1995 ABANDONED
NETHERLANDS 10-104-006NL DCA 4/18/1995 95917624.9 8/30/2000 EP0765340 ABANDONED
UNITED STATES 10-104-006USB CIP 4/18/1995 08/423,584 8/19/1997 5,658,939 EXPIRED
WIPO 10-104-006WOA CEQ 4/18/1995 PCT/US95/04954 WO95/28420 NAT PHASE
UNITED STATES 10-104-006USC CON 6/6/1995 08/485,826 7/8/1997 5,646,165 EXPIRED
UNITED STATES 10-104-006USD CON 6/6/1995 08/473,647 6/23/1998 5,770,600 ISSUED
UNITED STATES 10-104-006USE CON 2/10/1998 09/021,663 ABANDONED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 19
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTI-COAGULANT PROTEINS (Subject to out-license
to ARCA Biopharma formerly known as Nuvelo)
UNITED STATES 10-101-001USO CON CON 11/454,308 ABANDONED
UNITED STATES 10-101-001US NEW 10/18/1994 08/326,110 8/31/1999 5,945,275 ISSUED
UNITED STATES 10-101-001USB CIP 6/5/1995 08/465,380 1/26/1999 5,863,894 ISSUED
UNITED STATES 10-101-001USE CIP 6/5/1995 08/486,397 2/2/1999 5,866,542 ISSUED
UNITED STATES 10-101-001USF CIP 6/5/1995 08/486,399 2/2/1999 5,866,543 ISSUED
UNITED STATES 10-101-001USD CIP 6/5/1995 08/461,965 2/16/1999 5,872,098 ISSUED
UNITED STATES 10-101-001USC CON 6/6/1995 08/480,478 1/26/1999 5,864,009 ISSUED
AUSTRIA 10-101-001AT DCA 10/17/1995 95939520.3 11/29/2006 0788546 ABANDONED
AUSTRALIA 10-101-001AUA DCA 10/17/1995 41307/96 1/27/2000 711405 ABANDONED
BELGIUM 10-101-001BEA DCA 10/17/1995 95939520.3 11/29/2006 0788546 ABANDONED
CANADA 10-101-001CAA DCA 10/17/1995 2,202,351 ABANDONED
SWITZERLAND 10-101-001CH DCA 10/17/1995 95939520.3 11/29/2006 0788546 ABANDONED
GERMANY 10-101-001DE DCA 10/17/1995 69535317 11/29/2006 69535317 ISSUED
EUROPEAN PATENT 10-101-001EPA DCA 10/17/1995 95939520.3 11/29/2006 0788546 ISSUED
SPAIN 10-101-001ES DCA 10/17/1995 95939520.3 11/29/2006 0788546 ISSUED
FRANCE 10-101-001FR DCA 10/17/1995 95939520.3 11/29/2006 0788546 ISSUED
UNITED KINGDOM 10-101-001GBA DCA 10/17/1995 95939520.3 11/29/2006 0788546 ISSUED
GREECE 10-101-001GR DCA 10/17/1995 3061013 11/29/2006 0788546 ABANDONED
HUNGARY 10-101-001HUA DCA 10/17/1995 P9800027 5/24/2006 225126 ABANDONED
IRELAND 10-101-001IEA CEQ 10/17/1995 95939520.3 0788546 ABANDONED
ITALY 10-101-001ITA CEQ 10/17/1995 95939520.3 0788546 ISSUED
JAPAN 10-101-001JPA DCA 10/17/1995 8-513399 6/2/2006 3811186 ISSUED
SOUTH KOREA 10-101-001KRA DCA 10/17/1995 10-1997-0702517 11/23/2005 0532190 ABANDONED
MONACO 10-101-001MC DCA 10/17/1995 95939520.3 11/29/2006 0788546 ABANDONED
NETHERLANDS 10-101-001NL DCA 10/17/1995 95939520.3 11/29/2006 0788546 ABANDONED
NEW ZEALAND 10-101-001NZAA DIV 10/17/1995 509891 ABANDONED
NEW ZEALAND 10-101-001NZA DCA 10/17/1995 296648 PUBLISHED
POLAND 10-101-001PLA DCA 10/17/1995 P319782 10/17/1995 183855 ABANDONED
PORTUGAL 10-101-001PT DCA 10/17/1995 95939520.3 11/29/2006 0788546 ABANDONED
SWEDEN 10-101-001SE DCA 10/17/1995 95939520.3 11/29/2006 0788546 ABANDONED
WIPO 10-101-001WOA DCA 10/17/1995 PCT/US95/13231 WO96/12021 NAT PHASE
UNITED STATES 10-101-001USG CIP 4/19/1996 08/634,641 9/21/1999 5,955,294 ISSUED
UNITED STATES 10-101-001USAA DCA 11/24/1997 08/809,455 7/18/2000 6,090,916 ISSUED
UNITED STATES 10-101-001USN CON 2/12/1999 09/249,471 3/21/2000 6,040,441 ISSUED
UNITED STATES 10-101-001USK CON 2/12/1999 09/249,473 3/18/2003 6,534,629 ISSUED
UNITED STATES 10-101-001USH CON 2/12/1999 09/249,448 9/19/2000 6,121,435 ISSUED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 20
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTI-COAGULANT PROTEINS continued
UNITED STATES 10-101-001USL CON 2/12/1999 09/249,451 7/11/2000 6,087,487 ISSUED
UNITED STATES 10-101-001USI CON 2/12/1999 09/249,461 8/1/2000 6,096,877 ISSUED
UNITED STATES 10-101-001USJ CON 2/12/1999 09/249,472 4/4/2000 6,046,318 ISSUED
UNITED STATES 10-101-001USAB CON 2/4/2000 09/498,272 ABANDONED
UNITED STATES 10-101-001USM CON 2/4/2000 09/498,556 3/29/2005 6,872,808 ISSUED
NEW ZEALAND 10-101-001NZAB DIV 12/17/2004 537271 1/11/2007 537271 ISSUED
UNITED STATES 10-101-001USO CON 3/29/2005 11/092,336 ABANDONED
JAPAN 10-101-001JPA DIV DIV 10/19/2005 2005-304883 3/28/2008 4101833 ISSUED
NEW ZEALAND 10-101-001NZAB DIV DIV 6/19/2006 547989 ABANDONED
EUROPEAN PATENT 10-101-001EPA DIV DIV 11/6/2006 06123554.5 ABANDONED
JAPAN 10-101-001JPA DIV2 DIV 12/28/2006 2006-356647 ABANDONED
DENMARK 10-101-001DK DCA 2/28/2007 95939520.3 0788546 ABANDONED
HONG KONG 10-101-001HK DCA 9/14/2007 07110084.9 ABANDONED
UNITED STATES 10-101-001USO CON DIDIV 10/27/2008 12/290,059 PUBLISHED
METHOD OF TREATMENT OF HEMORRHAGIC DISEASE USING A FACTOR VII/A TISSUE FACTOR (Subject to out-
license to ARCA Biopharma formerly known as Nuvelo)
UNITED STATES 10-101-002US NEW 5/6/2003 10/431,629 11/7/2006 7,132,398 ISSUED
WIPO 10-101-002WO CEQ 5/5/2004 PCT/US04/13942 NAT PHASE
SOUTH AFRICA 10-101-002ZA DCA 5/5/2004 2005/09858 PENDING
UNITED STATES 10-101-002US CON CON 9/12/2006 11/520,079 2/12/2008 7,329,640 ISSUED
PROCESS FOR MANUFACTURING OF NEMATODE-EXTRACTED ANTICOAGULANT PROTEIN (NAP) (Subject to out-
license to ARCA Biopharma formerly known as Nuvelo)
UNITED STATES 10-101-003US NEW 5/15/2003 10/440,475 ABANDONED
AUSTRALIA 10-101-003AU DCA 5/14/2004 2004240623 10/28/2010 2004240623 ABANDONED
CANADA 10-101-003CA DCA 5/14/2004 2,525,831 ABANDONED
CHINA 10-101-003CN DCA 5/14/2004 200480020327.X 200480020327.X ISSUED
EUROPEAN PATENT 10-101-003EP CEQ 5/14/2004 04752181.0 ABANDONED
INDIA 10-101-003IN DCA 5/14/2004 5456/DELNP/2005 ABANDONED
JAPAN 10-101-003JP DCA 5/14/2004 2006-533059 ABANDONED
MEXICO 10-101-003MX DCA 5/14/2004 PA/A/2005/012298 3/27/2009 265473 ISSUED
RUSSIA 10-101-003RU CEQ 5/14/2004 2005139130 5/20/2009 2355770 ISSUED
WIPO 10-101-003WO CEQ 5/14/2004 PCT/US04/15100 NAT PHASE
SOUTH AFRICA 10-101-003ZA DCA 5/14/2004 2005/10150 2005/10150 ISSUED
UNITED STATES 10-101-003US CON CON 12/20/2005 11/313,303 10/9/2007 7,279,309 ISSUED
UNITED STATES 10-101-003 US CON2 CON 6/14/2007 11/818,324 PUBLISHED
NON COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION HAVING A
PYRIDONE GROUP
UNITED STATES 10-107-P004AUS NEW 12/4/2001 60/337,100 ABANDONED
UNITED STATES 10-107-004AUS CIP 12/4/2002 10/309,781 10/28/2007 7,262,211 ISSUED
WIPO 10-107-004AWO CEQ 12/4/2002 PCT/US02/38788 ABANDONED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 22
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE 10, THE ENCODED
PROTEINS AND METHODS BASED THEREON
UNITED STATES 10-109-P010A NEW 5/14/2001 60/291,001 ABANDONED
AUSTRALIA 10-109-010AAU DCA 5/14/2002 2002305595 ABANDONED
CANADA 10-109-010ACA DCA 5/14/2002 2,447,050 ABANDONED
EUROPEAN PATENT 10-109-010AEP DCA 5/14/2002 02734425.8 ABANDONED
JAPAN 10-109-010AJP DCA 5/14/2002 2002-589707 ABANDONED
SOUTH KOREA 10-109-010AKR DCA 5/14/2002 10-2003-7014855 ABANDONED
NEW ZEALAND 10-109-010ANZ DCA 5/14/2002 528931 ABANDONED
UNITED STATES 10-109-010AUS FCA 5/14/2002 10/147,211 9/26/2006 7,112,430 ISSUED
WIPO 10-109-010AWO CEQ 5/14/2002 PCT/US02/15332 NAT PHASE
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE 14, ENCODED
PROTEINS AND METHODS BASED THEREON (MTSP14)
UNITED STATES 10-109-P008A NEW 3/22/2001 60/278,166 ABANDONED
AUSTRALIA 10-109-008AAU DCA 3/20/2002 2002254357 ABANDONED
CANADA 10-109-008ACA DCA 3/20/2002 2,441,378 ABANDONED
EUROPEAN PATENT 10-109-008AEP DCA 3/20/2002 02723586.0 ABANDONED
JAPAN 10-109-008AJP DCA 3/20/2002 2002575305 ABANDONED
SOUTH KOREA 10-109-008AKR DCA 3/20/2002 10-2003-7012261 ABANDONED
NEW ZEALAND 10-109-008ANZ DCA 3/20/2002 527970 ABANDONED
UNITED STATES 10-109-008AUS FCA 3/20/2002 10/104,271 2/6/2007 7,172,892 ISSUED
WIPO 10-109-008AWO CEQ 3/20/2002 PCT/US02/09039 NAT PHASE
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE 9, THE ENCODED
PROTEINS AND METHODS BASED THEREON
UNITED STATES 10-109-P009A NEW 3/27/2001 60/279,228 ABANDONED
AUSTRALIA 10-109-009AAU DCA 3/27/2002 2002252531 ABANDONED
CANADA 10-109-009ACA DCA 3/27/2002 2,442,089 ABANDONED
EUROPEAN PATENT 10-109-009AEP DCA 3/27/2002 02721608.4 ABANDONED
JAPAN 10-109-009AJP DCA 3/27/2002 2002-575309 ABANDONED
SOUTH KOREA 10-109-009AKR DCA 3/27/2002 10-2003-7012622 ABANDONED
NEW ZEALAND 10-109-009ANZ DCA 3/27/2002 527971 ABANDONED
UNITED STATES 10-109-009AUS FCA 3/27/2002 10/112,221 9/12/2006 7,105,333 ISSUED
WIPO 10-109-009AWO CEQ 3/27/2002 PCT/US02/09611 NAT PHASE
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE 9, THE ENCODED
PROTEINS AND METHODS BASED THEREON
UNITED STATES 10-109-P009B NEW 5/15/2001 60/291,501 ABANDONED
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASES, THE ENCODED
PROTEINS AND METHODS BASED THEREOF (MTSP 1, 3, 4 & 6)
GERMANY 10-109-002ADE DCA EP1252300 ISSUED
UNITED STATES 10-109-P002B OTH 2/18/2000 60/183,542 ABANDONED
UNITED STATES 10-109-P002CUS OTH 6/22/2000 60/213,124 ABANDONED
UNITED STATES 10-109-P002DUS OTH 7/26/2000 60/220,970 ABANDONED
UNITED STATES 10-109-P002E OTH 9/22/2000 60/234,840 ABANDONED
AUSTRALIA 10-109-002AAU DCA 2/2/2001 2001233262 ABANDONED
CANADA 10-109-002ACA DCA 2/2/2001 2,396,774 ABANDONED
EUROPEAN PATENT 10-109-002AEP DCA 2/2/2001 01905377.6 1/19/2011 EP1252300 ISSUED
FRANCE 10-109-002AFR DCA 2/2/2001 01905377.6 1/19/2011 EP1252300 ISSUED
UNITED KINGDOM 10-109-002AGB DCA 2/2/2001 01905377.6 1/19/2011 EP1252300 ISSUED

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon Patent Portfolio Status Report
Patent Report by Invention Printed: 10/15/2014 Page 23
COUNTRY REFERENCE# TYPE FILED SERIAL# ISSUED PATENT# STATUS
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASES, (MTSP 1, 3, 4 & 6) continued…
IRELAND 10-109-002AIE DCA 2/2/2001 01905377.6 1/19/2011 EP1252300 ISSUED
ISRAEL 10-109-002AIL DCA 2/2/2001 150168 ABANDONED
JAPAN 10-109-002AJP DCA 2/2/2001 2001-558009 ABANDONED
SOUTH KOREA 10-109-002AKR DCA 2/2/2001 10-2002-7009973 ABANDONED
NEW ZEALAND 10-109-002ANZ DCA 2/2/2001 519635 ABANDONED
RUSSIA 10-109-002ARU DCA 2/2/2001 2002120920 ABANDONED
UNITED STATES 10-109-002AUS CIP 2/2/2001 09/776,191 4/20/2010 7,700,341 ISSUED
WIPO 10-109-002AWO CEQ 2/2/2001 PCT/US01/03471 WO01/57194 NAT PHASE
SOUTH AFRICA 10-109-002AZA DCA 2/2/2001 2002/5678 12/31/2003 2002/5678 ISSUED
NEW ZEALAND 10-109-002ANZ DIV DIV 11/15/2005 543579 ABANDONED
UNITED STATES 10-109-002AUS DIV DIV 10/30/2009 12/590,011 2/15/2011 7,888,092 ISSUED
UNITED STATES 10-109-002AUS DIV2 DIV 11/12/2010 12/927,372 PUBLISHED
NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASES, THE ENCODED
PROTEINS AND METHODS BASED THEREOF (MTSP3)
UNITED STATES 10-109-P002AUS NEW 2/3/2000 60/179,982 ABANDONED
NUCLEIC ACIDS MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASE, THE ENCODING
PROTEINS AND METHODS BASED THEREON (MTSP7)
UNITED STATES 10-109-P007A NEW 3/13/2001 60/275,592 ABANDONED
UNITED STATES 10-109-007AUS FCA 3/13/2002 10/099,700 10/24/2006 7,125,703 ISSUED
WIPO 10-109-007AWO CEQ 3/13/2002 PCT/US02/07903 ABANDONED
NUCLEOTIDE AND PROTEIN SEQUENCES OF PROTEASE DOMAINS OF ENDOTHELIASE AND METHODS
BASED THEREON (Endotheliase 1 & 2—MTSP 2 & 5)
UNITED KINGDOM 10-109-001AGB CEQ 6/13/2007 EP 1 230 349 ISSUED
UNITED STATES 10-109-P001A NEW 11/18/1999 60/166,391 ABANDONED
AUSTRALIA 10-109-001AAU DCA 11/17/2000 16239/01 9/21/2006 784746 ABANDONED
CANADA 10-109-001ACA DCA 11/17/2000 2,387,805 8/28/2012 2,387,805 ISSUED
EUROPEAN PATENT 10-109-001AEP DCA 11/17/2000 00978819.1 6/13/2007 EP 1 230 349 ISSUED
IRELAND 10-109-001AIE CEQ 11/17/2000 00978819.1 6/13/2007 1230349 ISSUED
ISRAEL 10-109-001AIL DCA 11/17/2000 149340 ABANDONED
JAPAN 10-109-001AJP DCA 11/17/2000 2001-538483 ABANDONED
SOUTH KOREA 10-109-001AKR DCA 11/17/2000 10-2002-7006388 ABANDONED
NEW ZEALAND 10-109-001ANZ DCA 11/17/2000 518407 5/10/2004 518407 ABANDONED
NEW ZEALAND 10-109-001ANZA DIV 11/17/2000 529387 8/11/2005 529387 ABANDONED
RUSSIA 10-109-001ARU DCA 11/17/2000 2002113076 ABANDONED
WIPO 10-109-001AWO CEQ 11/17/2000 PCT/US00/31803 WO01/36604 NAT PHASE
SOUTH AFRICA 10-109-001AZA DCA 11/17/2000 2002/3366 9/23/2003 2002/3366 ISSUED
UNITED STATES 10-109-001AUS FCA 11/20/2000 09/717,473 10/2/2007 7,276,364 ISSUED
PLASMINOGEN ACTIVATOR INHIBITOR ANTAGONISTS
UNITED STATES 10-108-001AUS NEW 11/19/1999 09/444,172 10/28/2003 6,638,977 ISSUED
UNITED STATES 10-108-P001A NEW 2/28/2000 60/185,564 ABANDONED
UNITED STATES 10-108-001AUSB CIP 11/17/2000 09/716,036 1/13/2004 6,677,473 ISSUED
POTENT ANTIGEN PRESENTING CELL COMPOSITION
UNITED STATES 14-121-001US NEW 7/12/1995 08/501,987 9/19/2000 6,121,044 ISSUED
AUSTRALIA 14-121-001AU DCA 7/12/1996 64576/96 3/27/1999 701943 ISSUED
CANADA 14-121-001CA DCA 7/12/1996 2,226,490 ABANDONED
EUROPEAN PATENT 14-121-001EP DCA 7/12/1996 EP96923765.0 ABANDONED
JAPAN 14-121-001JP DCA 7/12/1996 9-506009 ABANDONED
WIPO 14-121-001WO CEQ 7/12/1996 PCT/US96/11640 1/30/1997 WO97/03186 NAT PHASE

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Dendreon
Status Chart September 2014
Application Application Registration Registration Case
Title/Mark Country All Goods/Services One Line
No. Date No. Date Status
United States of Class 42: Research and developmentof pharmaceutical products
America 78/733,522 Oct-14-2005 3,726,707 Dec-15-2009 Registered
United States of Class 42: Research and development of pharmaceutical products for others
America 78/395,102 Apr-01-2004 3,581,625 Feb-24-2009 Registered
United States of Class 05: Pharmaceuticals for use in the treatment of cancer, infectious and
America 77/463,424 May-01-2008 4,158,044 Jun-12-2012 autoimmune diseases Registered
ANTIGEN United States of Class 42: Research and development of pharmaceutical products
DELIVERY 78/651,515 Jun-15-2005 3,228,929 Apr-10-2007 Registered
CASSETTE America
Class 01: Kit for cell separation consisting primarily of density gradient solutions and a
centrifugation tube or a syringe with a modified internal constriction for scientific and
United States of research applications
DACS 74/681,428 May-30-1995 2,188,041 Sep-08-1998 Class 05: Kit for cell separation consisting primarily of density gradient solutions and a Registered
America centrifugation tube or a syringe with a modified internal constriction for medical and
clinical applications
United States of Class 42: Research and development of pharmaceutical products for others
DENDREON 75/282,526 Apr-29-1997 2,530,065 Jan-15-2002 Registered
America
United States of Class 05: Pharmaceuticals for use in the treatment of infectious and autoimmune
DENDREON 75/283,623 Apr-29-1997 2,465,920 Jul-03-2001 diseases and cancer Registered
America
Class 05: Pharmaceuticals for use in the treatment of autoimmune and infectious
DENDREON United States of 76/165,904 Nov-09-2000 3,616,391 May-05-2009 diseases Registered
(Refile) America
DENDREON and United States of Class 42: Research and development of pharmaceutical products for others
Design America 78/395,105 Apr-01-2004 3,581,626 Feb-24-2009 Registered
Class 05: Pharmaceuticals for use in the treatment of cancer, infectious and
United States of autoimmune diseases
America 77/463,413 May-01-2008 4,099,276 Feb-14-2012 Registered
DENDREON
TARGETING Class 05: Pharmaceuticals for use in the treatment of cancer and autoimmune and
United States of
CANCER 78/733,533 Oct-14-2005 3,982,430 Jun-21-2011 infectious diseases Registered
TRANSFORMING America
LIVES Design
Sep-19-2014 1:01 PM 1 / 5

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Application Application Registration Registration Case
Title/Mark Country All Goods/Services One Line
No. Date No. Date Status
Class 09: Computer software used for scheduling, controlling, tracking, monitoring,
managing, analyzing and recording medical and laboratory procedures for patients;
computer software used for scheduling, controlling, tracking, monitoring, managing,
and recording shipment and transmission of patient medical information, laboratory
samples, diagnostic samples and clinical samples; computer software for controlling,
scheduling, tracking, monitoring, managing, analyzing, recording, and ensuring the
transmission security and integrity of medical and diagnostic data and information
Class 42: Consulting services in the fields of biotechnology, pharmaceutical research
and development, and laboratory medical sample testing for scientific and research
INTELLIVENGE United States of purposes; research and development in the fields of medical, pharmaceutical,
85/780,732 Nov-15-2012 Allowed
(Refile) America diagnostic and blood treatment products and procedures; computer services, namely,
providing a website featuring online non-downloadable software that enables users to
remotely manage, administer, modify and control their end user computer devices and
software applications to implement, schedule, control, track, monitor, manage,
process, analyze and record medical and laboratory procedures for patients and
shipment and transmission of patient medical information, laboratory samples,
diagnostic medical samples and clinical medical samples; medical laboratory services
Class 44: Medical diagnostic testing, monitoring and reporting services; medical
treatment services; blood testing, and blood treatment and processing for the purpose
of medical clinical diagnosis; consulting services in the fields of medical treatment and
medicines, medical diagnostic testing, and diagnostic and clinical blood treatment
procedure
NEUVENGE United States of Class 05: Pharmaceuticals for use in the treatment of cancer, infections and
(Refile) America 85/657,232 Jun-20-2012 autoimmune diseases Allowed
Class 09: Computer software used for scheduling, controlling, tracking, monitoring,
managing, analyzing and recording medical and laboratory procedures for patients;
computer software used for scheduling, controlling, tracking, monitoring, managing,
and recording shipment and transmission of patient medical information, laboratory
samples, diagnostic samples and clinical samples; computer software for controlling,
scheduling, tracking, monitoring, managing, analyzing, recording, and ensuring the
transmission security and integrity of medical and diagnostic data and information
Class 42: Consulting services in the fields of biotechnology, pharmaceutical research
and development, and laboratory medical sample testing for scientific and research
POWERED BY purposes; research and development in the fields of medical, pharmaceutical,
INTELLIVENGE United States of diagnostic and blood treatment products and procedures; computer services, namely,
and Design America 85/960,682 Jun-14-2013 providing a website featuring online non-downloadable software that enables users to Allowed
remotely manage, administer, modify and control their end user computer devices and
software applications to implement, schedule, control, track, monitor, manage,
process, analyze and record medical and laboratory procedures for patients and
shipment and transmission of patient medical information, laboratory samples,
diagnostic medical samples and clinical medical samples; medical laboratory services
Class 44: Medical diagnostic testing, monitoring and reporting services; medical
treatment services; blood testing, and blood treatment and processing for the purpose
of medical clinical diagnosis; consulting services in the fields of medical treatment and
medicines, medical diagnostic testing, and diagnostic and clinical blood treatment
procedure
United States of Class 05: Pharmaceutical preparations for use in the treatment of cancer
PROVENGE 75/927,064 Feb-23-2000 2,545,242 Mar-05-2002 Registered
America
Sep-19-2014 1:01 PM 2 / 5

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Application Application Registration Registration Case
Title/Mark Country All Goods/Services One Line
No. Date No. Date Status
THE United States of Class 42: Research and development of pharmaceutical products
DIFFERENCE IS 85/960,680 Jun-14-2013 Allowed
PERSONAL America
THE Class 05: Pharmaceuticals for use in the treatment of cancer and autoimmune and
United States of
DIFFERENCE IS 85/960,681 Jun-14-2013 infectious diseases Allowed
PERSONAL America
Class 05: Pharmaceuticals, antibodies, and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies;
pharmaceuticals for use in the prevention and treatment of genetically induced
DENDREON Australia 920752 Jul-24-2002 920752 Mar-04-2003 Registered
conditions, diseases, and disorders; kits for cell separation for medical and clinical
use; cells for medical and clinical use
Class : Pharmaceuticals for use in the treatment of cancer; Research and Application
Canada 1685568 Jul-16-2014 development of pharmaceutical products. Filed
Class : pharmaceuticals for use in the treatment of autoimmune diseases;
pharmaceuticals for use in the treatment of infectious diseases namely antivirals and
antibacterials’; pharmaceuticals for use in the treatment of cancer’; research and
DENDREON Canada 1148456 Jul-30-2002 TMA799,137 Jun-02-2011 Registered
development of pharmaceutical products for others’
Class : Pharmaceutical preparations for use in the treatment of cancer
PROVENGE Canada 1537312 Jul-27-2011 TMA848037 Apr-09-2013 Registered
Class 10: Kits for cell separation for medical and clinical use
DENDREON China 3462760 Feb-20-2003 3462760 Sep-21-2004 Registered
Class 05: Pharmaceuticals, antibodies, and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies;
DENDREON China 3338807 Oct-17-2002 3338807 May-07-2004 pharmaceuticals for use in the prevention and treatment of genetically induced Registered
conditions, diseases, and disorders; cells for medical and clinical use
Class 01: Kits for cell separation, cells, reagents, antibodies, and antigens for
scientific and laboratory research and use (cl. 01)
Pharmaceuticals for use in the treatment of cancer, infectious and autoimmune
diseases; pharmaceuticals, antibodies, and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies;
European pharmaceuticals for use in the prevention and treatment of genetically induced
Community 3919073 Jul-12-2004 3919073 Nov-16-2005 conditions, diseases and disorders; kits for cell separation for medical and clinical use; Registered
cells for medical and clinical use; kits for cell separation, cells, reagents, antibodies,
and antigens for pharmaceutical, veterinary and medical research and use (cl. 05)
Research and development of pharmaceutical products for others; research and
development services in the fields of medicine, pharmaceuticals, pharmacology,
immunotherapy, and veterinary science (cl. 42)
Sep-19-2014 1:01 PM 3 / 5

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Application Application Registration Registration Case
Title/Mark Country All Goods/Services One Line
No. Date No. Date Status
Class 01: Kits for cell separation, cells, reagents, antibodies, and antigens for
scientific and laboratory research and use
Class 05: Pharmaceuticals, antibodies, and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies;
pharmaceuticals for use in the prevention and treatment of genetically induced
European conditions, diseases and disorders; kits for cell separation for medical and clinical use;
DENDREON 2786317 Jul-24-2002 2786317 Jan-21-2004 cells for medical and clinical use; kits for cell separation, cells, reagents, antibodies, Registered
Community and antigens for pharmaceutical, veterinary and medical research and use
Class 42: Research and development services in the fields of medicine,
pharmaceuticals, pharmacology, immunotherapy, and veterinary science
Class 44: Consultation services in the fields of medicine, pharmaceuticals,
pharmacology, immunotherapy, and veterinary science
Class 01: Kits for cell separation, cells, reagents, antibodies, and antigens for
scientific and laboratory research and use
Class 05: Pharmaceuticals for use in the treatment of cancer, infectious and
autoimmune diseases; pharmaceuticals, antibodies, and antigens for use in the
prevention and treatment of cancer, autoimmune and infectious diseases and
disorders, and allergies; pharmaceuticals for use in the prevention and treatment of
DENDREON and European genetically induced conditions, diseases and disorders; kits for cell separation for
3919081 Jul-12-2004 3919081 Nov-16-2005 Registered
Design Community medical and clinical use; cells for medical and clinical use; kits for cell separation,
cells, reagents, antibodies, and antigens for pharmaceutical, veterinary and medical
research and use
Class 42: Research and development of pharmaceutical products for others; research
and development services in the fields of medicine, pharmaceuticals, pharmacology,
immunotherapy, and veterinary science
Class 05: Pharmaceutical, veterinary and sanitary preparations; pharmaceutical
preparations for use in the treatment of cancer; dietetic substances adapted for
medical use (cl. 05)
Research and consultancy services relating to medical science and pharmaceutical
preparation; information services relating to medical science and pharmaceutical
European preparations (cl. 42)
PROVENGE 1816974 Aug-21-2000 1816974 Oct-05-2001 Class 42: Pharmaceutical, veterinary and sanitary preparations; pharmaceutical Registered
Community preparations for use in the treatment of cancer; dietetic substances adapted for
medical use (cl. 05)
Research and consultancy services relating to medical science and pharmaceutical
preparation; information services relating to medical science and pharmaceutical
preparations (cl. 42)
Class 05: Pharmaceuticals, antibodies and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies;
pharmaceuticals for use in the prevention and treatment of genetically induced
DENDREON Hong Kong 2002 11420 Jul-24-2002 200316300 Dec-30-2003 Registered
conditions, diseases, and disorders; knits for cell separation for medical and clinical
use; cells for medical and clinical use
Sep-19-2014 1:01 PM 4 / 5

LOGO

In re Dendreon Corporation — Case No. 14-12515
Schedule B22—Patents, copyrights, and other intellectual property
Application Application Registration Registration Case
Title/Mark Country All Goods/Services One Line
No. Date No. Date Status
Class 05: Pharmaceuticals, antibodies, and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies
pharmaceuticals for use in the prevention and treatment of genetically induced
DENDREON Ireland 02/1488 Jul-25-2002 225773 Jun-30-2003 Registered
conditions, diseases, and disorders kits for cell separation for medical and clinical use;
cells for medical and clinical use
Class 42: Research and development of pharmaceutical products for others
Japan 65402/2004 Jul-14-2004 4844004 Mar-04-2005 Registered
Class 05: Pharmaceuticals for use in the treatment of cancer, infectious and
Japan 65401/2004 Jul-14-2004 4825474 Dec-10-2004 autoimmune diseases Registered
Class 05: Kits for cell separation for medical and clinical use; cells for medical and
DENDREON Japan 2002-071245 Aug-22-2002 4748818 Feb-20-2004 clinical use Registered
Class 05: Pharmaceuticals for use in the treatment of cancer, infectious and
DENDREON and Japan 82921/2004 Sep-08-2004 4844098 Mar-04-2005 autoimmune diseases Registered
Design (b/w)
DENDREON and Class 42: Research and development of pharmaceutical products for others
Design (color) Japan 65404/2004 Jul-14-2004 4844005 Mar-04-2005 Registered
DENDREON and Class 42: Research and development of pharmaceutical products for others
Design (color) Japan 82922/2004 Sep-08-2004 4854919 Apr-08-2005 Registered
Class 05: Pharmaceutical preparations
PROVENGE Japan 2002-046880 Jun-06-2002 4655127 Mar-20-2003 Registered
Class 10: Kits for cell separation for medical and clinical use
DENDREON New Zealand 664161 Sep-09-2002 664161 Mar-13-2003 Registered
Class 05: Pharmaceuticals, antibodies and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies;
DENDREON New Zealand 661517 Jul-29-2002 661517 Mar-13-2003 pharmaceuticals for use in the prevention and treatment of genetically induced Registered
conditions, diseases, and disorders
Class 05: Kits for cell separation for medical and clinical use
DENDREON Norway 200206940 Jul-26-2002 218776 May-02-2003 Registered
Class 05: Pharmaceuticals, antibodies, and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious diseases and disorders, and allergies
Republic of pharmaceuticals for use in the prevention and treatment of genetically induced
DENDREON 40-02-34025 Jul-25-2002 40-0575330 Feb-23-2004 Registered
Korea conditions, diseases, and disorders kits for cell separation for medical and clinical use;
cells for medical and clinical use
Class 05: Pharmaceuticals, antibodies, and antigens for use in the prevention and
treatment of cancer, autoimmune and infectious disease and disorders, and allergies;
pharmaceuticals for use in the prevention and treatment of genetically induced
conditions, diseases, and disorders; kits containing chemical products for cell
DENDREON Switzerland 06607/2002 Jul-26-2002 507918 Apr-03-2003 Registered
separation for medical and clinical use; cells for medical and clinical use
Class 10: Kits containing medical apparatus for cell separation for medical and clinical
use
Sep-19-2014 1:01 PM 5 / 5

LOGO

B6D (Official Form 6D) (12/07)
In re Dendreon Corporation Case No. 14-12515 (LSS)
,
Debtor
SCHEDULE D—CREDITORS HOLDING SECURED CLAIMS
State the name, mailing address, including zip code, and last four digits of any account number of all entities holding claims secured by property of the debtor as of
the date of filing of the petition. The complete account number of any account the debtor has with the creditor is useful to the trustee and the creditor and may be provided
if the debtor chooses to do so. List creditors holding all types of secured interests such as judgment liens, garnishments, statutory liens, mortgages, deeds of trust, and
other security interests.
List creditors in alphabetical order to the extent practicable. If a minor child is a creditor, the child’s initials and the name and address of the child’s parent or
guardian, such as “A.B., a minor child, by John Doe, guardian.” Do not disclose the child’s name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m). If all secured
creditors will not fit on this page, use the continuation sheet provided.
If any entity other than a spouse in a joint case may be jointly liable on a claim, place an “X” in the column labeled “Codebtor” ,include the entity on the appropriate
schedule of creditors, and complete Schedule H—Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be
liable on each claim by placing an “H”, “W”, “J”, or “C” in the column labeled “Husband, Wife, Joint, or Community”.
If the claim is contingent, place an “X” in the column labeled “Contingent”. If the claim is unliquidated, place an “X” in the column labeled “Unliquidated”. If the
claim is disputed, place an “X” in the column labeled “Disputed”. (You may need to place an “X” in more than one of these three columns.)
Total the columns labeled “Amount of Claim Without Deducting Value of Collateral” and “Unsecured Portion, if Any” in the boxes labeled “Total(s)” on the last
sheet of the completed schedule. Report the total from the column labeled “Amount of Claim” also on the Summary of Schedules and, if the debtor is an individual with
primarily consumer debts, report the total from the column labeled “Unsecured Portion” on the Statistical Summary of Certain Liabilities and Related Data.
Check this box if debtor has no creditors holding secured claims to report on this Schedule D.
C Husband, Wife, Joint, or Community C U D AMOUNT OF
CREDITOR’S NAME O O N I
AND MAILING ADDRESS E D H DATE CLAIM WAS INCURRED, T N I L P S WITHOUT CLAIM UNSECURED
INCLUDING ZIP CODE, B W NATURE OF LIEN, AND I Q U DEDUCTING PORTION, IF
AND ACCOUNT NUMBER O T J DESCRIPTION AND VALUE G N I U E T VALUE OF ANY
C OF PROPERTY
(See instructions above.) R E D D COLLATERAL
SUBJECT TO LIEN N A
T T
Account No. E
D
Value $
Account No.
Value $
Account No.
Value $
Account No.
Value $
0 Subtotal
continuation sheets attached
(Total of this page)
Total 0.00 0.00
(Report on Summary of Schedules)

LOGO

B6E (Official Form 6E) (4/13)
In re Dendreon Corporation Case No. 14-12515 (LSS)
, Debtor
SCHEDULE E—CREDITORS HOLDING UNSECURED PRIORITY CLAIMS
A complete list of claims entitled to priority, listed separately by type of priority, is to be set forth on the sheets provided. Only holders of unsecured claims entitled to priority should be listed in this schedule. In the boxes provided on the attached sheets, state the name, mailing address, including zip code, and last four digits of the account number, if any, of all entities holding priority claims against the debtor or the property of the debtor, as of the date of the filing of the petition. Use a separate continuation sheet for each type of priority and label each with the type of priority.
The complete account number of any account the debtor has with the creditor is useful to the trustee and the creditor and may be provided if the debtor chooses to do so. If a minor child is a creditor, state the child’s initials and the name and address of the child’s parent or guardian, such as “A.B., a minor child, by John Doe, guardian.” Do not disclose the child’s name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).
If any entity other than a spouse in a joint case may be jointly liable on a claim, place an “X” in the column labeled “Codebtor,” include the entity on the appropriate schedule of creditors, and complete Schedule H-Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be liable on each claim by placing an “H,” “W,” “J,” or “C” in the column labeled “Husband, Wife, Joint, or Community.” If the claim is contingent, place an “X” in the column labeled “Contingent.” If the claim is unliquidated, place an “X” in the column labeled “Unliquidated.” If the claim is disputed, place an “X” in the column labeled “Disputed.” (You may need to place an “X” in more than one of these three columns.) Report the total of claims listed on each sheet in the box labeled “Subtotals” on each sheet. Report the total of all claims listed on this Schedule E in the box labeled “Total” on the last sheet of the completed schedule. Report this total also on the Summary of Schedules.
Report the total of amounts entitled to priority listed on each sheet in the box labeled “Subtotals” on each sheet. Report the total of all amounts entitled to priority listed on this Schedule E in the box labeled “Totals” on the last sheet of the completed schedule. Individual debtors with primarily consumer debts report this total also on the Statistical Summary of Certain Liabilities and Related Data.
Report the total of amounts not entitled to priority listed on each sheet in the box labeled “Subtotals” on each sheet. Report the total of all amounts not entitled to priority listed on this Schedule E in the box
labeled “Totals” on the last sheet of the completed schedule. Individual debtors with primarily consumer debts report this total also on the Statistical Summary of Certain Liabilities and Related Data.
Check this box if debtor has no creditors holding unsecured priority claims to report on this Schedule E.
TYPES OF PRIORITY CLAIMS (Check the appropriate box(es) below if claims in that category are listed on the attached sheets)
Domestic support obligations
Claims for domestic support that are owed to or recoverable by a spouse, former spouse, or child of the debtor, or the parent, legal guardian, or responsible relative of such a child, or a governmental unit to whom such a domestic support claim has been assigned to the extent provided in 11 U.S.C. § 507(a)(1).
Extensions of credit in an involuntary case
Claims arising in the ordinary course of the debtor’s business or financial affairs after the commencement of the case but before the earlier of the appointment of a trustee or the order for relief. 11 U.S.C. § 507(a)(3).
Wages, salaries, and commissions
Wages, salaries, and commissions, including vacation, severance, and sick leave pay owing to employees and commissions owing to qualifying independent sales representatives up to $12,475* per person earned within 180 days immediately preceding the filing of the original petition, or the cessation of business, whichever occurred first, to the extent provided in 11 U.S.C. § 507(a)(4).
Contributions to employee benefit plans
Money owed to employee benefit plans for services rendered within 180 days immediately preceding the filing of the original petition, or the cessation of business, whichever occurred first, to the extent provided in 11 U.S.C. § 507(a)(5).
Certain farmers and fishermen
Claims of certain farmers and fishermen, up to $6,150* per farmer or fisherman, against the debtor, as provided in 11 U.S.C. § 507(a)(6).
Deposits by individuals
Claims of individuals up to $2,775* for deposits for the purchase, lease, or rental of property or services for personal, family, or household use, that were not delivered or provided. 11 U.S.C. § 507(a)(7).
Taxes and certain other debts owed to governmental units
Taxes, customs duties, and penalties owing to federal, state, and local governmental units as set forth in 11 U.S.C. § 507(a)(8).
Commitments to maintain the capital of an insured depository institution
Claims based on commitments to the FDIC, RTC, Director of the Office of Thrift Supervision, Comptroller of the Currency, or Board of Governors of the Federal Reserve System, or their predecessors or successors, to maintain the capital of an insured depository institution. 11 U.S.C. § 507 (a)(9).
Claims for death or personal injury while debtor was intoxicated
Claims for death or personal injury resulting from the operation of a motor vehicle or vessel while the debtor was intoxicated from using alcohol, a drug, or another substance. 11 U.S.C. § 507(a)(10).
* Amount subject to adjustment on 4/01/16, and every three years thereafter with respect to cases commenced on or after the date of adjustment.
0 continuation sheets attached

LOGO

B6F (Official Form 6F) (12/07)
In re Dendreon Corporation Case No. 14-12515 (LSS)
,
Debtor
SCHEDULE F—CREDITORS HOLDING UNSECURED NONPRIORITY CLAIMS
State the name, mailing address, including zip code, and last four digits of any account number, of all entities holding unsecured claims without priority against the
debtor or the property of the debtor, as of the date of filing of the petition. The complete account number of any account the debtor has with the creditor is useful to the
trustee and the creditor and may be provided if the debtor chooses to do so. If a minor child is a creditor, state the child’s initials and the name and address of the child’s
parent or guardian, such as “A.B., a minor child, by John Doe, guardian.” Do not disclose the child’s name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m). Do not
include claims listed in Schedules D and E. If all creditors will not fit on this page, use the continuation sheet provided.
If any entity other than a spouse in a joint case may be jointly liable on a claim, place an “X” in the column labeled “Codebtor,” include the entity on the appropriate
schedule of creditors, and complete Schedule H—Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be
liable on each claim by placing an “H,” “W,” “J,” or “C” in the column labeled “Husband, Wife, Joint, or Community.”
If the claim is contingent, place an “X” in the column labeled “Contingent.” If the claim is unliquidated, place an “X” in the column labeled “Unliquidated.” If the
claim is disputed, place an “X” in the column labeled “Disputed.” (You may need to place an “X” in more than one of these three columns.)
Report the total of all claims listed on this schedule in the box labeled “Total” on the last sheet of the completed schedule. Report this total also on the Summary of
Schedules and, if the debtor is an individual with primarily consumer debts, report this total also on the Statistical Summary of Certain Liabilities and Related Data.
Check this box if debtor has no creditors holding unsecured claims to report on this Schedule F.
CREDITOR’S NAME, C Husband, Wife, Joint, or Community C U D
O O N I
MAILING ADDRESS D H N L S
E DATE CLAIM WAS INCURRED AND T I P
INCLUDING ZIP CODE, B W CONSIDERATION FOR CLAIM. IF CLAIM I Q U
AND ACCOUNT NUMBER T J N U T AMOUNT OF CLAIM
O IS SUBJECT TO SETOFF, SO STATE. G I E
(See instructions above.) C
R E D D
N A
Account No. T T
E
D
See Schedule F Attachment
—
624,050,463.03
Account No.
Account No.
Account No.
Subtotal
0 continuation sheets attached 624,050,463.03
(Total of this page)
Total
(Report on Summary of Schedules) 624,050,463.03

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim ABC IMAGING OF WASHINGTON, ABC IMAGING INC. PO BOX 890623 CHARLOTTE NC 28289 TRADE PAYABLE $323.47
ABGENICS, INC. 42245 REMINGTON AVE. SUITE 13 TEMECULA CA 92590 TRADE PAYABLE $10,845.84
ACCELLENT ENDOSCOPY 4776 SOLUTIONS CENTER # 203520 DALLAS TX 75320 TRADE PAYABLE $71,157.02 ACCURATE SOLUTIONS - ATLANTA, INC. 6303 WOODLORE DR NW ACWORTH GA 30101 TRADE PAYABLE $14,710.52 ADP SCREENING & SELECTION
SERVICES PO BOX 645177 CINCINNATI OH 45264 TRADE PAYABLE X $0.00 ADP, INC. PO BOX 842875 BOSTON MA 02284 TRADE PAYABLE X $0.00 AEROTEK, INC. 757 3RD AVENUE #201 NEW YORK NY 10017 TRADE PAYABLE X $0.00 AGENCIES OF CHANGE, LLC TECHNOLOGY SPA PO BOX 671498 DALLAS TX 75267 TRADE PAYABLE $1,465.00 AGILENT TECHNOLOGIES FILE 73738 PO BOX 60000 SAN FRANCISCO CA 94160 TRADE PAYABLE $849.60 AGR ADVISORS, INC. PO BOX 52235 NEWARK NJ 07101 TRADE PAYABLE $2,497.60 AHAB SHIPPING, INC. 309 S CLOVERDALE ST #D1 SEATTLE WA 98108 TRADE PAYABLE X $0.00 AIRGAS DRY ICE PO BOX 951873 DALLAS TX 75395 TRADE PAYABLE $402.31
AIRGAS USA, LLC (SOUTH DIVISION) PO BOX 532609 ATLANTA GA 30353 TRADE PAYABLE $12,397.38
AIRGAS USA, LLC (WEST DIVISION) PO BOX 7423 PASADENA CA 91109 TRADE PAYABLE $29,844.91 ALL 1 VENDING, INC. PO BOX 1981 DOUGLASVILLE GA 30133 TRADE PAYABLE $13,721.76 ALL TEMP MECHANICAL, INC 527 N.W. 196TH PL. SHORELINE WA 98177 TRADE PAYABLE $438.00 ALS GROUP USA, CORP. PO BOX 975444 DALLAS TX 75397-5444 TRADE PAYABLE $1,210.00
4 EMBARCADERO CENTER SUITE
ALTO LITIGATION, PC 1400 SAN FRANCISCO CA 94111 TRADE PAYABLE $54,494.25 AMERICAN RED CROSS PO BOX 100805 PASADENA CA 91189 TRADE PAYABLE $495,321.00 APPISTRY, INC. 1141 S 7TH ST #300 ST LOUIS MO 63104 TRADE PAYABLE $866.67 ARAGEN BIOSCIENCE, INC 380 WOODVIEW AVENUE MORGAN HILL CA 95037 TRADE PAYABLE $4,650.00 ARAMARK REFRESHMENT SERVICES, LLC 11118 117TH PLACE NE KIRKLAND WA 98033 TRADE PAYABLE $1,966.75 ARAMARK REFRESHMENT SERVICES, LLC (CA) 17044 MONTANERO AVE, SUITE #4 CARSON CA 90746 TRADE PAYABLE $1,634.18 ARNOLD & PORTER LLP PO BOX 759451 BALTIMORE MD 21275 TRADE PAYABLE X $0.00 ASSOCIATED MEDICAL
PROFESSIONALS OF NY, LLC 1226 EAST WATER STREET SYRACUSE NY 13210 TRADE PAYABLE X $0.00 AT&T PO BOX 5019 CAROL STREAM IL 60197 TRADE PAYABLE $2,230.77 5670 PEACHTREE DUNWOODY RD
ATLANTA BLOOD SERVICES STE 1075 ATLANTA GA 30342 TRADE PAYABLE $2,800.00 AVAION, INC. 4280 OAKVIEW LANE N PLYMOUTH MN 55442 TRADE PAYABLE $12,875.00 1325 SOUTH CLIFF
AVERA MCKENNAN P.O. BOX 5045 AVENUE SIOUX FALLS SD 57117 TRADE PAYABLE $7,500.00 AVIDEX 13555 BEL - RED ROAD STE 226 BELLEVUE WA 98005 TRADE PAYABLE $4,498.11
BAKERSFIELD MEMORIAL HOSPITAL FILE 55653 LOS ANGELES CA 90074 TRADE PAYABLE $9,000.00 700 S. FLOWER
BANK OF NEW YORK MELLON TRUST ATTENTION: CORPORATE TRUST TRUSTREET, SUITE 500 LOS ANGELES CA 90017 BOND DEBT $620,000,000.00 BATCHELOR & KIMBALL, INC. P.O. BOX 70 LITHONIA GA 30058 TRADE PAYABLE $1,650.00 BD BIOSCIENCES PO BOX 100921 PASADENA CA 91189 TRADE PAYABLE $5,914.35 BECKMAN COULTER INC DEPT CH 10164 PALATINE IL 60055 TRADE PAYABLE $10,943.50
BEKINS NORTHWEST 6501 216TH ST SW MOUNTLAKE TERRACE WA 98043 TRADE PAYABLE $360.00
1 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim BENAROYA RESEARCH INSTITUTE AT BRI # 3067500 (P10-2) SCOTT
VIRGINIA MASON SPALDING 1201 9TH AVENUE SEATTLE WA 98101 TRADE PAYABLE X $0.00 170 S.
INDEPENDENCE JONATHAN D. THE CURTIS MALL W. SUITE
BILL JENKINSON MARGOLIS EDELSTEIN HERBST CENTER 400E PHILADELPHIA PA 19106-3337 THREATENED LITIGATION X X X UNKNOWN BIOCLINICA, INC. P.O. BOX 824134 PHILADELPHIA PA 19182 TRADE PAYABLE $5,544.15 BIOLEGEND 9727 PACIFIC HEIGHTS BLVD. SAN DIEGO CA 92121 TRADE PAYABLE $308.75 BIOMEDICAL RESEARCH ALLIANCE
OF NEW YORK LLC 1981 MARCUS AVENUE, SUITE 210 LAKE SUCCESS NY 11042 TRADE PAYABLE X $0.00 BIOMERIEUX INC PO BOX 500308 ST.LOUIS MO 63150 TRADE PAYABLE X $0.00
13319 COLLECTIONS
BIORELIANCE BANK OF AMERICA CENTER DRIVE CHICAGO IL 60693 TRADE PAYABLE $7,030.95 BIO-TEK INSTRUMENTS INC PO BOX 29817 NEW YORK NY 10087 TRADE PAYABLE $406.82
BLOOD CENTERS OF AMERICA, INC. PO BOX 84-5732 BOSTON MA 02284 TRADE PAYABLE $292,200.00 BLOOD SYSTEMS LABORATORIES PO BOX 53022 PHOENIX AZ 85072 TRADE PAYABLE $3,080.00 BRIDGE ASSOCIATES
INTERNATIONAL, LLC 1375 CANAL ROAD PRINCESTON NJ 08540 TRADE PAYABLE $11,534.05 BRIGHAM & WOMEN’S HOSPITAL PO BOX 3715 BOSTON MA 02241 TRADE PAYABLE $15,975.00 BUILDINGI 188 106TH AVENUE NE STE 610 BELLEVUE WA 98004 TRADE PAYABLE $1,463.50 BUNZL DISTRIBUTION-SEATTLE PO BOX 59709 LOS ANGELES CA 90074 TRADE PAYABLE $14,108.19 C.B. TANG M.D.,INC. DBA
CAREONSITE 1250 PACIFIC AVE. LONG BEACH CA 90813 TRADE PAYABLE $962.00 CABLEVISION PO BOX 371378 PITTSBURGH PA 15250 TRADE PAYABLE $77.81 2520 RENAISSANCE BOULEVARD
CADIENT GROUP, INC. STE 100 KING OF PRUSSIA PA 19406 TRADE PAYABLE X $0.00 CANGENE BIO PHARMA 1111 S PACA ST BALTIMORE MD 21230 TRADE PAYABLE $19,124.64 CARDINAL HEALTH 200, LLC PNC BANK CORPORATE P.O. BOX 643983 PITTSBURGH PA 15264 TRADE PAYABLE X $0.00 CDW PO BOX 75723 CHICAGO IL 60675 TRADE PAYABLE $1,036.65 P.O. BOX 52187 / BUSINESS
CENTURYLINK SERVICES PHOENIX AZ 85072 TRADE PAYABLE $892.81 CHARLES RIVER LABORATORIES GPO BOX 27812 NEW YORK NY 10087 TRADE PAYABLE $10,495.00 CHARTER MEDICAL, LTD. P.O. BOX 417394 BOSTON MA 02241 TRADE PAYABLE X $0.00 CHEM TREAT, INC./TRIDENT
TECHNOLOGIES 15045 COLLECTIONS CENTER DR. CHICAGO IL 60693 TRADE PAYABLE $245.70 ATTN: K.
C/O KYROS LAW WILLIAM
CHRISTOPHER BOLLING, ET AL RE: BOLLING V DENDREON OFFICES KYROS 17 MILES RD HINGHAM MA 02043 LITIGATION X X X UNKNOWN CINTAS CORPORATION P.O. BOX 740855 CINCINNATI OH 45274 TRADE PAYABLE $1,602.70 CISCO SYSTEMS INC PO BOX 911869 DALLAS TX 75391 TRADE PAYABLE $3,487.42
CIT TECHNOLOGY FINANCE SERVICES P.O. BOX 100706 PASADENA CA 91189 TRADE PAYABLE $1,859.94 CITY ELECTRIC SUPPLY COMPANY P.O. BOX 71465 NORTH CHARLESTON SC 29415 TRADE PAYABLE $441.13 DEPARTMENT OF WATERSHED
CITY OF ATLANTA MANAGEMENT P.O. BOX 105275 ATLANTA GA 30348 TRADE PAYABLE $227.84 CITY OF HOPE NATIONAL MEDICAL ATTN: OFFICE OF CLINICAL TRIAL 1500 EAST DUARTE
CENTER FINANCE ROAD DUARTE CA 91010 TRADE PAYABLE X $0.00 CITY OF SEAL BEACH 211 EIGHT STREET SEAL BEACH CA 90740 TRADE PAYABLE $1,855.09 CITY OF SEATTLE - UTILITIES ESD FINANCE DIVISION PO BOX 34016 SEATTLE WA 98124 TRADE PAYABLE $5,386.05
2 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim CITY OF SEATTLE - UTILITIES BOX
34017 DEPT OF FINANCE PO BOX 34017 SEATTLE WA 98124 TRADE PAYABLE $43,.66 CITY OF UNION CITY 5047 UNION STREET UNION CITY GA 30291 TRADE PAYABLE $12,841.71 CLEANROOM MANAGEMENT
ASSOCIATES INC 415 OLD WASHOE CIRCLE CARSON CITY NV 89704 TRADE PAYABLE $5,080.00
CLEVELAND CLINIC FOUNDATION CANCER RESEARCH PO BOX 931568 CLEVELAND OH 44193 TRADE PAYABLE X $0.00 CLINICAL RESOURCE NETWORK PO BOX 75314 CHICAGO IL 60675 TRADE PAYABLE X $0.00 COGHLAN GROUP, INC. 1500 BUSINESS PARK DRIVE BASTROP TX 78602 TRADE PAYABLE $79,816.85 COMCAST PO BOX 37601 PHILADELPHIA PA 19101 TRADE PAYABLE $62.87 2200 RENAISSANCE BLVD. SUITE
COMMUNICATIONS MEDIA, INC. 160 KING OF PRUSSIA PA 19406 TRADE PAYABLE $14,908.26 UROLOGY RESEARCH / DONNA
COMMUNITY CARE PHYSICIANS, PC JULIAN PO BOX 10025 ALBANY NY 12201 TRADE PAYABLE X $0.00 CL#4600, PO BOX
COMPAS, INC. ATTN: ACCOUNTS RECIEVABLE 95000 PHILADELPHIA PA 19195 TRADE PAYABLE $37,782.02 COMPUTER PROTECTION 1215 PACIFIC OAKS PLACE SUITE
TECHNOLOGY INC. 106 ESCONDIDO CA 92029 TRADE PAYABLE $2,669.00 COMPUTERSHARE INC ACCOUNTING DEPARTMENT P.O. BOX 360857 PITTSBURGH PA 15251 TRADE PAYABLE $9,926.93
CONSOLIDATED DISPOSAL SERVICE PO BOX 78829 PHOENIX AZ 85062 TRADE PAYABLE $697.95 CONVERGINT TECHNOLOGIES 35257 EAGLE WAY CHICAGO IL 60678 TRADE PAYABLE $1,204.33 COOLEY LLP 101 CALIFORNIA ST 5TH FL SAN FRANCISCO CA 94111 TRADE PAYABLE X $0.00 COVANCE CENTRAL LABORATORY
SER PO BOX 820824 PHILADELPHIA PA 19182 TRADE PAYABLE $1,755.49 CROWN LIFT TRUCKS CROWN EQUIPMENT CORP. P.O. BOX 641173 CINCINNATI OH 45264 TRADE PAYABLE $143.37 CRYSTAL SPRINGS DS WATERS OF AMERICA, INC. PO BOX 660579 DALLAS TX 75266 TRADE PAYABLE $227.65 CSS BUILDING SERVICES, INC. 12 STULTS ROAD, SUITE 132 DAYTON NJ 08810 TRADE PAYABLE $35,247.00 DAVIS WRIGHT TREMAINE LLP 1201 THIRD AVENUE SEATTLE WA 98101 TRADE PAYABLE $806.41
DIAMOND CLEANING SERVICES, INC. 17520 155TH AVE SE RENTON WA 98058 TRADE PAYABLE $15,105.42 3009 DOUGLAS
DIRECT TECHNOLOGY DIRECT APPS, INC. BLVD., STE. 300 ROSEVILLE CA 95661 TRADE PAYABLE $149,952.00 DIRECTV PO BOX 60036 LOS ANGELES CA 90060 TRADE PAYABLE $54.64 DK PIERCE & ASSOCIATES, INC 112 N. NINTH STREET
ZIONSVILLE IN 46077 TRADE PAYABLE $1,040.00 DLA PIPER LLP (US) PO BOX 75190 BALTIMORE MD 21275 TRADE PAYABLE X $0.00 DOCUMENT TECHNOLOGIES, LLC DTI P.O. BOX 935151 ATLANTA GA 31193 TRADE PAYABLE $95,821.70 DOOGAN, INC J.P.‘S VENDING 3 BURNHAM ROAD MORRIS PLAINS NJ 07950 TRADE PAYABLE $1,344.00
DUKE UNIVERSITY MEDICAL CENTER DIVISION OF MEDICAL ONCOLOGY DUMC 3476 DURHAM NC 27710 TRADE PAYABLE X $0.00 ECLAT INTEGRATED SOFTWARE
SOLUTIONS, INC. 10707 CORPORATE DR. STAFFORD TX 77477 TRADE PAYABLE X $0.00 C/O J2 GLOBAL
EFAX CORPORATE COMMUNICATIONS, INC. PO BOX 51873 LOS ANGELES CA 90051 TRADE PAYABLE $1,386.06
ENERGY SYSTEMS SOUTHEAST, LLC 3235 VETERANS CIRCLE BIRMINGHAM AL 35235 TRADE PAYABLE $9,233.00 ERNST & YOUNG LLP 999 Third Avenue Suite 3500 Seattle WA 98104 - 4086 TRADE PAYABLE X $0.00 EUROFINS LANCASTER
LABORATORIES DEPT. #1999 P.O. BOX 11407 BIRMINGHAM AL 35246 TRADE PAYABLE $1,300.00 EVERBANK COMMERCIAL FINANCE, INC. PO BOX 911608 DENVER CO 80291 TRADE PAYABLE $387.44 FEDEX PO BOX 94515 PALATINE IL 60094 TRADE PAYABLE X $0.00
3 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim FEDEX FREIGHT INC. DEPT LA 21415 PASADENA CA 91185 TRADE PAYABLE X $0.00 FENWAL INC 26762 NETWORK PLACE CHICAGO IL 60673 TRADE PAYABLE $64,528.72 FENWICK & WEST LLP PO BOX 742814 LOS ANGELES CA 90074 TRADE PAYABLE $1,037.69 801 PENNSYLVANIA AVE NW STE
FERGUSON STRATEGIES LLC 230 WASHINGTON DC 20004 TRADE PAYABLE $15,000.00 515 S. FLOWER STREET, 32ND
FIFTH STREET PROPERTIES LLC FLOOR LOS ANGELES CA 90071 TRADE PAYABLE X $36,837.01 FILTERFRESH COFFEE 204 COLUMBUS AVENUE ROSELLE NJ 07203 TRADE PAYABLE $781.20 FIRST CLASS VENDING INC. 6875 SUVA STREET BELL GARDENS CA 90201 TRADE PAYABLE $3,220.17 FISHER BIOSERVICES INC PO BOX 418395 BOSTON MA 02241 TRADE PAYABLE $14,777.70
FISHER CLINICAL SERVICES, INC 13741 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 TRADE PAYABLE $5,061.68
13551 COLLECTIONS
FISHER SCIENTIFIC ACCT# 713614 - 004 CTR DR. CHICAGO IL 60693 TRADE PAYABLE $4,849.83 FLW OF PA, INC. 527 W. LANCASTER AVE FRAZER PA 19355 TRADE PAYABLE $5,181.95 GARRATT CALLAHAN COMPANY 50 INGOLD ROAD BURLINGAME CA 94010 TRADE PAYABLE $50.00 SOUTHERN CALIFORNIA GAS
GAS COMPANY COMPANY PO BOX C MONT PK CA 91756 TRADE PAYABLE $13,671.20 GENERAL ELECTRIC CAPITAL
CORPORATION PO BOX 642555 PITTSBURGH PA 15264 TRADE PAYABLE $1,938.15 GENERAL UNDERGROUND FIRE
PROTECTION INC PO BOX 29830 ANAHEIM CA 92809 TRADE PAYABLE $1,775.46 GEORGIA NATURAL GAS PO BOX 105445 ATLANTA GA 30348 TRADE PAYABLE $20,210.36
WOMBLE CARLYLE 222 DELAWARE MARK L. DESGROSSEILLIERS & SANDRIDGE & RICE, AVENUE, SUITE
GLAXOSMITHKLINE, LLC MATTHEW P. WARD LLP 1501 WILMINGTON DE 19801 LITIGATION X X X UNKNOWN GLOBAL EQUIPMENT COMPANY PO BOX 905713 CHARLOTTE NC 28290 TRADE PAYABLE $99.09 GLOBAL EXPERIENCE SPECIALISTS, INC. BANK OF AMERICA PO BOX 96174 CHICAGO IL 60693 TRADE PAYABLE $6,835.16 GOURMONDO CATERING CO. 309 S. CLOVERDALE SEATTLE WA 98108 TRADE PAYABLE $305.72
GRAINGER INC PO BOX 419267 DEPT 753 - 851035956 KANSAS CITY MO 64141 TRADE PAYABLE $4,319.26 17607 GOLD PLAZA, GU RESEARCH NETWORK LLC LYNDSAY MORTON STE 101 OMAHA NE 68130 TRADE PAYABLE X $0.00
GUARDSMARK INC PO BOX 11407 BIRMINGHAM AL 35246 TRADE PAYABLE X $0.00 12902 MAGNOLIA
H. LEE MOFFITT CANCER CENTER MRC - 4 RES ADMIN DRIVE TAMPA FL 33612 TRADE PAYABLE X $0.00
HEALTH POLICY STRATEGIES, INC. 8100 SPLIT OAK DRIVE BETHESDA MD 20817 TRADE PAYABLE $2,428.20 HEALTH RESEARCH INC. ROSWELL ELM AND CARLTON
PARK DIVISION ATTN: JOHN T. BLANDINO, MS, CRA STREETS BUFFALO NY 14263 TRADE PAYABLE X $0.00
HEMACARE CORPORATION 15350 SHERMAN WAY, SUITE 350 VAN NUYS CA 91406 TRADE PAYABLE $27,000.00 2799 WEST GRAND BLVD, HENRY FORD HEALTH SYSTEM PALLISTER PLACE T - 139 DETROIT MI 48202 TRADE PAYABLE $2,210.00 HOGAN LOVELLS US LLP 555 THIRTEENTH ST NW WASHINGTON DC 20004 TRADE PAYABLE X $0.00 600 PEACHTREE ST, HUNTON & WILLIAMS, LLP. BANK OF AMERICA PLAZA N.E. SUITE 4100 ATLANTA GA 30308 TRADE PAYABLE X $0.00 HYATT LEGAL PLANS INC. PO BOX 78000 DEPT. 781523 DETROIT MI 48278 TRADE PAYABLE X $0.00 INDIANA UNIVERSITY CLINICAL TRIALS OFFICE PO BOX 660326 INDIANAPOLIS IN 46266 TRADE PAYABLE $600.00
4 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim INGALLINA’S BOX LUNCH INC 135 S LUCILE ST SEATTLE WA 98108 TRADE PAYABLE $205.59 INMARK LLC PO BOX 536888 ATLANTA GA 30353 TRADE PAYABLE $6,488.24 INNOVATION MANAGEMENT
GROUP, INC. 179 NIBLICK ROAD, #454 PASO ROBLES CA 93446 TRADE PAYABLE $57.53
INSITE QUALITY ASSURANCE, INC. 2205 197TH AVE SE SAMMAMISH WA 98075 TRADE PAYABLE $9,044.00
INSTRUMENT TECHNOLOGIES INC 9225 CHINDEN BLVD, STE E BOISE ID 83714 TRADE PAYABLE $325.00 INTEGRATED SALES AND
MARKETING CONSULTANTS, LLC 50 KENZEL AVENUE NUTLEY NJ 07110 TRADE PAYABLE $96,362.00 INTELLIGENT ACCESS SYSTEMS OF
NORTH CAROLINA, LLC 256 HEIN DR GARNER NC 27529 TRADE PAYABLE $326.55 INTERNATIONAL BUSINESS
MACHINES CORPORATION PO BOX 676673 DALLAS TX 75267 TRADE PAYABLE $1,023.25 INTERPLAN AG LANDSBERGER STRASSE 155 MUNCHEN D80687 Germany TRADE PAYABLE $111.89 3950 SORRENTO VALLEY BLVD. STE
INVIVOGEN A SAN DIEGO CA 92121 TRADE PAYABLE $189.00 IRON MOUNTAIN INC. PO BOX 27129 NEW YORK NY 10087 TRADE PAYABLE $2,401.23 875 GREENTREE
ITXM DIAGNOSTICS FIVE PARKWAY CENTER ROAD PITTSBURGH PA 15220 TRADE PAYABLE $39,150.00 JIBE CONSULTING, INC. 5000 MEADOWS ROAD, STE 300 LAKE OSWEGO OR 97035 TRADE PAYABLE $2,402.50
JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS
SCHOOL OF MEDICINE C/O BANK OF AMERICA CENTER DRIVE CHICAGO IL 60693 TRADE PAYABLE X $0.00 JOHNSON CONTROLS, INC. PO BOX 730068 DALLAS TX 75373 TRADE PAYABLE $1,948.76 JONES DAY PO BOX 70294 CLEVELAND OH 44190 TRADE PAYABLE $225.00 KAYE - SMITH PO BOX 956 RENTON WA 98057 TRADE PAYABLE X $0.00 KEY AIR CONDITIONING
CONTRACTORS, INC. 10905 LAUREL AVE SANTA FE SPRINGS CA 90670 TRADE PAYABLE $11,200.00 KEY BIOLOGICS, LLC 1256 UNION AVENUE, SUITE 200 MEMPHIS TN 38104 TRADE PAYABLE $2,390.00 KILPATRICK TOWNSEND & STOCKTON LLP DEPT #34542, P.O. BOX 39000 SAN FRANCISCO CA 94139 TRADE PAYABLE X $0.00 KING & SPALDING, LLP PO BOX 116133 ATLANTA GA 30368 TRADE PAYABLE X $0.00 KING COUNTY FINANCE ROOM 600 500 FOURTH AVE SEATTLE WA 98104 TRADE PAYABLE $1,037.92 475 SANSOME
KINSALE HOLDINGS, INC SUITE 700 STREET SAN FRANCISCO CA 94111 TRADE PAYABLE X $0.00 KORN/FERRY INTERNATIONAL NW 5064 PO BOX 1450 MINNEAPOLIS MN 55485 TRADE PAYABLE $5,309.00 LABORATORY CORPORATION OF
AMERICA HOLDINGS PO BOX 12140 BURLINGTON NC 27216 TRADE PAYABLE $35,239.90 LABWARE INC #3 ML RD, STE 102 WILMINGTON DE 19806 TRADE PAYABLE $24,966.42 2950 ATLANTA ROAD
LASHUNDA BANKS, ET AL. ATTN JEFFREY G. CASURELLA SE SMYRNA GA 30080 - 3655 LITIGATION X X X UNKNOWN
LEVEL 3 COMMUNICATIONS, INC. P.O. BOX 910182 DENVER CO 80291 TRADE PAYABLE $393.90 COMPASS PROFESSIONAL HEALTH 3102 OAK LAWN, LIFE ACCOUNT, LLC SERVICES SUITE 215 DALLAS TX 75219 TRADE PAYABLE $39.00 LIFE STREAM ATTN: ACCOUTS RECEIVABLE PO BOX 1429 SAN BERNARDINO CA 92402 TRADE PAYABLE $8,790.00 12088 COLLECTION
LIFE TECHNOLOGIES CORPORATION C/O BANK OF AMERICA CENTER DR CHICAGO IL 60693 TRADE PAYABLE X $0.00
LIZ WILSON CLINICAL RESEARCH INC. 737 WESTWOOD DR SANTA BARBARA CA 93109 TRADE PAYABLE X $0.00
5 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim LONZA WALKERSVILLE, INC 12261 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 TRADE PAYABLE $888.05 419 LAFAYETTE STREET, 2ND
MALECARE, INC. FLOOR NEW YORK NY 10003 TRADE PAYABLE $2,083.33 MANAGED CARE & HEALTHCARE
COMMUNICATIONS, LLC. 666 PLAINSBORO ROAD, STE 300 PLAINSBORO NJ 08536 TRADE PAYABLE $62,500.00 MARIA DE SANTIS KUNDRATSTRASSE 3 WIEN AUSTRIA TRADE PAYABLE $4,422.92 MATTHEW COOPERBERG, MD 425 SPRUCE ST. SAN FRANCISCO CA 94118 TRADE PAYABLE $1,053.08 MAXSAM INC 6947 COAL CREEK PARKWAY SE SUITE 3300 NEWCASTLE WA 98059 TRADE PAYABLE $9,720.00 MAYO CLINIC PO BOX 860334 MINNEAPOLIS MN 55486 TRADE PAYABLE X $0.00
MCMASTER-CARR SUPPLY COMPANY PO BOX 7690 CHICAGO IL 60680 TRADE PAYABLE $451.22 600 UNIVERSITY
MCNAUL EBEL NAWROT & HELGREN ONE UNION SQ STREET STE 2700 SEATTLE WA 98101 TRADE PAYABLE $34,719.05 MEDPRO SYSTEMS, LLC 100 STIERLI COURT, SUITE 100 MT. ARLINGTON NJ 07856 TRADE PAYABLE $6,291.35 MERCER (US) INC. PO BOX 730212 DALLAS TX 75373 TRADE PAYABLE X $0.00 MESA LABORATORIES, INC. 12100 W 6TH AVE LAKEWOOD CO 80228 TRADE PAYABLE $1,048.67 MESA MONITORING, INC. 12100 W 6TH AVE LAKEWOOD CO 80228 TRADE PAYABLE $880.90 MESO SCALE DIAGNOSTICS, LLC. ACCOUNTS RECEIVABLE PO BOX 75112 BALTIMORE MD 21275 TRADE PAYABLE $10,073.84 METTLER TOLEDO 22670 NETWORK PLACE CHICAGO IL 60673 TRADE PAYABLE $963.48 130 TOWN CENTER DRIVE, SUITE
MICHIGAN INSTITUTE OF UROLOGY 101 TROY MI 48084 TRADE PAYABLE X $0.00 MITSUBISHI ELECTRIC & 25480 NETWORK
ELECTRONICS USA INC. MEUS GROUP 03 PLACE CHICAGO IL 60673 TRADE PAYABLE $107.75 MOBILE MINI LLC PO BOX 7144 PASADENA CA 91109 TRADE PAYABLE $123.86 MORRIS, NICHOLS, ARSHT & 1201 NORTH MARKET STREET
TUNNELL LLP SUITE 1600 WILMINGTON DE 19801 TRADE PAYABLE X $0.00 DEPT OF UROLOGY, MOUNT SINAI SCHOOL OF MEDICINE ONE GUSTAVE L. LEVY PLACE BOX 1272 NEW YORK NY 10029 TRADE PAYABLE X $0.00 NATIONAL ONCOLOGY
CONSULTANTS 8228 MAYFIELD RD – SUITE 2A CHESTERLAND OH 44026 TRADE PAYABLE $5,000.00 NEAL SHORE, MD 4 NELSON COURT MYRTLE BEACH CA 29572 TRADE PAYABLE $4,500.00 NEW YORK BLOOD CENTER PO BOX 9674 UNIONDALE NY 11553 TRADE PAYABLE $61,470.00 NEW YORK UNIVERSITY SCHOOL OF
MEDICINE BANK OF AMERICA PO BOX 415026 BOSTON MA 02241 TRADE PAYABLE X $0.00 NIXON PEABODY LLP PO BOX 28012 NEW YORK NY 10087 TRADE PAYABLE X $0.00 NORTH COAST ELECTRIC PO BOX 34399 SEATTLE WA 98124 TRADE PAYABLE $655.22 13800 TUKWILA
BRINTON BUSINESS VENTURES, INTERNATIONAL
NORTHWEST COFFEE SERVICES INC. BLVD TUKWILA WA 98168 TRADE PAYABLE $769.41 NORTHWEST MEDICAL SPECIALTIES, 1624 SOUTH I STREET
PLLC RESEARCH DEPT # 305 TACOMA WA 98405 TRADE PAYABLE $19,200.00 NORTHWEST RADIATION SERVICES, INC. 11539 PALATINE AVE N SEATTLE WA 98133 TRADE PAYABLE $225.00 NOVITEX ENTERPRISE SOLUTIONS, INC. P.O. BOX 845801 DALLAS TX 75284 TRADE PAYABLE $9,296.78 #401, 1228 KENSINGTON ROAD
NULLI SECUNDUS INC NW CALGARY T2N 3P7 CANADA TRADE PAYABLE $35,304.75 OAG AVIATION WORLDWIDE LLC 24336 NETWORK PLACE CHICAGO IL 60673 TRADE PAYABLE $812.50 OHA RECEIPTING UNIT/DRUG
REBATE 500 SUMMER ST NE E-08 SALEM OR 97301-1077 TRADE PAYABLE $30,387.20 ONCOLOGY SPECIALISTS SC P.O. BOX 736 PARK RIDGE IL 60068 TRADE PAYABLE X $0.00
6 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim ONEBLOOD, INC PO BOX 628342 ORLANDO FL 32862 TRADE PAYABLE $54,650.00 OPTIMUM LIGHTPATH CABLEVISION LIGHTPATH, INC. PO BOX 360111 PITTSBURGH PA 15251 TRADE PAYABLE $1,042.50 ORACLE AMERICA INC. PO BOX 44471 SAN FRANCISCO CA 94144 TRADE PAYABLE $43,806.72 2400 HARTMAN
OREGON UROLOGY INSTITUE, P.C. DIVISION OF CLINICAL RESEARCH LANE, STE 101 SPRINGFIELD OR 97477 TRADE PAYABLE X $0.00
PACIFIC OFFICE AUTOMATION (OR) 14747 NW GREENBRIER PKWY BEAVERTON OR 97006 TRADE PAYABLE $1,231.69 PACIFIC OFFICE AUTOMATION INC
(CA) PO BOX 31001-0273 PASADENA CA 91110 TRADE PAYABLE $7,998.80 PAREXEL INTERNATIONAL, LLC 9268 PAYSPHERE CIRCLE CHICAGO IL 60674 TRADE PAYABLE $120,096.83 PATRICK OBUKOWICZ 620 N 42ND ST. UNIT B SEATTLE WA 98103 TRADE PAYABLE $1,534.62 PAYER SCIENCES, LLC 217 HALLS MILL ROAD LEBANON NJ 08833 TRADE PAYABLE $7,500.00
PEARSON CONSULTING GROUP, LLC 7701 ESCALA DRIVE AUSTIN TX 78735 TRADE PAYABLE $2,000.00 PERFICIENT, INC. BOX 200026 PITTSBURGH PA 15251 TRADE PAYABLE $2,450.00 PHARMACEUTICAL RESEARCH
ASSOCIATES, INC P.O. BOX 200072 DALLAS TX 75320 TRADE PAYABLE X $0.00
PIEDMONT - BRIDGEWATER, NJ, LLC. 2129 PAYSPHERE CIRCLE CHICAGO IL 60674 TRADE PAYABLE X $4,003.42 PLANTSCAPES, INC 1127 POPLAR PL S SEATTLE WA 98144 TRADE PAYABLE $26.01 POLARIS MANAGEMENT PARTNERS, LLC 100 BROADWAY, 7 FL NEW YORK NY 10005 TRADE PAYABLE $3,100.00
PORZIO BROMBERG & NEWMAN, PC 100 SOUTHGATE PARKWAY MORRISTOWN NJ 07962 TRADE PAYABLE X $0.00
PREMIER CARES FOUNDATION INC. PO BOX 93 PLEASANT VALLEY NY 12569 TRADE PAYABLE $5,000.00 PREMIER MEDICAL GROUP OF THE
HUDSON VALLEY 1 COLUMBIA ST, SUITE 390 POUGHKEEPSIE NY 12601 TRADE PAYABLE X $0.00
PRICEWATERHOUSECOOPERS, LLP PO BOX 514038 LOS ANGELES CA 90051 TRADE PAYABLE X $0.00 PRINTWEST INC PO BOX 692 WOODINVILLE WA 98072 TRADE PAYABLE $3,053.48 ATTN: D. COMPTON, K.HEYMAN, 300 DELAWARE AVE
PROCTOR HEYMAN LLP M. ADAMS STE 200 WILMINGTON DE 19801 TRADE PAYABLE $4,653.57 PROGISTICS DISTRIBUTION INC. PO BOX 5045 HAYWARD CA 94540 TRADE PAYABLE $21.69
ACCOUNTS RECEIVABLE 2 GURDWARA AVE., 2 GURDWARA
PROTUS IP SOLUTIONS, INC DEPARTMENT SUITE 300 AVE., SUITE 300 OTTAWA K2E 1A2 CANADA TRADE PAYABLE $84.00 PROVIDENCE PORTLAND MEDICAL
CENTER ATTENTION SUE RICH PO BOX 13993 PORTLAND OR 97213 TRADE PAYABLE X $0.00 PRUDENTIAL OVERALL SUPPLY P.O. BOX 11210 SANTA ANA CA 92711 TRADE PAYABLE $71,095.70 PUGET SOUND BLOOD CENTER 921 TERRY AVE SEATTLE WA 98104 TRADE PAYABLE $1,029.25 PUGET SOUND DISPATCH 74 SOUTH HUDSON SEATTLE WA 98134 TRADE PAYABLE $509.10 PUGET SOUND ENERGY BOT-01H PO BOX 91269 BELLEVUE WA 98009 TRADE PAYABLE $15,209.67 PURETEC INDUSTRIAL WATER 3151 STURGIS ROAD OXNARD CA 93031 TRADE PAYABLE $83.93 QIAGEN INC P.O. BOX 5132 CAROL STREAM IL 60197 TRADE PAYABLE $575.94 ATTN: C/O LEVI & DOUGLAS E 30 BROAD ST, QUINTAL RE: QUINTAL V BAYH KORSINSKY JULIE 24TH FLOOR NEW YORK NY 10004 LITIGATION X X X UNKNOWN R.W. DAVIS OIL CO INC. 4383 LILBUM INDUSTRIAL WAY LILBUM GA 30047 TRADE PAYABLE $2,910.69 RADIANT SYSTEMS INC. 107B - CORPORATE BOULEVARD SOUTH PLAINFIELD NJ 07080 TRADE PAYABLE X $0.00 RAGNI CORPORATION 16779 NE 121ST ST. REDMOND WA 98052 #N/A TRADE PAYABLE $3,840.00 RAININ INSTRUMENT LLC 27006 NETWORK PLACE CHICAGO IL 60673 TRADE PAYABLE $3,652.83
7 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim RAOUL S. CONCEPCION 2801 CHARLOTTE AVENUE NASHVILLE TN 37209 TRADE PAYABLE $3,900.00 RAYMOND H. POCOROBA 68 TURTLEBACK RD CALIFON NJ 07830 TRADE PAYABLE $3,400.00 RECALL TOTAL INFORMATION 015295 COLLECTIONS CENTER
MANAGEMENT, INC DRIVE CHICAGO IL 60693 TRADE PAYABLE $3,340.58 RECOLOGY CLEANSCAPES PO BOX 34260 SEATTLE WA 98124 TRADE PAYABLE $1,575.04 REED SMITH, LLP PO BOX 360110 PITTSBURGH PA 15251 TRADE PAYABLE X $0.00 REDLINE SOLUTIONS, INC. 2000 WYATT DRIVE, SUITE 11 SANTA CLARA CA 95054 TRADE PAYABLE $178.65 REGENTS OF THE UNIVERSITY OF UCSD OFFICE OF CLINICAL TRIAL
CALIFORNIA ADMIN 9444 MEDICAL DRIVE LA JOLLA CA 92037 TRADE PAYABLE X $0.00 REGENTS OF THE UNIVERSITY OF SAN
CALIFORNIA, SAN FR UNIVERSITY OF CA FRANCISCO SAN FRANCISCO CA 94143 TRADE PAYABLE X $0.00 REGENTS OF THE UNIVERSITY OF 13001 EAST 17TH
COLORADO MAIL STOP F547 PLACE AURORA CO 80045 TRADE PAYABLE X $0.00 REGIONAL CANCER CARE
ASSOCIATES LLP FINANCE DEPARTMENT 100 FIRST ST. STE 301 HACKENSACK NJ 07601 TRADE PAYABLE $71,331.00 REPRINTS DESK, INC. DEPT CH 16507 PALATINE IL 60055 TRADE PAYABLE $1,133.81 REPUBLIC SERVICES PO BOX 78829 PHOENIX AZ 85062 TRADE PAYABLE $589.91 920 NORTH KING
RICHARDS, LAYTON & FINGER ONE RODNEY SQUARE STREET WILMINGTON DE 19801 TRADE PAYABLE $12,380.12 United ROBERT J JONES GREENPARK CHARLOTTE ST HELENSBURGH G84 7SE Kingdom TRADE PAYABLE $314.59 RX MOSAIC HEALTH LLC 711 THIRD AVE, 18TH FLOOR NEW YORK NY 10017 TRADE PAYABLE $46,090.39 SAINT - GOBAIN PERFORMANCE
PLASTICS CORPORATION LOCKBOX# 7799 PO BOX 7247 PHILADELPHIA PA 19170 TRADE PAYABLE X $0.00 SARGAS PHARMACEUTICAL
ADHERENCE & COMPLIANCE 6401 TRUXTON AVE SUITE 220 BAKERSFIELD CA 93311 TRADE PAYABLE $34,350.00 SAVVIS COMMUNICATIONS
CORPORATION 13322 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 TRADE PAYABLE $132,716.57 SCS FLOORING SYSTEMS 530 S MAIN STREET #110 ORANGE CA 92868 TRADE PAYABLE $552.64 SEATTLE MAINTENANCE SERVICES, INC. PO BOX 95384 SEATTLE WA 98145 TRADE PAYABLE $200.00 SECURITIES EXCHANGE COMMISSION 100 F ST NE WASHINGTON DC 20549 INVESTIGATION X X X UNKNOWN SEITZ ROSS ARONSTAM & MORITZ
LLP ATTN: COLLINS L. SEITZ WILMINGTON DE 19801 TRADE PAYABLE $3,447.00 SGS LIFE SCIENCE SERVICES PO BOX 2502 CAROL STREAM IL 60132 TRADE PAYABLE X $0.00 LOCKBOX NUMBER
SHAREHOLDER.COM PO BOX 8500 30200 PHILADELPHIA PA 19178 TRADE PAYABLE $2,231.30 SHARP MEMORIAL HOSPITAL ATTN: CATHY WOOD 7901 FROST ST SAN DIEGO CA 92123 TRADE PAYABLE X $0.00 SHRED - IT SHRED - IT USA - LOS ANGELES PO BOX 101007 PASADENA CA 91189 TRADE PAYABLE $470.31 SHRED - IT US JV LLC PO BOX 101007 PASADENA CA 91189 TRADE PAYABLE $905.07 SIDLEY AUSTIN LLP PO BOX 0642 CHICAGO IL 60690 TRADE PAYABLE X $0.00 SIEMENS INDUSTRY, INC. PO BOX 2134 CAROL STREAM IL 60132 TRADE PAYABLE $1,173.00 SIMPLEXGRINNELL DEPT CH 10320 PALATINE IL 60055 TRADE PAYABLE $116.07 RM B - 209, 14 ZHONG HE STREET, SINO BIOLOGICAL, INC. BDA BEIJING 100176 CHINA TRADE PAYABLE $5,108.00 SOURCE HEALTHCARE ANALYTICS, LLC PO BOX 277158 ATLANTA GA 30384 TRADE PAYABLE $57,866.83 SPARKLETTS PO BOX 660579 DALLAS TX 75266 TRADE PAYABLE $483.15 SPRINT PO BOX 219100 KANSAS CITY MO 64121 TRADE PAYABLE $22,292.33 14612 NE 91ST
STAFFORD PRESS WESTERN TAG & LABEL STREET REDMOND WA 98052 TRADE PAYABLE $1,694.97 STAPLES ADVANTAGE DEPT LA PO BOX 83689 CHICAGO IL 60696 TRADE PAYABLE $6,601.60
8 of 10

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule F - Creditors Holding Unsecured Nonpriority Claims
Date Claim was Incurred and Consideration for Claim. If Claim is Subject to
Creditor Name Address1 Address2 Address3 Address4 City State Zip Country Setoff, so State. Contingent Unliquidated Disputed Amount of Claim STERICYCLE INC P.O. BOX 6582 CAROL STREAM IL 60197 TRADE PAYABLE $21,610.87 STERITECH GROUP, INC PO BOX 472127 CHARLOTTE NC 28247 TRADE PAYABLE $834.36 STERLING COURIER SYSTEMS PO BOX 35418 NEWARK NJ 07193 TRADE PAYABLE X $0.00 STOEL RIVES LLP STE 2600 900 SW FIFTH AVE PORTLAND OR 97204 TRADE PAYABLE X $0.00 STRATUSG LLC 7438 SE 40TH MERCER ISLAND WA 98040 TRADE PAYABLE $2,100.00 TAOS MOUNTAIN, INC. PO BOX 225 SANTA CLARA CA 95052 TRADE PAYABLE $132,275.00 TECHNICAL SAFETY SERVICES INC DEPT 33265 PO BOX 39000 SAN FRANCISCO CA 94139 TRADE PAYABLE $4,757.00 1499 BLAKE ST UNIT
TEKNOVARE PRODOP CORPORATION 1 - K DENVER CO 80202 TRADE PAYABLE $60,698.96 THERMO FISHER SCIENTIFIC
(ASHEVILLE) LLC PO BOX 842339 DALLAS TX 75284 TRADE PAYABLE $136.63 THOMAS JEFFERSON UNIVERSITY 1020 LOCUST ST., HOSPTIAL ATTN.: KAREN GOSIK RM# 490 JAH PHILADELPHIA PA 19107 TRADE PAYABLE X $0.00 T-MOBILE P.O. BOX 660252 DALLAS TX 75266 TRADE PAYABLE $4,407.04 TMS HEALTH, LLC C/O ACS P.O. BOX 201322 DALLAS TX 75320 TRADE PAYABLE $1,489.31 TOTALFUNDS BY HASLER P.O. BOX 30193 TAMPA FL 33630 TRADE PAYABLE $1,000.00 TRANE U.S., INC. 3600 PAMMEL CREEK ROAD LA CROSSE WI 54601 TRADE PAYABLE $3,330.59 TRANSCAT, INC. PO BOX 62827 BALTIMORE MD 21264 TRADE PAYABLE $2,857.88 TRANSPERFECT TRANSLATION
INTERNATIONAL, INC 3 PARK AVENUE, 39THFLR NEW YORK NY 10016 TRADE PAYABLE $7,643.37 TRIALOMICS, LLC 900 LENORA ST. UNIT 508 SEATTLE WA 98121 TRADE PAYABLE $1,660.00 TRINITY PARTNERS, LLC 230 THIRD AVE WALTHAM MA 02451 TRADE PAYABLE $124,674.35 TSI INCORPORATED PO BOX 86 SDS 12 - 0764 MINNEAPOLIS MN 55486 TRADE PAYABLE $579.87 1151 ENTERPRISE DR
TULANE MEDICAL CENTER UNIV HEALTHCARE SYSTEM LLC 100 COPPELL TX 75019 TRADE PAYABLE $1,720.00 UNITED BIOSOURCE CORPORATION
(UBC) 3822 SUMMIT KANSAS CITY MO 64111 TRADE PAYABLE X $0.00 UNITED PARCEL SERVICE - UPS PO BOX 894820 LOS ANGELES CA 90189 TRADE PAYABLE $51.50 5841 S MARYLAND
AVE RMW604
UNIVERSITY OF CHICAGO SONYA BOWEN, FINANCIAL ADMIN (MC6091) CHICAGO IL 60637 TRADE PAYABLE X $0.00
UNIVERSITY OF CONNECTICUT ATTN: DAVID LARKIN, RESEARCH 263 FARMINGTON
HEALTH CENTER ADMINISTRATION & FINANCE AVE. MC 5335 FARMINGTON CT 06030 TRADE PAYABLE X $0.00 UNIVERSITY OF NORTH CAROLINA AT FINANCE & BUSINES OPERATIONS: CHAPE
L HILL L.SOLANA 170 MANNING DRIVE CHAPEL HILL NC 27599 TRADE PAYABLE X $0.00 UNIVERSITY OF SOUTHERN SPONSORED PROJECTS 3500 S FIGUEROA
CALIFORNIA ACCOUNTING STREET SUITE 102 LOS ANGELES CA 90089 TRADE PAYABLE X $0.00 UROLOGIC SPECIALISTS OF
OKLAHOMA, INC. 10901 E 48TH STREET SOUTH TULSA OK 74146 TRADE PAYABLE X $0.00 UROLOGICAL ASSOCIATES OF
SOUTHERN ARIZONA 2260 W. ORANGE GROVE RD. TUCSON AZ 85741 TRADE PAYABLE X $0.00 UROLOGY CENTER OF COLORADO, PC 2777 MILE HIGH STADIUM CIRCLE DENVER CO 80211 TRADE PAYABLE X $0.00
UROLOGY CENTERS OF ALABAMA 3485 INDEPENDENCE DRIVE HOMEWOOD AL 35209 TRADE PAYABLE X $0.00
UROLOGY OF VIRGINIA ATTN: LAURIE JACKSON RESEARCH 225 CLEARFIELD AVE VIRGINIA BEACH VA 23462 TRADE PAYABLE X $0.00 US BANK EQUIPMENT FINANCE PO BOX 790448 ST LOUIS MO 63179 TRADE PAYABLE $1,209.24 VARIDESK, LLC PO BOX 3588 COPPELL TX 75019 TRADE PAYABLE $330.04 VEOLIA ES TECHNICAL SOLUTIONS, L.L.C. PO BOX 73709 CHICAGO IL 60673 TRADE PAYABLE $4,029.07
9 of 10

LOGO

B6G (Official Form 6G) (12/07)
In re Dendreon Corporation Case No. 14-12515 (LSS)
, Debtor
SCHEDULE G—EXECUTORY CONTRACTS AND UNEXPIRED LEASES
Describe all executory contracts of any nature and all unexpired leases of real or personal property. Include any timeshare interests. State nature of debtor’s interest in contract, i.e., “Purchaser”, “Agent”, etc. State whether debtor is the lessor or lessee of a lease. Provide the names and complete mailing addresses of all other parties to each lease or contract described. If a minor child is a party to one of the leases or contracts, state the child’s initials and the name and address of the child’s parent or guardian, such as “A.B., a minor child, by John Doe, guardian.” Do not disclose the child’s name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).
Check this box if debtor has no executory contracts or unexpired leases.
Description of Contract or Lease and Nature of Debtor’s Interest. Name and Mailing Address, Including Zip Code, State whether lease is for nonresidential real property. of Other Parties to Lease or Contract State contract number of any government contract.
See Schedule G Attachment
0 continuation sheets attached to Schedule of Executory Contracts and Unexpired Leases

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
21st Century Oncology, LLC 2234 Colonial Blvd Fort Myers FL 33907 Clinical Trial/Study Agreement
3. Med. Abteilung - Zentrum für Onkologie und Clinical Trial/Study Agreement for P11 - 1 Hämatologie, Kaiser Franz Josef - Spital, SMZ - Süd Kundratstrasse 3 A1100 Wien 4MULA Consulting, LLC 765 WARREN STREET WESTFIELD NJ 07090 Professional Services Agreement Abgenix, Inc. 42245 REMINGTON AVE. SUITE 13 TEMECULA CA 92590 Co - Development Agreement Accellent Inc. 4776 Solutions Center # 203520 DALLAS TX 75320 Supply Agreement ADP, Inc PO BOX 842875 BOSTON MA 02284 Payroll Services Agreement Adult & Pediatric Urology 2351 Connecticut Ave. S., Suite 200 Sartell MN 56377 Clinical Trial/Study Agreement Advanced Medical Specialties 8940 North Dendall Drive, Suite 300E Miami FL 33176 Clinical Trial/Study Agreement Advanced Urology, P.C. 11960 Lioness Way, Suite 210 Parker CO 80134 Clinical Trial/Study Agreement for P10 - 3 Advanced Urology, PC 11960 Lioness Way, Suite 210 Parker CO 80134 Clinical Trial/Study Agreement for P12 - 1 Advantage Management Solutions, Inc. 220 COMMERCE DR. SUITE 400 FT WASHINGTON PA 19034 IT Agreement Aerie Canal Consulting, LLC MONTE D. LEVINSON 311 NW 50TH ST. SEATTLE WA 98107 Professional Services Agreement Aerotek Scientific LLC 3689 COLLECTION CTR. DR. CHICAGO IL 60693 Staffing Agency Agreement AES Clean Technology, Inc. 422 STUMP RD MONTGOMERYVILLE PA 18936 Service Agreement Agencies of Change, LLC dba imcÂ² health & wellness Hosting Services Agreement PO BOX 671498 TECHNOLOGY SPA DALLAS TX 75267 Agencies of Change, LLC dba imcÂ² health & wellness Marketing Services Agreement PO BOX 671498 TECHNOLOGY SPA DALLAS TX 75267 Airgas Puritan Medical Division 4007 Paramount Blvd Suite 100 Lakewood CA 90712 Supply Agreement Airgas South, Inc. PO BOX 532609 ATLANTA GA 30353 Supply Agreement Airgas USA, LLC PO BOX 532609 ATLANTA GA 30353 Supply Agreement for 1539 Freezer Airgas USA, LLC PO BOX 532609 ATLANTA GA 30353 Supply Agreement for 1538 Freezer Airgas - East, Inc. 325 McCausland Court Cheshire CT 06410 Supply Agreement Airport Center III 13191 Crossroads Pkwy N. 6th fl CITY OF INDUSTRY CA 91746 Real Property Lease Alabama Oncology, LLC Bruno Cancer Center 810 St. Vincents Drive Birmingham AL 35205 Clinical Trial/Study Agreement Alaska Clinical Research Center, LLC 188 W. Northern Lights Blvd. Suite 800 Anchorage AK 99504 Clinical Trial/Study Agreement Alison Del Vento LLC PO BOX 99447 TWELVE AND TWENTY LLC SEATTLE WA 98139 Professional Services Agreement All Temp Mechanical Inc. 527 N.W. 196TH PL. SHORELINE WA 98177 Vendor Agreement Amato, Robert MD 3816 Ruskin St Houston TX 77005 Professional Services Agreement American Express Travel Related Services Company Vendor Agreement PO BOX 360001 TRAVEL RELATED SERVICES CO. FORT LAUDERDALE FL 33336 American National Red Cross PO BOX 100805 PASADENA
CA 91189 Leukapheresis Collection Agreement AmerisourceBergen Corporation 3101 Gaylord Parkway Frisco TX 75034 IT Agreement Amgen Inc. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 Maintenance Agreement Amgen Inc. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 Rights Agreement Amgen Inc. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 Vendor Agreement Analytica LA - SER International, Inc. 24 W 40TH ST - 8TH FLOOR NEW YORK NY 10018 Service Agreement Andrew Sandler Redacted Employment Agreement Apheresis Care Group, Inc. 2100 Webster St #512 San Francisco CA 94115 Manufacturing Agreement ARCA Biopharma, Inc. 8001 Arista Place Suite 200 Broomfield CO 80021 Assumption Agreement ARCA Biopharma, Inc. 8001 Arista Place Suite 200 Broomfield CO 80021 License Agreement Ariba PO BOX 642962 PITTSBURGH PA 15264 Vendor Agreement and Renewal Arizona Institute of Urology 1100 North El Dorado Place Tucson AZ 85715 Clinical Trial/Study Agreement for P12 - 1 Arizona Institute of Urology, PLLC 1100 North El Dorado Place Tucson AZ 85715 Clinical Trial/Study Agreement for P10 - 3 Arizona Radiation Therapy Management, Inc. 2234 Colonial Blvd. Fort Meyers FL 33907 Clinical Trial/Study Agreement Arlington Cancer Center 906 W. Randol Mill Rd Arlington TX 76012 Clinical Trial/Study Agreement Armstrong, Andrew J. MD 201 Pitch Pine Lane Chapel Hill NC 27514 Consulting Services Agreement ASD Specialty Healthcare, Inc. 3101 Gaylord Parkway Frisco TX 75034 Distributor Agreement Asheville Hematology & Oncology 20 Medical Park Drive Asheville NC 28803 Clinical Trial/Study Agreement
Assign Clinical Research GmbH, Assign Group FANNY - ZOBEL - STR 5 12435 BERLIN GERMANY Supply Agreement and all Modifications and Revisions Assign Clinical Research GmbH, Assign Group FANNY - ZOBEL - STR 5 12435 BERLIN Supply Agreement Assign International GmbH FANNY - ZOBEL - STR 5 12435 BERLIN GERMANY CRO Agreement Associated Medical Professionals of New York, PLLC Clinical Trial/Study Agreement for N10 - 1 1226 East Water Street Syracuse NY 13210 Associated Medical Professionals of New York, PLLC Clinical Trial/Study Agreement for P11 - 4 1226 East Water Street Syracuse NY 13210 Associated Medical Professionals of New York, PLLC Clinical Trial/Study Agreement for P12 - 2 1226 East Water Street Syracuse NY 13210 Associated Medical Professionals of NY, PLLC 1226 East Water Street Syracuse NY 13210 Clinical Trial/Study Agreement for P10 - 3
1 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Associated Medical Professionals of NY, PLLC (AMP) Clinical Trial/Study Agreement for P12-1 1226 East Water Street Syracuse NY 13210 Associated Urological Specialists, LLC 7530 West College Drive, Ste. D Palos Heights IL 60463 Clinical Trial/Study Agreement Associated Urologists of North Carolina 3821 Ed Drive Raleigh NC 27612 Clinical Trial/Study Agreement Atlanta Blood Services 5670 Peachtree Dunwoody Rd STE 1075 ATLANTA GA 30342 Leukapheresis Collection Agreement Atlanta Hematology Oncology Associates 105 Collier Road NorthWest Suite 3040 Atlanta GA 303091710 Clinical Trial/Study Agreement Atlantic Urological Associates 1061 Medical Center Dr Suite 300 Orange City FL 32763 Clinical Trial/Study Agreement Augusta Oncology Associates, P.C. 3696 Wheeler Road Augusta GA 30909 Clinical Trial/Study Agreement Austin Preclinical Consulting LLC 11 HARTWELL BROOK DR. NASHUA NH 03060 Consulting Services Agreement Avaion, Inc. 4280 OAKVIEW LANE N PLYMOUTH MN 55442 Commercial Marketing Agreement Avera Cancer Institute 1000 East 23rd Street Suite 230 Sioux Falls SD 57105 Clinical Trial/Study Agreement Axess Oncology, Inc. TWO CONCOURSE PARKWAY SUITE 255 ATLANTA GA 30338 Service Agreement Axio Research Corporation 2601 4TH AVENUE STE 200 SEATTLE WA 98121 Clinical Trial/Study Agreement Axis Studios 911 PINE ST. SUITE 301 SEATTLE WA 98101 Maintenance Agreement BAMAP 2100 Webster St #512 San Francisco CA 94115 Manufacturing Agreement Barbara Ann Karmanos Cancer Center KARMANOS CANCER CENTER, C/O CHERYL Clinical Trial/Study Agreement 4100 JOHN R HW04HO GUNNELLS DETROIT MI 48201 Bart’s and the London NHS Trust, of the Royal London Clinical Trial/Study Agreement for P11 Hospital, Whitechapel The Royal London Hospital Barts & The London NHS Trust, Whitechapel London E1 1BB England Bayer Corporation 511 Benedict Avenue Tarrytown NY 105915097 License Agreement Bayer Corporation 511 Benedict Avenue Tarrytown NY 105915097 License Agreement Beckman Coulter, Inc. DEPT CH 10164 PALATINE IL 60055 Supply Agreement Becton, Dickinson and Company 1 Becton Drive Franklin Lakes NJ 74171880 Purchase Agreement Benaroya Research Center at Virginia Mason 1201 9TH AVENUE BRI # 3067500 (P102) SCOTT SPALDING SEATTLE WA 98101 Clinical Trial/Study Agreement BioClinica, Inc. P.O. BOX 824134 PHILADELPHIA PA 19182 Laboratory Services Agreement Biological Specialty Corporation 2165 N LINE ST COLMAR PA 18915 Manufacturing Agreement BioPharm Communications 290 UNION SQUARE DRIVE NEW HOPE PA 18938 Marketing Services Agreement BioPharm Systems, Inc. 2000 ALAMEDA DE LAS PULGAS STE 154 SAN MATEO CA 94403 Vendor Agreement BioPharma Resource Groups, LLC 61360 Ward Road Bend OR 97702 Subscription Services Agreement BioReliance Corporation 13319 COLLECTIONS CENTER DRIVE BANK OF AMERICA CHICAGO IL 60693
Vendor Agreement Blood & Tissue Center of Central Texas 4300 N. Lamar Blvd Austin TX 78756 Leukapheresis Collection Agreement Blood and Cancer Center of East Texas 825 Medical Drive Tyler TX 75701 Clinical Trial/Study Agreement Blood Assurance 705 E 4th St Chattanooga TN 37403 Leukapheresis Collection Agreement Blood Bank of Alaska 4000 Laurel St Anchorage AK 99508 Leukapheresis Collection Agreement Blood Bank of San Bernardino & Riverside Counties Leukapheresis Collection Agreement PO Box 1429 LifeStream San Bernardino CA 924021429 Blood Centers of America, Inc. PO BOX 84-5732 BOSTON MA 02284 Leukapheresis Collection Agreement Blood Systems Incorporated 6210 E Oak St Scottsdale AZ 85257 Leukapheresis Collection Agreement Blood Systems, Inc. PO BOX 53022 PHOENIX AZ 85072 Leukapheresis Collection Agreement BloodSource 10536 Peter A McCuen Blvd Mather CA 95655 Leukapheresis Collection Agreement Blutspendedienst Baden-WÅ±rttemberg â€” Hessen Leukapheresis Collection Agreement gGmbH Friedrich-Ebert-Str. 107 68167 Mannheim Germany Bonfils Blood Center P.O. BOX 1921 ENGLEWOOD CO 80150 Leukapheresis Collection Agreement Brenda Ranchino Research 1785 KELLEY DRIVE HOFFMAN ESTATES IL 60192 Consulting Services Agreement Brookhaven National Laboratory OFFICE OF INTELLECTUAL PROPERTY AND License Agreement BLDG 185 PO BOX 5000 SPONSORED RESEARCH UPTON NY 11973 Bryn Mawr Urology Group 919 Conestoga Rd. Bldg 1 Suite 300 Rosemont PA 19010 Service Agreement and Amendments Building Information Systems LLC, dba Buildingi 188 106TH AVENUE NE STE 610 BELLEVUE WA 98004 IT Agreement Building Information Systems LLC, dba Buildingi 188 106TH AVENUE NE STE 610 BELLEVUE WA 98004 Hosting Services Agreement Business Wire DEPARTMENT 34182 P.O. BOX 39000 SAN FRANCISCO CA 94139 Media Services Agreement
Cadent Medical Communications P.O. BOX 505214 ST LOUIS MO 63150 Professional Services Agreement and Amendments Cambridgesoft Corporation PO BOX 673669 DETROIT MI 48267 IT Agreement Campbell Alliance Group, Inc. BANK OF AMERICA 62670 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Marketing Services Agreement Cancer Care Associates of York 25 Monument Road Suite 296 York PA 17403 Clinical Trial/Study Agreement Cancer Center of Kansas 818 N. Emporia, Suite 403 Wichita KS 67214 Clinical Trial/Study Agreement for P11-4 Cancer Center of Kansas 818 N. Emporia, Suite 403 Wichita KS 67214 Clinical Trial/Study Agreement for P12-1 Cancer Center of Kansas, P.A. 818 N EMPORIA, STE 403 WICHITA KS 67214 Clinical Trial/Study Agreement for P10-3 Cancer Centers of Southwest Oklahoma 104 NW 31st Street Lawton OK 73505 Clinical Trial/Study Agreement Cancer Specialists of North Florida 9143 Philips Highway, Suite 560 Jacksonville FL 32256 Clinical Trial/Study Agreement for P11-4 Cancer Specialists of South Texas, PA 1625 Rodd Field Road Corpus Christi TX 78412 Clinical Trial/Study Agreement
2 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Cancer Therapy Research Center @ UTHSC 7979 Wurzbach Road, 4th Floor, Zeller bldg. Clinical Trial/Study Agreement for N10-1 Mailcode 8232 San Antonio TX 78229 Cangene bioPharma, Inc. 1111 S PACA ST BALTIMORE MD 21230 Master Services Agreement and Amendments Cardinal Health 108, Inc. 7000 Cardinal Place Dublin OH 43017 Distributor Agreement Cardinal Health 118, LLC d/b/a VitalSource GPO 25386 NETWORK PLACE CHICAGO IL 60673 Pricing/Rebate Agreement and Amendments Cardinal Health 118, LLC d/b/a VitalSource GPO 25386 NETWORK PLACE CHICAGO IL 60673 Program Agreements Cardinal Health 118, LLC d/b/a VitalSource GPO 25386 NETWORK PLACE CHICAGO IL 60673 Vendor Agreement Carolina Urologic Research Center 823 82nd Parkway, Suite B Myrtle Beach SC 29572 Clinical Trial/Study Agreement for P10-2 Carolina Urologic Research Center 823 82nd Parkway, Suite B Myrtle Beach SC 29572 Clinical Trial/Study Agreement for P10-3 Carolina Urologic Research Center 823 82nd Parkway, Suite B Myrtle Beach SC 29572 Clinical Trial/Study Agreement for P11-3 Carolina Urologic Research Center 823 82nd Parkway, Suite B Myrtle Beach SC 29572 Clinical Trial/Study Agreement for P11-4 Carolina Urologic Research Center 823 82nd Parkway, Suite B Myrtle Beach SC 29572 Clinical Trial/Study Agreement for P12-1 Carolina Urologic Research Center 823 82nd Parkway, Suite B Myrtle Beach SC 29572 Clinical Trial/Study Agreement for P12-2 Carolina Urologic Research Center 823 82nd Parkway, Suite B Myrtle Beach SC 29572 Research Investigation Agreement Carolina Urology Partners 924 Cox Road Gastonia NC 28054 Clinical Trial/Study Agreement for P10-3 Carolina Urology Partners 924 Cox Road Gastonia NC 28054 Clinical Trial/Study Agreement for P11-4 Carolina Urology Partners 924 Cox Road Gastonia NC 28054 Clinical Trial/Study Agreement for P12-1 Carter Bloodcare P.O. BOX 916068 FT. WORTH TX 76191 Leukapheresis Collection Agreement Cascade Regional Blood Services 220 South I Street Tacoma WA 98405 Leukapheresis Collection Agreement CCHC New Bern Cancer Care 1010 Mdical Park Avenue New Bern NC 28562 Clinical Trial/Study Agreement Center for Medicaid and State Operations Drug Rebate Agreement Family and Children’s Health Programs Group, Dvision of Benefits, Coverage and Payment Post Office Box 26686 Baltimore MD 21207-0486 Charleston Hematology Oncology Associates, PA 125 Doughty Street Suite 280 Charleston SC 294035736 Clinical Trial/Study Agreement Chesapeake Urology Associates 806 Landmark Dr., Suite 118 Glen Burnie MD 21061 Clinical Trial/Study Agreement Chesapeake Urology Research Associates 6535 North Charles Street PPN Suite 625 Towson MD 21204 Clinical Trial/Study Agreement for P10-3 Chesapeake Urology Research Associates 6569 North Charles St., Suite 708 Baltimore MD 21204 Clinical Trial/Study Agreement for P11-4 Chronic Disease Fund, Inc. 6900 NORTH DALLAS PARKWAY SUITE 200 PLANO TX 75024 Service Agreement Cisco Systems, Inc. P.O. BOX 742927 LOS ANGELES CA 90074 IT Agreement
Cisco Systems, Inc. PO BOX 911869 DALLAS TX 75391 Equipment Lease Agreement Citrix Systems Inc. 851 W. Cypress Creed Road Fort Lauderdale FL 33309 Maintenance Agreement City Of Hope Medical Center 1500 East Duarte Rd. Building 51 Duarte CA 91010 Clinical Trial/Study Agreement City Of Hope Medical Center 1500 East Duarte Rd. Building 51 Duarte CA 91010 Clinical Trial/Study Agreement for N10-1 City of Hope National Medical Center ATTN: OFFICE OF CLINICAL TRIAL FINANCE 1500 EAST DUARTE ROAD DUARTE CA 91010 Clinical Trial/Study Agreement for P10-3 Classic Conferences, Inc. 1 UNIVERSITY PLAZA, SUITE 310 HACKENSACK NJ 07601 Vendor Agreement Cleanroom Management Associates, Inc. 415 OLD WASHOE CIRCLE CARSON CITY NV 89704 Service Agreement Clearwater Cancer Institute 3601 CCI Drive Huntsville AL 35805 Clinical Trial/Study Agreement Cleveland Clinic - Taussig Cancer Institute 9500 Euclid Avenue Cleveland OH 44195 Clinical Trial/Study Agreement for P12-2 Clinical Resource Network PO BOX 75314 CHICAGO IL 60675 Clinical Trial/Study Agreement CMC ICOS Biologics, Inc. ATTN: ACCOUNTING P.O. BOX 13858 MILL CREEK WA 98082 License Agreement CMC ICOS Biologics, Inc. ATTN: ACCOUNTING P.O. BOX 13858 MILL CREEK WA 98082 Media Services Agreement Coastal Bend Blood Center 209 N. PADRE ISLAND DR. CORPUS CHRISTI TX 78406 Leukapheresis Collection Agreement Columbia University Medical Center 177 Fort Washington Ave. Milstein Hospital Building, 6N435 New York NY 10032 Clinical Trial/Study Agreement for P07-2 Columbia University Medical Center 177 Fort Washington Ave. Milstein Hospital Building, 6N435 New York NY 10032 Clinical Trial/Study Agreement for P09-1 Columbia University, The Trustees of Columbia University Medical Center 622 West 168th Street, PH1540 New York NY 10032 Clinical Trial/Study Agreement for N10-1 Communications Media, Inc. 2200 RENAISSANCE BLVD. SUITE 160 KING OF PRUSSIA PA 19406 Commercial Marketing Agreement Communications Media, Inc. 2200 RENAISSANCE BLVD. SUITE 160 KING OF PRUSSIA PA 19406 Commercial Marketing Agreement Community Blood Center Community Tissue Services Leukapheresis Collection Agreement Community Blood Center 349 S Main Street Dayton OH 45402 Community Blood Center of Greater Kansas City 4040 Main Street Kansas City MO 64111 Leukapheresis Collection Agreement Compas, Inc. ATTN: ACCOUNTS RECIEVABLE CL#4600, PO BOX 95000 PHILADELPHIA PA 19195 Commercial Marketing Agreement Complete Health Vizion 120 Eagle Rock Avenue East Hanover NJ 07936 Service Agreement Compliance Implementation Services 3809 WEST CHESTER PIKE STE 100 NEWTOWN PA 19073 Service Agreement Comprehensive Cancer Care 12855 North Forty Drive, Suite 200 St. Louis MO 63141 Clinical Trial/Study Agreement Comprehensive Cancer Center Desert Regional Medical Center 1180 N. Indian Clinical Trial/Study Agreement for P10-3 Canyon Dr. #E 320 Palm Springs CA 92262 Comprehensive Cancer Centers of Nevada 3730 S Eastern Ave. Las Vegas NV 89169 Clinical Trial/Study Agreement for P10-2 Comprehensive Cancer Centers of Nevada 3730 S Eastern Ave. Las Vegas NV 89169 Clinical Trial/Study Agreement for P10-3 Comprehensive Cancer Centers of Nevada 3730 S Eastern Ave. Las Vegas NV 89169 Clinical Trial/Study Agreement for P11-4 Comprehensive Urologic Care, SC 22285 N Pepper Rd, #201 Lake Barrington IL 60010 Clinical Trial/Study Agreement for P12-1
3 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Computer Sciences Corporation 3170 Fairview Park Drive Falls Church VA 22042 IT Agreement
Computer Sciences Corporation 3170 Fairview Park Drive Falls Church VA 22042 IT Support Agreement
Concepcion, Raoul S. MD Urology Associates 2801 Charlotte Avenue Nashville TN 37209 Consulting Services Agreement and Amendment Concur Technologies, Inc. 62157 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Service Agreement Contra Costa Oncology 500 Lennon Lane Walnut Creek CA 94598 Clinical Trial/Study Agreement for P10-3 Contra Costa Oncology 500 Lennon Lane Walnut Creek CA 94598 Clinical Trial/Study Agreement for P12-1 Covance Central Laboratory Services PO BOX 820824 PHILADELPHIA PA 19182 Clinical Trial/Study Agreement and Amendments Covance Central Laboratory Services PO BOX 820824 PHILADELPHIA PA 19182 Clinical Trial/Study Agreement for N10-1 Covance Central Laboratory Services PO BOX 820824 PHILADELPHIA PA 19182 Clinical Trial/Study Agreement for P10-1 Covance Central Laboratory Services PO BOX 820824 PHILADELPHIA PA 19182 Clinical Trial/Study Agreement for P12-2 CPPIB Credit Investments Inc One Queen Street East, Suite 2600 PO Box 1011 Toronto ON M5C 2W5 CANADA Purchase Agreement CPZ Consultants, LLC Pamela Zinn 207 Kathleen Way Glenmoore PA 19343 Consulting Services Agreement and Amendment Crawford, E. David, M.D. Campus Box F710 1665 N Ursula Street Aurora CO 80010 Consulting Services Agreement Creative Group, Inc. 619 N. LYNNDALE DRIVE APPLETON WI 54914 Service Agreement Crown Lift Trucks CROWN EQUIPMENT CORP. P.O. BOX 641173 CINCINNATI OH 45264 Maintenance Agreement CSS Building Services Inc 12 STULTS ROAD SUITE 132 DAYTON NJ 08810 Master Services Agreement Cumberland County Hospital System, Inc. dba Cape Clinical Trial/Study Agreement Fear Valley Health System Cape Fear Valley Health System 1638 Owen Drive Fayetteville NC 28304 Custom Mechanical Solutions, Inc 2517 EASTLAKE AVE EAST, SUITE 200 SEATTLE WA 98102 Vendor Agreement Cytel Inc. BOX 83359 WOBURN MA 01813 IT Agreement Cyto Care EU GMBH Gonzagagasse 17 1010 Vienna Austria Leukapheresis Collection Agreement Dana-Farber Cancer Institute 450 Brookline Ave., Dana 1230 Boston MA 02215 Clinical Trial/Study Agreement and Amendments Dana-Farber Cancer Institute 44 Binney St., D1230 Boston MA 21156084 Clinical Trial/Study Agreement for P10-3 Dartmouth Hitchcock Medical Center/Norris Cancer Clinical Trial/Study Agreement Center One Medical Center Drive, Rubin 8 Lebanon NH 03756 Datafarm, Inc. 100 Locke Drive Marlborough MA 01752 IT Agreement DAVA Oncology, LP P.O. BOX 674107 DALLAS TX 75267 Marketing Services Agreement Dean F. Bajorin, MD 1275 YORK AVE NEW YORK NY 10021 Clinical Trial/Study Agreement and Amendments Delaware Valley Urology, LLC 2003 LINCOLN DRIVE WEST SUITE B MARLTON NJ 08053
Clinical Trial/Study Agreement for P10-3 Delaware Valley Urology, LLC 15000 Midlantic Drive, Suite 100 Mt. Laurel NJ 08054 Clinical Trial/Study Agreement for P11-4 Delaware Valley Urology, LLC 15000 Midlantic Drive, Suite 100 Mt. Laurel NJ 08054 Clinical Trial/Study Agreement for P12-1 Department of Health and Human Services Division of Benefits, Coverage and Payment Post Office Box 26686 Baltimore MD 212070486 Service Agreement DEVLINHAIR Productions, Inc. 120 Wooster Street New York NY 10012 Service Agreement Digital Science Press, Inc. 2217 5TH STREET BERKELEY CA 94710 Marketing Services Agreement Diosynth RTP, Inc. DEPT CH 16878 PALATINE IL 60055 Manufacturing Agreement Direct Technology DIRECT APPS, INC. 3009 DOUGLAS BLVD., STE. 300 ROSEVILLE CA 95661 Support Agreement DK Pierce & Associates 112 N. NINTH STREET ZIONSVILLE IN 46077 Service Agreement Department of Medical and Physiological Biomedical Center, Uppsala University, Box 575, Clinical Trial/Study Agreement Dr. Hakan Pertoft Chemistry S751 23 Uppsala SWEDEN
Dr. Peter Dreger Universitat Kiel Chemnitzstr. 33, D24116 Kiel Germany Clinical Trial/Study Agreement Dreicer, Robert, M.D. 35120 Quartermane Circle Solon OH 44139 Clinical Trial/Study Agreement Drumm, William 3116 Lake Drive Apt 12 Marina CA 93933 Clinical Trial/Study Agreement DTI of Washington, LLC, d/b/a EED, a DTI Company Services Agreement The Plaza at Yarrow Bay, Suite 200 3933 Lake Wahington Blvd NE Kirkland WA 98033
Duke University DUMC 3476 DIVISION OF MEDICAL ONCOLOGY DURHAM NC 27710 Clinical Trial/Study Agreement for N10-1 Duke University DUMC 3476 DIVISION OF MEDICAL ONCOLOGY DURHAM NC 27710 Clinical Trial/Study Agreement for P09-1 Duke University DUMC 3476 DIVISION OF MEDICAL ONCOLOGY DURHAM NC 27710 Clinical Trial/Study Agreement for P10-3 Duke University Clinical Trial/Study Agreement for P12-2
10 Bryan-Searle Dr., 471 Seeley Mudd Building Durham NC 27710
Duke University Medical Center 2200 West Main Street, suite 820 Durham NC 27705 Clinical Trial/Study Agreement Duke University Medical Center 2200 West Main Street, suite 820 Durham NC 27705 Clinical Trial/Study Agreement Duke University Medical Center 2200 West Main Street, suite 820 Durham NC 27705 Clinical Trial/Study Agreement
Duke University Medical Center Clinical Trial/Study Agreement for P07-2
10 Bryan-Searle Dr., 471 Seeley Mudd Building GU Oncology Research Program Durham NC 27710
Durham Veterans Affairs Medical Center 508 Fulton Street , Mailcode 112 Durham NC 27705 Clinical Trial/Study Agreement for P12-1 Dynavax Technologies Corporation 2929 Seventh Street Suite 100 Berkeley CA 94710 Supply Agreement E Squared Communications I, LLC 1300 PARKWOOD CIRCLE SE SUITE 450 ATLANTA GA 30339 Commercial Marketing Agreement E*Trade Financial ATTN: ACCOUNTS RECEIVABLE PO BOX 3512 ARLINGTON VA 22203 Service Agreement Eastern Connecticut Hematology Oncology Eastern Connecticut Hematology and Oncology Clinical Trial/Study Agreement Associates 330 Washington Street, Suite 220 Norwich CT 06360
4 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
El Dorado Research 1100 N. El Dorado Place Tucson AZ 85715 Clinical Trial/Study Agreement Elsevier B.V. ELSEVIER INFORMATION SYSTEMS GMBH PO BOX 72478258 PHILADELPHIA PA 19170 Media Services Agreement EMC Corporation 4246 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Software Support Agreement Emory University, Winship Cancer Institute 1365-C Clifton Road, NE Atlanta GA 30322 Clinical Trial/Study Agreement Energy Systems Southeast, LLC 3235 VETERANS CIRCLE BIRMINGHAM AL 35235 Service and Maintenance Agreement EnergyConnect, Inc. 901 Campisi Way, Suite 260 Campbell CA 95008 Vendor Agreement Envision Pharma, Inc. PO BOX 75575 BALTIMORE MD 21275 IT Agreement Expression Analysis, Inc. 4324 SOUTH ALSTON AVE. SUITE 101 DURHAM NC 27713 Service Agreement Facilitate Ltd 28-30 ROBERT STREET BRIGHTON BN1 4AH UK Regulatory Service Agreement Facilitate Ltd 28-30 ROBERT STREET BRIGHTON BN1 4AH UK Service Agreement Fallon Medica, LLC 620 SHREWSBURY AVENUE TINTON FALLS NJ 07701 Commercial Marketing Agreement Family Cancer Center Foundation Inc. 6005 Park Avenue, Suite 1000-B Memphis TN 38119 Clinical Trial/Study Agreement
Femrite and Associates, LLC W7071 RIMROCK LANE GREENVILLE WI 54942 Consulting Services Agreement and Amendment Fenwal Inc. 26762 NETWORK PLACE CHICAGO IL 60673 Supply Agreement Fenwal Inc. 26762 NETWORK PLACE CHICAGO IL 60673 Service Agreement Fenwal Inc. 26762 NETWORK PLACE CHICAGO IL 60673 Supply Agreement Ferguson Strategies, LLC 801 Pennsylvania Ave NW Ste 230 Washington DC 20004 Consulting Services Agreement Fidelity Management Trust Company 82 Devonshire Street Boston MA 02109 Vendor Agreement and Amendment First Urology, PSC 101 Hospital Blvd. Jeffersonville IN 47130 Clinical Trial/Study Agreement for P10-3 First Urology, PSC 101 Hospital Blvd. Jeffersonville IN 47130 Clinical Trial/Study Agreement for P11-4 First Urology, PSC 101 Hospital Blvd. Jeffersonville IN 47130 Clinical Trial/Study Agreement for P12-1 Fisher BioServices, Inc. PO BOX 418395 BOSTON MA 02241 Supply Agreement Fisher Clinical Services 13741 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Warehouse Services Agreement Fisher Clinical Services 13741 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Clinical Trial/Study Agreement Fisher Clinical Services 13741 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Supply Agreement Florida Blood Services Tisha Foster, MD 8669 Commodity Circle Orlando FL 32819 Leukapheresis Collection Agreement Florida Cancer Institute - New Hope 8763 River Crossing Blvd New Port Richey FL 34655 Clinical Trial/Study Agreement Forbes Consulting Group, LLC THIRD FLOOR 24 HARTWELL AVENUE LEXINGTON MA 02421 Marketing Services Agreement Fort Wayne Medical Oncology and Hematology, Inc. Clinical Trial/Study Agreement for P10-3 11143 Parkview Plaza Suite 100 Fort Wayne IN 46845 Fort Wayne Medical Oncology Hematology 7910 W Jefferson Blvd, Suite 108 Ft. Wayne IN 46804 Clinical Trial/Study Agreement for P12-2 Fox Chase Cancer Center
333 Cottman Avenue Philadelphia PA 19111 Clinical Trial/Study Agreement Fox Chase Cancer Center 333 Cottman Avenue Philadelphia PA 19111 Clinical Trial/Study Agreement for N10-1 Fraunhofer Institute for Cell Therapy and Immunology Fraunhofer Institute for Cell Therapy and Secrecy Agreement (IZI) Immunology (IZI) Perlickstr. 1, D04103 Leipzig Germany Fred Hutchinson Cancer Research Center 1100 FAIRVIEW AVE N SEATTLE WA 98109 Clinical Trial/Study Agreement Fresenius Management Services 920 Winter Street Waltham MA 02451 Clinical Trial/Study Agreement for P07-1 Fresenius Management Services 920 Winter Street Waltham MA 02451 Clinical Trial/Study Agreement for P07-2 Frix Technologies LLC dba FreeDoc PO BOX 2007 BOTHELL WA 98041 Service Agreement FSP-RIC, LLC 515 S. FLOWER ST 32ND FLOOR LOS ANGELES CA 90071 Real Property Lease GE Capital Corporation PO BOX 642555 PITTSBURGH PA 15264 Lease Agreement GE Capital Corporation PO BOX 642555 PITTSBURGH PA 15264 Vendor Agreement GE Healthcare Bio-Sciences Corp. PO BOX 643065 PITTSBURGH PA 15264 Patent Rights Agreement GEL Interactive CADIENT GROUP, INC. 2520 RENAISSANCE BOULEVARD STE 100 KING OF PRUSSIA PA 19406 Software License Agreement Genesis Healthcare Partners 5395 Ruffin Rd., Suite 202 San Diego CA 92123 Clinical Trial/Study Agreement for P10-3 Genesis Healthcare Partners 5395 Ruffin Rd., Suite 202 San Diego CA 92123 Clinical Trial/Study Agreement for P12-1 Genesis Heathcare Partners 5395 Ruffin Rd., Suite 202 San Diego CA 92123 Clinical Trial/Study Agreement George, Stephen, Ph.D. 27 Pennington Place Durham NC 27707 Clinical Trial/Study Agreement Georgetown University 2115 WISCONSIN AVENUE, SUITE 603 WASHINGTON DC 20007 Clinical Trial/Study Agreement Georgetown University 2115 WISCONSIN AVENUE, SUITE 603 WASHINGTON DC 20007 License Agreement Georgetown University Medical Center 3800 Reservoir Rd. NW Washington DC 20007 Clinical Trial/Study Agreement for P10-3 Georgetown University Medical Center 3800 Reservoir Rd. NW Lombardi Comprehensive Cancer Center Washington DC 20007 Clinical Trial/Study Agreement for P11-3 Georgia Cancer Specialists I, P.C. Clinical Trial/Study Agreement Sponsored Projects Adminstration, Box EP-15 1430 Tulane Avenue New Orleans LA 70112 Georgia Power Company 96 ANNEX ATLANTA GA 30396 Utility Agreement Georgia Regents University Cj-3301, 1120 15th Street Augusta GA 30912 Clinical Trial/Study Agreement Georgia Urology, P.A. 5670 Peachtree Dunwoody Rd, Suite 1250 Atlanta GA 30342 Clinical Trial/Study Agreement Gettysburg Cancer Center 20 Expedition Trail, Suite 101 Gettysburg PA 17325 Clinical Trial/Study Agreement for P10-3 Global Experience Specialists, Inc. BANK OF AMERICA PO BOX 96174 CHICAGO IL 60693 Master Services Agreement and Amendments Green Key Temp, LLC 475 PARK AVENUE SOUTH 7TH FLOOR NEW YORK NY 10016 Clinical Trial/Study Agreement
5 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Gregory Cox Redacted Employment Agreement
Group Services for America’s Blood Centers C/O BLOOD CENTERS OF AMERICA PO BOX 845732 BOSTON MA 02284 Leukapheresis Collection Agreement and Amendment GU Research Network, LLC 17607 Gold Plaza Omaha NE 68130 Clinical Trial/Study Agreement for N10-1 GU Research Network, LLC 17607 Gold Plaza Omaha NE 68130 Clinical Trial/Study Agreement for P10-3 GU Research Network, LLC 17607 Gold Plaza Omaha NE 68130 Clinical Trial/Study Agreement for P11-3 GU Research Network, LLC 17607 Gold Plaza Omaha NE 68130 Clinical Trial/Study Agreement for P12-3 Guardsmark, Inc. PO BOX 11407 BIRMINGHAM AL 35246 Vendor Agreement Gulf Coast Regional Blood Center 1400 La Concha Lane Houston TX 77054 Leukapheresis Collection Agreement Harbin Clinic 255 West 5th Street Rome GA 30165 Clinical Trial/Study Agreement for P10-3 Harrison Health Hematology & Oncology 19500 10th Avenue, Suite 100 Poulsbo WA 98370 Clinical Trial/Study Agreement for P10-3 Health Research Associates, Inc. 1640 MARENGO STREET, 7TH FLOOR LAC+USC MEDICAL CENTER LOS ANGELES CA 90033 Clinical Trial/Study Agreement for P10-3 Health Research Association, Inc. LAC+USC MEDICAL CENTER 1640 MARENGO ST LOS ANGELES CA 90033 Clinical Trial/Study Agreement for N10-1 Health Research Inc (RPCI) Elm and Carlton Streets Buffalo NY 14263 Clinical Trial/Study Agreement Healthcare Solutions Holding, LLC 7172 Columbia Gateway Drive Suite 300 Columbia MD 21046 Consulting Services Agreement Heartland Oncology and Hematology, PLLC One Edmundson Place, Suite 100 Council Bluffs IA 51503 Clinical Trial/Study Agreement for P10-3 HemaCare Corporation 15350 SHERMAN WAY, SUITE 350 VAN NUYS CA 91406 Leukapheresis Collection Agreement and Amendment Hematology Oncology Associates 1801 SE Hillmoor Drive Suite B108 Port St Lucie FL 34952 Clinical Trial/Study Agreement Hematology - Oncology Associates of Northern New Clinical Trial/Study Agreement for P10-3 Jersey, PA (HOANNJ) - Morristown 100 Madison Avenue Morristown NJ 79606136 Hendrick Cancer Center 2000 Pine Street Abilene TX 79601 Clinical Trial/Study Agreement Henry Ford Health System 2799 West Grand Blvd, Pallister Place T-139 Detroit MI 48202 Clinical Trial/Study Agreement for P10-3 Higano, Celestia, M.D. Seattle Cancer Care Alliance 825 Eastlake Ave E, G4830 Seattle WA 98109 Services Agreement Highland Clinic 1455 East Bert Kouns, Industrial Loop Shreveport LA 71105 Clinical Trial/Study Agreement for P10-3 Highland Clinic 301 East Bert Kouns Industrial Loop Hematology/Oncology Shreveport LA 71105 Clinical Trial/Study Agreement for P11-4 Highland Clinic 301 East Bert Kouns Industrial Loop Shreveport LA 71105 Clinical Trial/Study Agreement for P12-1 Hillman Cancer Center 5150 Centre Ave., 4th Floor Pittsburgh PA 15232 Clinical Trial/Study Agreement for P10-3 Houston Metro Urology 4323 Richmond Ave Houston TX 77027 Clinical Trial/Study Agreement Howard Hughes Medical Institute 4000 Jones Bridge Road Chevy Chase MD 20815
Vendor Agreement Howard University Cancer Center 2041 Georgia Avenue NW Washington Dc 20060 Clinical Trial/Study Agreement for P10-3 Howard University Cancer Center 2041 Georgia Ave. NW Washington DC 20060 Clinical Trial/Study Agreement for P11-4 Howard University Hospital 2041 Georgia Ave. NW Washington DC 20060 Clinical Trial/Study Agreement for P12-1 Hoxworth Blood Center UNIVERSITY OF CINCINNATI PO BOX 691060 CINCINNATI OH 45269 Leukapheresis Collection Agreement Hubert H. Humphrey Cancer Center 3435 West Broadway, Suite 1135 Robbinsdale MN 55422 Clinical Trial/Study Agreement for P10-3 Huntsman Cancer Center 1950 Circle of Hope Salt Lake City UT 84112 Clinical Trial/Study Agreement for P10-3 Huntsman Cancer Hospital University of Utah, School of Medicine, Division Clinical Trial/Study Agreement for P11-4
30 North 1900 East. of Urology Salt Lake City UT 84132
Idaho Urologic Institute 2855 E. Magic View Dr. Meridian ID 83642 Clinical Trial/Study Agreement Image Zone, Inc 11 WEST 69TH ST #10A NEW YORK NY 10023 Master Services Agreement Indiana Blood Center 3848 SOLUTIONS CENTER CHICAGO IL 60677 Leukapheresis Collection Agreement Indiana University 535 Barnhill Dr., Suite 420 Indianapolis IN 46202 Clinical Trial/Study Agreement for N10-1 Indiana University 535 Barnhill Dr., Suite 420 Indianapolis IN 46202 Clinical Trial/Study Agreement for P07-2 Indiana University 535 Barnhill Dr., Suite 420 Indianapolis IN 46202 Clinical Trial/Study Agreement for P11-3 Informative Graphics Corporation 4835 E. Cactus Rd Suite 445 Scottsdale AZ 85254 IT Agreement Insite Quality Assurance, Inc. 2205 197TH AVE SE SAMMAMISH WA 98075 Vendor Agreement Institut Gustave Roussy (IGR) 39, rue Camille - Desmoulins 94805 Villejuif Clinical Trial/Study Agreement Integrated Community Oncology Network, LLC 9143 Phillips Highway Suite 560 Jacksonville FL 32256 Clinical Trial/Study Agreement Integrated Medical Professionals, PLLC 3111 New Hyde Park Rd. North Hills NY 11042 Clinical Trial/Study Agreement for P12 - 1 Integrated Safety Systems, Inc. PO Box 13542 Research Triangle Park NC 27709-3542 Clinical Trial/Study Agreement Integrated Sales and Marketing Consultants, LLC 50 KENZEL AVENUE NUTLEY NJ 07110 Professional Services Agreement Intellisphere, LLC 666 PLAINSBORO RD STE 300 PLAINSBORO NJ 08536 Sponsorship Services Agreement International Oncology Network 14060 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Pricing/Rebate Agreement IntrinsiQ, LLC 25 CORPORATE DRIVE, SUITE 300 BURLINGTON MA 01803 Service Agreement Invitrogen Corporation 12088 COLLECTIONS CENTER DR CHICAGO IL 60693 Supply Agreement INX LLC 1955 Lakeway Drive Suite 220 Lewisville TX 75057 Service Agreement Ironwood Cancer and Research 695 South Dobson Road Chandler AZ 852245665 Clinical Trial/Study Agreement for P10-3 ITxM FIVE PARKWAY CENTER 875 GREENTREE ROAD PITTSBURGH PA 15220 Leukapheresis Collection Agreement James Whitmore Redacted Employment Agreement Jed Kaminetsky, MD, PC 215 Lexington Ave 20th Floor New York NY 10016 Clinical Trial/Study Agreement Jewish Hospital & St. Mary’s HealthCare, Inc. 200 Abraham Flexner Way Louisville KY 40202 Clinical Trial/Study Agreement for P10-3 Jewish Hospital St. Mary’s Healthcare 2401 Terra Crossing Boulevard Louisville KY 40245 Clinical Trial/Study Agreement for P12-1
6 of 16

LOGO

In re Dendreon Corporation Case No. 14 - 12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Jibe Consulting, Inc. 5000 MEADOWS ROAD, STE 300 LAKE OSWEGO OR 97035 Consulting Services Agreement
Johns Hopkins Medicine - Sidney Kimmel Clinical Trial/Study Agreement for P10 - 2 Comprehensive Cancer Center 1650 Orleans Street, CRB1, Room 1M45 The Bunting Blaustein Cancer Research Building Baltimore MD 21231 Johns Hopkins Medicine - Sidney Kimmel Clinical Trial/Study Agreement for P12 - 2 Comprehensive Cancer Center 1650 Orleans Street, CRB1, Room 1M45 The Bunting Blaustein Cancer Research Building Baltimore MD 21231 Johnson Controls PO BOX 730068 DALLAS TX 75373 Service Agreement Johnson Controls PO BOX 730068 DALLAS TX 75373 Supply Agreement Joilet Oncology - Hematology Associates, Ltd. 2614 W. Jefferson St Joilet IL 60435 Clinical Trial/Study Agreement for P10 - 3 Kaiser Foundation Hospitals 3800 N INTERSTATE AVE PORTLAND OR 97227 Clinical Trial/Study Agreement Kaiser Foundation Hospitals 3800 N INTERSTATE AVE PORTLAND OR 97227 Clinical Trial/Study Agreement for P07 - 2 Kaiser Permanente, Portland 3600 N Interstate Ave. Portland OR 97227 Clinical Trial/Study Agreement for P07 - 2 Kansas City Urology Care, PA 10701 Nall Ave, Suite 100 Overland Park KS 66211 Clinical Trial/Study Agreement for P10 - 3 Kansas City Urology Care, PA 10701 Nall Ave, Suite 100 Overland Park KS 66211 Clinical Trial/Study Agreement for P12 - 1 Karmanos Hospital 4100 John R, 4th Floor, Mail Code HW04HO Detroit MI 48201 Clinical Trial/Study Agreement Kathleen J. Day & Associates, LLC 6665 SUMMITVIEW DR HOLLAND MI 49423 Service Agreement Kaye - Smith Enterprises, Inc. PO BOX 956 RENTON WA 98057 Service Agreement Kaye - Smith Enterprises, Inc. PO BOX 956 RENTON WA 98057 Service Agreement Kentucky Blood Center 3121 Beaumont Centre Circle Lexington KY 40513 Leukapheresis Collection Agreement Key Biologics, LLC 1256 UNION AVENUE, SUITE 200 MEMPHIS TN 38104 Leukapheresis Collection Agreement Kim, Helen 6719 Silent Creek Ave SE Snoqualmie WA 98065 Staffing Agency Agreement Kirsten J Smith, Coaching & Consulting PO BOX 396 REDMOND WA 98073 Service Agreement Knickerbocker Properties, Inc. PO BOX 511464 LOS ANGELES CA 90051 Real Property Lease
KnowledgePoint360 LLC WINDMILL STREET VICTORIA MILL, MACCLESFIELD CHESHIRE SK11 7HQ UK Vendor Agreement and Related Projects and Amendments Laboratory Corporation of America Holdings PO BOX 12140 BURLINGTON NC 27216 Commercial Marketing Agreement LabWare, Inc. Three Mill Road Suite 102 Wilmington DE 19806 Purchasing Agreement Lahey Hospital & Medical Center 41 Mall Road Burlington MA 01805 Clinical Trial/Study Agreement for P10 - 3 Lancaster Urology 2106 Harrisburg Pike, Suite 200 Lancaster PA 17604 Clinical Trial/Study Agreement for P10 - 3 Lancaster Urology 2106 Harrisburg Pike, Suite 200 Lancaster PA 17604 Clinical Trial/Study Agreement for P12 - 1 Lash Group Healthcare Consultants 12679 COLLECTIONS CENTER DRIVE CHICAGO IL 60693
Commercial Marketing Agreement Laura & Isaac Perlmutter Cancer Center at NYU Clinical Trial/Study Agreement Langone 160 East 34th St, 8th Floor New York NY 10016 Laura & Isaac Perlmutter Cancer Center at NYU Clinical Trial/Study Agreement for N10 - 1 Langone 160 East 34th St, 8th Floor Clinical Cancer Center New York NY 10016 Laura & Isaac Perlmutter Cancer Center at NYU Clinical Trial/Study Agreement for P09 - 1 Langone 160 East 34th St, 8th Floor Clinical Cancer Center New York NY 10016 Leading Effect, LLC 7637 N. JERSEY STREET PORTLAND OR 97203 Consulting Services Agreement Lexington Medical Center/Lexinton Oncology Clinical Trial/Study Agreement for P10 - 3 Associates 2728 Sunset Boulevard West Columbia SC 29169 Life Technologies Corporation C/O BANK OF AMERICA 12088 COLLECTION CENTER DR CHICAGO IL 60693 Service Agreement Life Technologies Corporation C/O BANK OF AMERICA 12088 COLLECTION CENTER DR CHICAGO IL 60693 Service Agreement Life Technologies Corporation C/O BANK OF AMERICA 12088 COLLECTION CENTER DR CHICAGO IL 60693 Service Agreement LifeServe Blood Center 431 E Locust Street Des Moines IA 50309 Leukapheresis Collection Agreement Linked Urology Research Network 5555 Glenridge Connector Suite 200 Atlanta GA 30342 Clinical Trial/Study Agreement Liquent, Inc. 101 Gibraltar Road Suite 200 Horsham PA 19044 Software Maintenance Agreement Little Rock Hematology Oncology 9500 Baptist Health Drive Little Rock AR 72205 Clinical Trial/Study Agreement for P10 - 3 Lonza Biologics PLC 228 Bath Road Slough Berkshire SL1 4DY England Supply Agreement and Amendment Lonza Biologics PLC 228 Bath Road Slough Berkshire SL1 4DY England Evaluation Agreement Louisiana Oncology Associates Clinical Trial/Study Agreement for P10 - 3 4809 Ambassador Caffery Parkway, Suite 110 Lafayette LA 70508 M.D. Practice Solutions, LLC 2245 ENTERPRISE DRIVE SUITE 4506 WESTCHESTER IL 60154 Service Agreement M3 Media Group, Inc. 18 WEST AIRY STREET 2ND FLOOR NORRISTOWN PA 19401 Media Services Agreement Mary L. Disis Univ of WA, Box 356527 1959 NE Pacific Street, Room BB 1321 Seattle WA 98195 Clinical Trial/Study Agreement Matthew Cooperberg, MD 425 SPRUCE ST. SAN FRANCISCO CA 94118 Service Agreement and SOW
Maxsam Partners, Inc. 6947 Coal Creek Parkway SE Suite 3300 Newcastle WA 98059 Staffing Agreement Maxsam Partners, Inc. 6947 Coal Creek Parkway SE Suite 3300 Newcastle WA 98059 IT Agreement
Mayo Clinic Rochester 200 First St. SW Rochester MN 55905 Clinical Trial/Study Agreement and Amendments Mayo Clinic Rochester 200 First St. SW Rochester MN 55905 Clinical Trial/Study Agreement for N10 - 1 McFarland Clinic, PC 1215 Duff Avenue 2nd Floor Ames IA 50010 Clinical Trial/Study Agreement for P10 - 3 McKesson Specialty Health Pharmaceutical & Biotech Distributor Agreement and Amendment Solutions, LP PO BOX 846025 DALLAS TX 75284
7 of 16

LOGO

In re Dendreon Corporation Case No. 14 - 12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
McMahon Publishing Group 545 W. 45TH ST 8TH FLOOR NEW YORK NY 10036 Media Services Agreement
MEDIC Regional Blood Center 1601 AILOR AVE KNOXVILLE TN 37921 Leukapheresis Collection Agreement Medical Oncology Associates, PS 6001 N Mayfair Street Spokane WA 99208 Clinical Trial/Study Agreement for P10 - 3 Medical Oncology Associates, PS 6001 North Mayfair Street Spokane WA 99208 Clinical Trial/Study Agreement for P12 - 1 MedPro Systems LLC 100 STIERLI COURT, SUITE 100 MT. ARLINGTON NJ 07856 IT Agreement MedReviews, LLC 494 8TH AVENUE STE 1000 NEW YORK NY 10001 Marketing Services Agreement MedVal Scientific Information Services, LLC 30 VREELAND DRIVE, SUITE 2 SKILLMAN NJ 08558 Marketing Services Agreement Medvet Science Pty Ltd 38 Payneham Road Stepney 5069 South Australia Purchasing Agreement Memorial Hospital of South Bend, Inc. 615 N. Michigan Street South Bend IN 46601 Clinical Trial/Study Agreement Memorial Sloan - Kettering Cancer Center Sidney Kimmel Center for Prostate and Urologic Clinical Trial/Study Agreement for N10 - 1 353 E. 68th St. Cancer New York NY 10065 Metaplan, LLC 101 WALL STREET PRINCETON NJ 08540 Marketing Services Agreement Metro Urology 2855 Campus Drive, Suite 530 Plymouth MN 55441 Clinical Trial/Study Agreement for P12 - 1 Metro Urology 6025 Lake Rd, Suite 200 Woodbury MN 55125 Clinical Trial/Study Agreement for P12 - 1 Michigan Blood 1036 Fuller Ave NE Grand Rapids MI 49501 Leukapheresis Collection Agreement Michigan Institute of Urology 130 Town Center Dr., Suites 101 & 200 Troy MI 48084 Clinical Trial/Study Agreement for N10 - 1 Michigan Institute of Urology 130 Town Center Dr., Suites 101 & 200 Troy MI 48084 Clinical Trial/Study Agreement for P10 - 3 Michigan Institute of Urology 130 Town Center Dr., Suites 101 & 200 Troy MI 48084 Clinical Trial/Study Agreement for P11 - 4 Michigan Institute of Urology, PC 130 Town Center Dr., Suites 101 & 200 Troy MI 48084 Clinical Trial/Study Agreement for P12 - 1 Microsoft Licensing, GP 1401 ELM STREET, 5TH FLOOR LOCKBOX: 842467 DALLAS TX 75202 IT Agreement Microsoft Licensing, GP 1401 ELM STREET, 5TH FLOOR LOCKBOX: 842467 DALLAS TX 75202 IT Agreement Mid Atlantic Clinical Research 7500 Greenway Center Dr., 8th Floor Greenbelt MD 20770 Clinical Trial/Study Agreement for P11 - 3 Mid Atlantic Urology Associates 7500 Greenway Center Dr., 8th Floor Greenbelt MD 20770 Clinical Trial/Study Agreement for P12 - 1 Mid - Illinois Hematology & Oncology Associates, LTD Clinical Trial/Study Agreement for P10 - 3 407 East Vernon Avenue Suite 104 Normal IL 61761 Midtown Urology 1924 PIEDMONT ROAD NE 2ND FLOOR ATLANTA GA 30324 Clinical Trial/Study Agreement Midwestern Regional Medical Center 2520 Elisha Avenue Zion IL 60099 Clinical Trial/Study Agreement for P10 - 3
Millennium Medical Education Rescoures Ltd. 1980 SOUTH EASTON ROAD, SUITE 240 ATTN: KATHY HAMMOND DOYLESTOWN PA 18901 Marketing Services Agreement Millennium Medical Publishing, Inc. 611 BROADWAY, SUITE 310 NEW YORK NY 10012 Marketing Services Agreement Minnesota Oncology Hematology, P.A. 910 East 26th Street, Suites 100 and 200 Minneapolis MN 55404 Clinical Trial/Study Agreement for P10 - 3 Mississippi Blood Services 115 TREE STREET FLOWOOD MS 39232 Leukapheresis Collection Agreement Moffitt Cancer Center 12902 Magnolia Drive Tampa FL 33612 Clinical Trial/Study Agreement for P12 - 2 Moffitt Cancer Center 12902 Magnolia Drive Tampa FL 33612 Clinical Trial/Study Agreement for N10 - 1 Montefiore Medical Center 111 East 210th St Bronx NY 10467 Clinical Trial/Study Agreement for P10 - 3 Montefiore Medical Center 111 East 210th Street New York NY 104672401 Clinical Trial/Study Agreement for P12 - 1 Montefiore - Einstein Center for Cancer Care 1695 Eastchester Road Bronx NY 10461 Clinical Trial/Study Agreement for P11 - 4 Mount Sinai Medical Center ATTN: IMEE UNTO, DIRECTOR, ONCOLOGY Clinical Trial/Study Agreement for P10 - 3 15TH STREET AT CALIFORNIA AVENUE NURSING SINAI CANCER CARE CENTER CHICAGO IL 60608 Mount Sinai School of Medicine One Gustave L. Levy Place, Box 1075 New York NY 10029 Clinical Trial/Study Agreement Mount Sinai School of Medicine One Gustave Levy Place, Box 1272 Department of Urology New York NY 10029 Clinical Trial/Study Agreement Mount Sinai School of Medicine One Gustave Levy Place, Box 1272 Department of Urology New York NY 10029 Clinical Trial/Study Agreement Mount Sinai School of Medicine One Gustave Levy Place, Box 1272 Department of Urology New York NY 10029 Clinical Trial/Study Agreement for N10 - 1 Mount Sinai School of Medicine One Gustave Levy Place, Box 1272 Department of Urology New York NY 10029 Clinical Trial/Study Agreement for P07 - 2 Mount Sinai School of Medicine One Gustave Levy Place, Box 1272 Department of Urology New York NY 10029 Clinical Trial/Study Agreement for P07 - 2 Mount Sinai School of Medicine One Gustave Levy Place, Box 1272 Department of Urology New York NY 10029 Clinical Trial/Study Agreement for P09 - 1 Mount Sinai School of Medicine One Gustave Levy Place, Box 1272 Department of Urology New York NY 10029 Clinical Trial/Study Agreement for P11 Myron I. Murdock, M.D., LLC 7235 B HANOVER PARKWAY ATTN: LISA DRESZER GREENBELT MD 20770 Clinical Trial/Study Agreement for P09 - 1 Myron I. Murdock, M.D., LLC 7235 B HANOVER PARKWAY ATTN: LISA DRESZER GREENBELT MD 20770 Clinical Trial/Study Agreement for P10 - 3 National Jewish Health Western Oncology and Clinical Trial/Study Agreement for P10 - 3 Hematology 400 Indiana St. Suite 230 Golden CO 80401 National Oncology Consultants 8228 MAYFIELD RD – SUITE 2A CHESTERLAND OH 44026 Consulting Services Agreement Neag Comprehensive Cancer Center Clinical Trial/Study Agreement for N10 - 1 University of Connecticut Health Center 263 Farmington Ave. Farmington CT 06030 Neal Shore, MD 4 NELSON COURT MYRTLE BEACH SC 29572 Service Agreement Nebraska Hematology - Oncology, PC 4004 Pioneer Woods Drive Lincoln NE 68506 Clinical Trial/Study Agreement for P10 - 3 New Jersey Urology 1515 Broad Street Suite B140 Bloomfield NJ 7003 Clinical Trial/Study Agreement for P10 - 3 New Link (University of Minnesota) 200 Oak Street SE Minneapolis MN 55455 Clinical Trial/Study Agreement
New Mexico Cancer Care Associates 490 - A West Zia Road Santa Fe NM 87505 Clinical Trial/Study Agreement for P10 - 3 New Mexico Oncology Hemotology Consultants, Ltd. Clinical Trial/Study Agreement for P10 - 3 4901 Lang Avenue, NE Albuquerque NM 87109
8 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
New York Blood Center, Inc. PO BOX 9674 UNIONDALE NY 11553 Leukapheresis Collection Agreement
New York University School of Medicine BANK OF AMERICA PO BOX 415026 BOSTON MA 02241 Clinical Trial/Study Agreement and Amendments New York University School of Medicine BANK OF AMERICA PO BOX 415026 BOSTON MA 02241 Clinical Trial/Study Agreement for P10-3 North Shore Hematology Oncology Associates, PC. Clinical Trial/Study Agreement for P10-3 235 North Belle Mead Road East Setauket NY 11733 North Shore Hematology Oncology Associates, PC. Clinical Trial/Study Agreement for P11-4 235 North Belle Mead Road East Setauket NY 11733 North Shore Hematology Oncology Associates, PLLC Clinical Trial/Study Agreement for P12-1 235 North Belle Mead Road East Setauket NY 11733 Northern Indiana Cancer Research Consortium 3975 William Richardson Drive South Bend IN 46628 Clinical Trial/Study Agreement for P12-1 Northern New Jersey Cancer Center 100 FIRST ST. SUITE 301 FINANCE DEPARTMENT HACKENSACK NJ 07601 Leukapheresis Collection Agreement Northwest Cancer Specialists 1498 SE TECH CENTER PL, SUITE 240 ATTN: TONI ANDERSON VANCOUVER WA 98683 Clinical Trial/Study Agreement Northwest Cancer Specialists, PC 19260 SW 65th Ave. Ste. 435 Tualatin OR 97062 Clinical Trial/Study Agreement for P07-2 Northwest Cancer Specialists, PC 19260 SW 65th Ave. Ste. 435 Tualatin OR 97062 Clinical Trial/Study Agreement for P10-3 Northwest Cancer Specialists, PC 19260 SW 65th Ave. Ste. 435 Tualatin OR 97062 Clinical Trial/Study Agreement for P11-4 Northwest Florida Hematology Oncology PA 301 W 26th Street Lynn Haven FL 32444 Clinical Trial/Study Agreement for P10-3 Northwest Georgia Oncology Centers, P.C. 340 Kennestone Hospital Blvd, Suite 200 Marietta GA 30060 Clinical Trial/Study Agreement for P10-3 Northwest Georgia Oncology Centers, P.C. 340 Kennestone Hospital Blvd, Suite 200 Marietta GA 30060 Clinical Trial/Study Agreement for P11-4 Northwest Medical Specialties, PLLC 1624 South I Street, Suite#200 Tacoma WA 98405 Clinical Trial/Study Agreement for P12-2 Norwalk Hospital 24 Stevens Street Norwalk CT 06856 Clinical Trial/Study Agreement for P10-3 Nulli Secundus Inc. #401, 1228 KENSINGTON ROAD NW CALGARY T2N 3P7 CANADA Vendor Agreement NuWest Group, Inc. dba LabTemps P.O. BOX 40285 BELLEVUE WA 98015 Professional Services Agreement NYU School of Medicine 550 First Avenue VET10W New York NY 10016 Clinical Trial/Study Agreement Ocala Oncology Center 433 Southwest 10th Street Ocala FL 34471 Clinical Trial/Study Agreement for P10-3 Ohio State University Comprehensive Cancer Center Clinical Trial/Study Agreement for P10-3 300 W. 10th Avenue Columbus OH 432101280 Oklahoma Blood Institute 1001 N Lincoln Blvd Oklahoma City OK 73104 Clinical Trial/Study Agreement Omnicia, Inc.
400 Oyster Point Blvd, Suite 311 South San Francisco CA 94080 IT Agreement OmniRIM Solutions, Inc. 1066 West Hastings Street, Ste 2400 Vancouver BC V6E 3X1 Canada IT Agreement OmniRIM Solutions, Inc. 1066 West Hastings Street, Ste 2400 Vancouver BC V6E 3X1 Canada Vendor Agreement Oncology Hematology West, PC dba Nebraska Cancer Clinical Trial/Study Agreement for P10-3 Specialists 17201 Wright Street, Suite 200 Omaha NE 68130 Oncology San Antonio Research, LLC 9102 Floyd Curl Drive San Antonio TX 78240 Clinical Trial/Study Agreement for P10-3 Oncology San Antonio Research, LLC 9102 Floyd Curl Drive San Antonio TX 78240 Clinical Trial/Study Agreement for P12-1 Oncology Specialists P.O. BOX 736 PARK RIDGE IL 60068 Clinical Trial/Study Agreement Oncology Specialists P.O. BOX 736 PARK RIDGE IL 60068 Clinical Trial/Study Agreement for P09-1 Oncology Specialists P.O. BOX 736 PARK RIDGE IL 60068 Clinical Trial/Study Agreement for P10-3 Oncology Specialists, S.C. 7900 Milwaukee Ave. Niles IL 60714 Clinical Trial/Study Agreement for P09-1 Oncology Specialists, S.C. 7900 Milwaukee Ave. Niles IL 60714 Clinical Trial/Study Agreement for P11 One World, Inc. 6 Campus Drive Parsippany NJ 07054 Marketing Services Agreement OneBlood, Inc PO BOX 628342 ORLANDO FL 32862 Leukapheresis Collection Agreement Onmark, Inc. 16360 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Pricing/Rebate Agreement and Amendments onPoint Oncology, LLC 3006 PINE TRAIL CIRCLE HUDSON OH 44236 Vendor Agreement OP Solutions, Inc. 237 1ST AVE 5TH FLOOR NEW YORK NY 10003 Clinical Trial/Study Agreement OP Solutions, Inc. 237 1ST AVE 5TH FLOOR NEW YORK NY 10003 Vendor Agreement Oracle Corporation PO BOX 44471 SAN FRANCISCO CA 94144 IT Agreement Oracle Corporation PO BOX 44471 SAN FRANCISCO CA 94144 IT Agreement Oracle Corporation PO BOX 44471 SAN FRANCISCO CA 94144 IT Agreement Oregon Health & Science University MAILDCODE L106SPA 0690 SW BANCROFT ST PORTLAND OR 97239 Clinical Trial/Study Agreement Oregon Health & Science University - Knight Cancer Clinical Trial/Study Agreement for N10-1 Institute 15700 SW Greystone Ct., Mail Code CMNB Hematology Oncology Beaverton OR 97006 Oregon Health and Science University 3303 SW Bond Ave., Mail Code CH14R Division of Hematology & Oncology Portland OR 97239 Clinical Trial/Study Agreement for P10-1 Oregon Health and Science University 3303 SW Bond Ave., Mail Code CH14R Division of Hematology & Oncology Portland OR 97239 Clinical Trial/Study Agreement for P11 Oregon Urology Institute 2400 Hartman Lane Springfield OR 97477 Clinical Trial/Study Agreement Oregon Urology Institute 2400 Hartman Lane Springfield OR 97477 Clinical Trial/Study Agreement for N10-1 Oregon Urology Institute 2400 Hartman Lane Springfield OR 97477 Clinical Trial/Study Agreement for P10-3 Oregon Urology Institute 2400 Hartman Lane Springfield OR 97477 Clinical Trial/Study Agreement for P11-4 Oregon Urology Institute Research 2400 Hartman Lane Springfield OR 97477 Clinical Trial/Study Agreement for P12-1 OriGen Biomedical Inc 7000 BURLESON BUILDING #D AUSTIN TX 78744 Supply Agreement Pacific Shores Oncology Medical Group 3791 Katella Avenue Suite 205 Los Alamitos CA 907203105 Clinical Trial/Study Agreement for P10-3
9 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Padmanee Sharma, M.D., Ph.D 4614 PINE STREET BELLAIRE TX 77401 Consulting Services Agreement
Palo Verde Cancer Specialists 5601 Eugie Ave, Suite 106 Glendale AZ 85304 Clinical Trial/Study Agreement for P10-3 PAREXEL International, LLC 9268 PAYSPHERE CIRCLE CHICAGO IL 60674 Vendor Agreement Patheon UK Limited Service Agreement ACCOUNTS, KINGFISHER DRIVE, COVINGHAM SWINDON, WILTSHIRE SN3 5BZ UK
Patient Access Network 1331 F ST NW STE 975 WASHINGTON DC 20004 Donation Agreement
Peachtree Hematology Oncology Consultants, P.C. Clinical Trial/Study Agreement 1800 Howell Mill Rd, Ste 800 Atlanta GA 30318 Pearson Consulting Group, LLC 7701 ESCALA DRIVE AUSTIN TX 78735 Professional Services Agreement Performance Power Concepts 11636 SE 5TH STREET, SUITE 200 BELLEVUE WA 98005 Service and Maintenance Agreement Pharma Start LLC 2100 SANDERS ROAD, SUITE 195 NORTHBROOK IL 60062 Vendor Agreement PharmaCell B.V. 6201 BH MAASTRICHT PO BOX 1331 NETHERLANDS Operating Agreement Pharmaceutical Research Associates, Inc. P.O. BOX 200072 DALLAS TX 75320 CRO Agreement Pharmaceutical Safety Assessments, Inc. 45 EAST CITY AVE, SUITE 455 BALA CYNWOOD PA 19004 Service Agreement PharmaLicence, LLC P.O. BOX 13 POWELL OH 43065 IT Agreement Pharmefex LLC 15633 SE 54TH ST BELLEVUE WA 98006 Consulting Services Agreement Physicians’ Clinic of Iowa, P.C.-Hematology & Oncology Clinical Trial/Study Agreement 855 A Avenue NE, Suite 420 Cedar Rapids IA 52402 Pilgrim Software, Inc DEPT AT 952090 ATLANTA GA 31192 Subscription Services Agreement Pinnacle Oncology Hematolgoy 9055 East Del Camino, Suite 100 Scottsdale AZ 85258 Clinical Trial/Study Agreement for P10-3 Pitney Bowes Management Services, Inc. P.O. BOX 845801 DALLAS TX 75284 Service Agreement for NJ Office Pitney Bowes Management Services, Inc. P.O. BOX 845801 DALLAS TX 75284 Service Agreement for Seattle Office PleaseTech Ltd. Rock House Mynyddbach Chepstow NP16 6RP UK Software Agreement and Amendments PMK Medical Group, Inc, dba Ventura County Clinical Trial/Study Agreement for P10-3 Hematology Oncology Specialists 1700 N. Rose Ave, Suite 320 Oxnard CA 93030 Point B Solutions Group, LLP 1420 5th Ave, Ste 2200 Seattle WA 98101 Professional Services Agreement Polaris Solutions, LLC 100 BROADWAY 7TH FLOOR NEW YORK NY 10005 Service Agreement Porzio Life Sciences, LLC PO BOX 1997 100 SOUTHGATE PARKWAY MORRISTOWN NJ 07962 Services Agreement Porzio Life Sciences, LLC PO BOX 1997 100 SOUTHGATE PARKWAY MORRISTOWN NJ 07962 Software Services Agreement Premier Medical Group of the Hudson Valley
1 COLUMBIA ST, SUITE 390 POUGHKEEPSIE NY 12601 Clinical Trial/Study Agreement Premier Medical Group of the Hudson Valley, P.C. Clinical Trial/Study Agreement for P12-1
1 Columbia St., Suite 390 Poughkeepsie NY 12601
Premier Medical Group of the Hudson Valley, PC 1 Columbia St., Suite 390 Poughkeepsie NY 12601 Clinical Trial/Study Agreement for P10-3 Premier Medical Group of the Hudson Valley, PC 1 Columbia St., Suite 390 Poughkeepsie NY 12601 Clinical Trial/Study Agreement for P11-4 Presbyterian Hospital Cancer Center 200 Hawthorne Lane Charlotte NC 28204 Clinical Trial/Study Agreement for P10-3 Prometheus Media LLC 195 BROADWAY, 29TH FLOOR NEW YORK NY 10007 Commercial Marketing Agreement Prometheus Media LLC 195 BROADWAY, 29TH FLOOR NEW YORK NY 10007 Commercial Marketing Agreement Prometheus Media LLC 195 BROADWAY, 29TH FLOOR NEW YORK NY 10007 Commercial Marketing Agreement Prostate Oncology 4676 Admiralty Way, Suite 101 Marina del Rey CA 90292 Clinical Trial/Study Agreement Prostate Oncology Specialists 4676 Admiralty Way, Suite 101 Marina del Rey CA 90292 Clinical Trial/Study Agreement for P12-1
Prostate Oncology Specialists, Inc. 4676 ADMIRALTY WAY STE 101 MARINA DEL REY CA 90292 Clinical Trial/Study Agreement and Amendments Prostate Oncology Specialists, Inc. 4676 ADMIRALTY WAY STE 101 MARINA DEL REY CA 90292 Clinical Trial/Study Agreement for P10-3 Prostate Oncology Specialists, Inc. 4676 Admiralty Way, Suite 101 Marina del Rey CA 90292 Clinical Trial/Study Agreement for P11-4 Providence Cancer Center 4805 NE Glisan St., #6N40/2N35 Oncology and Hematology Care Eastside Portland OR 97213 Clinical Trial/Study Agreement for P07-2 Providence Cancer Center 4805 NE Glisan St., #6N40/2N35 Oncology and Hematology Care Eastside Portland OR 97213 Clinical Trial/Study Agreement for P11-3 Providence Cancer Center 4805 NE Glisan St., #6N40/2N35 Oncology and Hematology Care Eastside Portland OR 97213 Clinical Trial/Study Agreement for P11-4 Providence Medical Center 4805 NE Glisan Street Room 2N82 Portland OR 97213 Clinical Trial/Study Agreement for P11 Providence Portland Medical Center ATTENTION SUE RICH PO BOX 13993 PORTLAND OR 97213 Clinical Trial/Study Agreement Prudential Cleanroom Services P.O. BOX 11210 SANTA ANA CA 92711 Supply Agreement Prudential Cleanroom Services P.O. BOX 11210 SANTA ANA CA 92711 Supply Agreement Puget Sound Blood Center 921 TERRY AVE SEATTLE WA 98104 Leukapheresis Collection Agreement Puget Sound Blood Center 921 TERRY AVE SEATTLE WA 98104 Leukapheresis Collection Agreement Q International Courier, Inc. Chelsea Piers, Pier 59 Suite 201 New York NY 10011 Courier Agreement Queens Medical Associates 176-60 Union Turnpike Suite 360 Fresh Meadows NY 11366 Clinical Trial/Study Agreement for P10-3 Radboud University Nijmegen Medical Centre Postbus 9101 Internal Postcode 659 Nijmegen, Gelderland 6500 HB Netherlands Vendor Agreement Radiant Systems, Inc. 107B - CORPORATE BOULEVARD SOUTH PLAINFIELD NJ 07080 Staffing Agency Agreement Radius Medical Animation LLC 5613 CROSS COUNTRY BLVD BALTIMORE MD 21209 Vendor Agreement Raleigh Hematology Oncology Associates, D.B.A. Clinical Trial/Study Agreement for P12-2 Cancer Centers of North Carolina 10 Bryan-Searle Dr., 471 Seeley Mudd Building Durham NC 27710 Rearview Marketing Solutions, Inc. 126 TOPAZ DRIVE FRANKLIN PARK NJ 08823 Marketing Services Agreement
10 of 16

LOGO

In re Dendreon Corporation Case No. 14 - 12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Recall Total Information Management, Inc. 015295 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Storage Agreement Recall Total Information Management, Inc. 015295 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Subscription Agreement Regents of the University of Minnesota NW 5957 PO BOX 1450 MINNEAPOLIS MN 55485 Clinical Trial/Study Agreement
Regional Cancer Care, P.A. 4411 Ben Franklin Boulevard Durham NC 27704 Clinical Trial/Study Agreement for P10-3 Regional Urology, LLC 255 Bert Kouns Shreveport LA 71106 Clinical Trial/Study Agreement for P12-1 Rhode Island Blood Center/Hospital 164 SUMMIT AVE, FAIN 2 ONCOLOGY NURSING EDUCATION DAY PROVIDENCE RI 02906 Leukapheresis Collection Agreement Richard Gaeto Redacted Employment Agreement Right Track Regulatory, Ltd. 3 BISHOP SQUARE 2ND FLOOR TITAN COURT HATFIELD AL109 UK Vendor Agreement Rimini Street, Inc 3993 HOWARD HUGES PKWY. SUITE 780 LAS VEGAS NV 89169 Master Services Agreement Rivet Software, Inc. 62927 COLLECTION CENTER DRIVE CHICAGO IL 60693 IT Agreement RMD Clinical Research Institute, LLC 675 W. North Ave #605 Melrose Park IL 60160 Clinical Trial/Study Agreement for P12-1 Robert A. Moss, M.D., F.A.C.P., Inc. 11100 Warner Ave Suite 200 Fountain Valley CA 92708 Clinical Trial/Study Agreement Robert Crotty Redacted Employment Agreement Rock River Valley Blood Center 419 NORTH SIXTH STREET ROCKFORD IL 61110 Leukapheresis Collection Agreement Rock Solid Meetings and Events SUITE D3/103 321 HIGH SCHOOL RD BAINBRIDGE ISLAND WA 98110 Service Agreement Rocky Mountain Cancer Centers 1800 Williams Street, Suite 200 Denver CO 80218 Clinical Trial/Study Agreement for P10-3 Roswell Park Cancer Institute Elm and Carlton Streets Buffalo NY 14263 Clinical Trial/Study Agreement Roswell Park Cancer Institute Elm and Carlton Streets Buffalo NY 14263 Clinical Trial/Study Agreement for N10-1 Roswell Park Cancer Institute Elm and Carlton Streets Buffalo NY 14263 Clinical Trial/Study Agreement for P10-3 RPR Investigations (Rinaldi) PO BOX 161 NESHANIC STATION NJ 08853 Service Agreement RR Donnelley 111 S. Wacker Drive Chicago IL 60606 Data Room Agreement Runzheimer International Ltd. 1 RUNZHEIMER PARKWAY WATERFORD WI 53185 Service Agreement Sacred Heart Medical Oncology Group 1545 Airport Blvd, Suite 2000 Pensacola FL 32504 Clinical Trial/Study Agreement Salesforce.com P.O. BOX 203141 DALLAS TX 75320 Subscription Services Agreement Sartor, Oliver, M.D. Tulane Medical School 1430 Tulane Ave, SL78 New Orleans LA 70112 Service Agreement SAS Institute, Inc. PO BOX 406922 ATLANTA GA 30384 Clinical Trial/Study Agreement SAVVIS Communications Corporation 13322 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Hosting Agreement SAVVIS Communications Corporation 13322 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Co-Location Agreement SAVVIS Communications Corporation 13322 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 IT Agreement
Schindler Elevator Corporation P.O. BOX 93050 CHICAGO IL 60673 Warranty Agreement Scranton Hematology Oncology 743 Jefferson Avenue, Suite 205 Scranton PA 18510 Clinical Trial/Study Agreement for P10-3 Seattle Cancer Care Alliance 825 Eastlake Ave. E., G4-830 Seattle WA 98109 Clinical Trial/Study Agreement for P07-2 Seattle Cancer Care Alliance 825 Eastlake Ave. E., G4 -830 Seattle WA 98109 Clinical Trial/Study Agreement for P10-2 Seattle Cancer Care Alliance 825 Eastlake Ave. E., G4-830 Seattle WA 98109 Clinical Trial/Study Agreement for P10-3 Seattle Cancer Care Alliance 825 Eastlake Ave. E., G4-830 Seattle WA 98109 Clinical Trial/Study Agreement for P11-4 See, William MD 9200 W. Wisconsin Ave Milwaukee WI 53226 Service Agreement Sharp HealthCare 7901 Frost St. Clinical Oncology Research San Diego CA 92123 Clinical Trial/Study Agreement for P07-2 Sharp HealthCare 7901 Frost St. San Diego CA 92123 Clinical Trial/Study Agreement for P10-3 Sharp Healthcare 7901 Frost St. Clinical Oncology Research San Diego CA 92123 Clinical Trial/Study Agreement for P11-3 Sharp Memorial Hospital ATTN: CATHY WOOD 7901 FROST ST SAN DIEGO CA 92123 Clinical Trial/Study Agreement Siemens Industry, Inc. PO BOX 2134 CAROL STREAM IL 60132 Master Services Agreement Sloan-Kettering Institute for Cancer Research PO BOX 29049 NEW YORK NY 10087 Clinical Trial/Study Agreement Small, Eric, M.D. 1600 Divisadero Street, A-734 San Francisco CA 94143 Clinical Trial/Study Agreement Source Healthcare Analytics, LLC PO BOX 277158 ATLANTA GA 30384 Commercial Marketing Agreement South Carolina Oncology Associates, PA 166 Stoneridge Drive Columbia SC 29210 Clinical Trial/Study Agreement for P10-3 South Carolina Oncology Associates, PA 166 Stoneridge Drive Columbia SC 29210 Clinical Trial/Study Agreement for P11-4 South Orange County Medical Research 25200 La Paz Road Laguna Hilla CA 92653 Clinical Trial/Study Agreement South Texas Accelerated Research Therapeutics PO BOX 1994 SAN ANTONIO TX 78297 Clinical Trial/Study Agreement South Texas Blood & Tissue Center 6211 IH-10 West San Antonio TX 78201 Leukapheresis Collection Agreement Southeast Nebraska Cancer Center 201 S. 68th St. Place, Suite 200 Lincoln NE 68510 Clinical Trial/Study Agreement for P10-3 Southeast Nebraska Cancer Center 201 S. 68th St. Place, Suite 200 Lincoln NE 68510 Clinical Trial/Study Agreement for P11-4 Southeast Nebraska Cancer Center 201 S. 68th St. Place, Suite 200 Lincoln NE 68510 Clinical Trial/Study Agreement for P12-1 Southeastern Research Group, Inc. 2000 Centre Pointe Boulevard Tallahassee FL 32308 Clinical Trial/Study Agreement for P10-3 Southwest Urology 6900 Pearl Road Suite 200 Middleburg Heights OH 44130 Clinical Trial/Study Agreement for P10-3 Sparta Cancer Center 89 Sparta Avenue Suite 130 Sparta NJ 78711777 Clinical Trial/Study Agreement for P10-3 Spotfire Tibco Software Inc 3303 Hillview Avenue Palo Alto CA 94304 IT Agreement Sprint Solutions, Inc 2001 Edmund Halley DR Reston VA 20191 Master Services Agreement St. Louis Cancer Care, LLP 12277 DePaul Dr., Suite 100 S Bridgeton MO 63044 Clinical Trial/Study Agreement for P10-3 St. Louis Cancer Care, LLP 12277 DePaul Dr., Suite 100 S Bridgeton MO 63044 Clinical Trial/Study Agreement for P11-4 Stanford University Medical Center 875 Blake Wilbur Dr. Stanford CA 94305 Clinical Trial/Study Agreement for N10-1
11 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Staten Island Urological Research, PC 1800 CLOVE ROAD STATEN ISLAND NY 10304 Clinical Trial/Study Agreement StatWorks, Inc. 101 B Street Carrboro NC 27510 Clinical Trial/Study Agreement
Steward Sr. Elizabeth’s Medical Center of Boston, Inc. Clinical Trial/Study Agreement for P10-3 736 Cambridge Street Boston MA 02135 Stovall Grainger Modleski Inc. 6515 TRILLIUM HOUSE LANE CENTREVILLE VA 20120 Marketing Services Agreement StratusG, LLC 7438 SE 40TH MERCER ISLAND WA 98040 Service Agreement StratusG, LLC 7438 SE 40TH MERCER ISLAND WA 98040 Service Agreement Suburban Hematology and Oncology Associates 631 Professional Drive Suite 450 Lawrenceville GA 30046 Clinical Trial/Study Agreement for P10-3 SuccessFactors, Inc. PO BOX 89 4642 LOS ANGELES CA 90189 Subscription Services Agreement Suncoast Communities Blood Bank 1760 Mound Street Sarasota FL 34236 Leukapheresis Collection Agreement Sutter Cancer Center 2800 L Street, Suite 410 Sacramento CA 95816 Clinical Trial/Study Agreement for P10-3 Sutter Medical Group 2800 L Street #300 Sacramento CA 95816 Clinical Trial/Study Agreement for P12-1 Swedish Health Services 747 Broadway Seattle WA 981224307 Clinical Trial/Study Agreement Tableau Software, Inc. PO BOX 204021 DALLAS TX 75320 IT Agreement Taos Mountain, Inc. PO BOX 225 SANTA CLARA CA 95052 IT Agreement Target Human Resources Inc. 1130 US HIGHWAY 202 BLDG E RARITAN NJ 08869 Service Agreement TEKNOVARE PRODOP CORPORATION 1499 BLAKE ST UNIT 1K DENVER CO 80202 Vendor Agreement Tennessee Oncology 300 20th Avenue Suite 301 Nashville TN 37203 Clinical Trial/Study Agreement for P10-3 Texas Oncology-Austin 901 West 38th Street, Suite 200 Austin TX 78705 Clinical Trial/Study Agreement for P10-3 Texas Oncology - Memorial City 925 Gessner Suite 550 Houston TX 77024 Clinical Trial/Study Agreement for P10-3 Texas Oncology - Waco 1700 W. Highway 6 Waco TX 76712 Clinical Trial/Study Agreement for P10 - 3 Texas Oncology - Abilene 1957 Artillary Road Abilene TX 79606 Clinical Trial/Study Agreement for P10-3 Texas Oncology - Baylor Charles A Sammons Cancer Clinical Trial/Study Agreement for P10-3 Center 3410 Worth Street, Suites 300 and 400 Dallas TX 75246 Texas Oncology - Beaumont, Mamie McFaddin Ward Clinical Trial/Study Agreement for P10-3 Cancer Center 690 North 14th Street Beaumont TX 77702 Texas Oncology - Dallas Presbyterian Hospital 8220 Walnut Hill Lane, Suite 700, Professional Clinical Trial/Study Agreement for P10-3 Bldg II Dallas TX 75231 Texas Oncology - Deke Slayton Cancer Center 501 Medical Center Boulevard Webster TX 77598 Clinical Trial/Study Agreement for P10-3 Texas Oncology - Denton South 3720 I 35 East Denton TX 76210 Clinical Trial/Study Agreement for P10-3 Texas Oncology-El Paso Center Treatment Center Clinical Trial/Study Agreement for P10-3 Gateway 7848 Gateway East El Paso TX 79915 Texas Oncology - Fort Worth 12th Ave 1001 12th Avenue, Suite 200 Fort Worth TX 76104 Clinical Trial/Study Agreement for P10-3
Texas Oncology - Fort Worth 12th Ave 1001 12th Avenue, Suite 200 Fort Worth TX 76104 Clinical Trial/Study Agreement for P11-4 Texas Oncology - Lewisville 2790 Lake Vista Drive Lewisville TX 75067 Clinical Trial/Study Agreement for P10 - 3 The Access Group (Access Communications) 400 Connell Drive, Floor 2 Berkeley Heights NJ 07922 Marketing Services Agreement The Blood Alliance 7595 Centurion Pkwy Jacksonville FL 32256 Leukapheresis Collection Agreement The Blood Center 1300 Division Road, Suite 102 West Warwick RI 02893 Leukapheresis Collection Agreement The Blood Connection 1099 Bracken Road Piedmont SC 29673 Leukapheresis Collection Agreement The Board of Trustees of The Leland Stanford Junio Clinical Trial/Study Agreement 301 Ravenswood Avenue, 2nd Floor Menlo Park CA 940253434 The Board of Trustees of The Leland Stanford Junio Clinical Trial/Study Agreement 301 Ravenswood Avenue, 2nd Floor Menlo Park CA 940253434 The Chester County Hospital and Health System 701 East Marshall Street West Chester PA 19380 Clinical Trial/Study Agreement The Jones Clinic, PC 7710 Wolf River Circle Germantown TN 38138 Clinical Trial/Study Agreement The Lynx Group, LLC 1249 South River Road Suite 202A Cranbury NJ 08512 Marketing Services Agreement The Medical Center, Inc. dba John B. Amos Cancer Clinical Trial/Study Agreement Center 710 Center Street Columbus GA 31902 The Northwestern Mutual Life Insurance Company Insurance Agreement C/O Unico Properties LLC 1301 Second Avenue, Suite 730 Seattle WA 98001 The Northwestern Mutual Life Insurance Company Insurance Agreement C/O Unico Properties LLC 1301 Second Avenue, Suite 730 Seattle WA 98001 The Regents of the Univ of CA, San Diego 9500 Gilman Drive University Center 202 La Jolla CA 92093 Clinical Trial/Study Agreement The Regional Cancer Center 2500 West 12th Street Erie PA 16505 Clinical Trial/Study Agreement for P10-3 The Scripps Research Institute 10550 North Torrey Pines Road La Jolla CA 92037 Clinical Trial/Study Agreement The Stamford Hospital 30 Shelburne Road Stamford CT 06904 Clinical Trial/Study Agreement The University of Chicago Medical Center 5841 S. Maryland Ave., Mail Code 2115 Chicago IL 606371470 Clinical Trial/Study Agreement for N10-1 The University of Kansas Cancer Center 2330 Shawnee Mission Parkway Westwood KS 66205 Clinical Trial/Study Agreement for N10-1 The University of Kansas Cancer Center 2330 Shawnee Mission Parkway Westwood KS 66205 Clinical Trial/Study Agreement for P10-3
12 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
The University of Texas - MD Anderson Cancer Center Clinical Trial/Study Agreement for N10 - 1 1155 Pressler St. CPB7.3508, Unit #1374 Houston TX 770303721 The University of Wisconsin - Carbone Cancer Center Clinical Trial/Study Agreement for N10 - 1 1111 Highland Ave., WIMR Room 7007 Madison WI 53705 The Urological Institute of Northeastern New York Clinical Trial/Study Agreement for P10-2
23 Hackett Blvd. Community Care Physicians, PC Albany NY 12208
The Urology Center of Colorado 2777 Mile High Stadium Circle Denver CO 80211 Clinical Trial/Study Agreement for N10-1 The Urology Center of Colorado 2777 Mile High Stadium Circle Denver CO 80211 Clinical Trial/Study Agreement for P10-2 The Urology Center of Colorado 2777 Mile High Stadium Circle Denver CO 80211 Clinical Trial/Study Agreement for P11-3 The Urology Center of Colorado 2777 Mile High Stadium Circle Denver CO 80211 Clinical Trial/Study Agreement for P11-4 The Urology Center of Colorado 2777 Mile High Stadium Circle Denver CO 80211 Clinical Trial/Study Agreement for P12-1 The Urology Center of Colorado 2777 Mile High Stadium Circle Denver CO 80211 Clinical Trial/Study Agreement for P12-2 The West Clinic, P.C. 100 N. Humphreys Boulevard Memphis TN 38120 Clinical Trial/Study Agreement for P10-3 Thomas Direct Studios 33 PLYMOUTH STREET SUITE LL3 MONTCLAIR NJ 07042 Marketing Services Agreement Thomas Jefferson University 1025 Walnut St, Suite 700 Philadelphia PA 19107 Clinical Trial/Study Agreement for N10-1 Thomas Jefferson University 1025 Walnut St, Suite 700 Philadelphia PA 19107 Clinical Trial/Study Agreement for P12-2 TMS Health, LLC C/O ACS P.O. BOX 201322 DALLAS TX 75320 Marketing Services Agreement Tower Urology 8635 West Third Street, Suite 1 West Los Angeles CA 90048 Clinical Trial/Study Agreement for P10-3 Tower Urology 8635 West Third Street, Suite 1 West Los Angeles CA 90048 Clinical Trial/Study Agreement for P11-4 Townsend, Townsend, and Crew LLP 2 Embarcadero Center San Francisco CA 94111 Vendor Agreement TransPerfect Translations International, Inc. 3 PARK AVENUE, 39THFLR NEW YORK NY 10016 Vendor Agreement Tri Valley Urology Medical Group 25495 Medical Center Drive Suite 2014 Murrieta CA 92562 Clinical Trial/Study Agreement Trialomics, LLC 900 LENORA ST. UNIT 508 SEATTLE WA 98121 Consulting Services Agreement Trinity Partners, LLC 230 THIRD AVE WALTHAM MA 02451 Commercial Marketing Agreement TriState Urologic Services PSC, Inc. DBA TUG Research Clinical Trial/Study Agreement 4700 SMITH ROAD dba THE UROLOGY GROUP CINCINNATI OH 45212 TRM Oncology SUITE 260 TWO CONCOURSE PARKWAY ATLANTA GA 30328 Marketing Services Agreement Trustees of Columbia Universiy in the City of New York, Clinical Trial/Study Agreement for P07-2 The 622 WEST 168TH ST PH15 CENTER 1540
OFFICE OF CLINICAL TRIALS NEW YORK NY 10032 Trustees of Columbia Universiy in the City of New York, Clinical Trial/Study Agreement for P09 - 1 The 622 WEST 168TH ST PH15 CENTER 1540 OFFICE OF CLINICAL TRIALS NEW YORK NY 10032 Trustees of Indiana University Office of Research Administration, Clinical Trials Clinical Trial/Study Agreement for N10 - 1 Contracting 550 University Blvd., Rm 5533 Indianapolis IN 46202 Trustees of Indiana University Office of Research Administration, Clinical Trials Clinical Trial/Study Agreement for P07-2 Contracting 550 University Blvd., Rm 5533 Indianapolis IN 46202 Trustees of Indiana University Office of Research Administration, Clinical Trials Clinical Trial/Study Agreement for P09 - 1 Contracting 550 University Blvd., Rm 5533 Indianapolis IN 46202 Tufts Medical Center 800 Washington St., Box 245 Boston MA 02111 Clinical Trial/Study Agreement for P10 - 3 Tufts Medical Center 800 Washington St., Box 245 Boston MA 02111 Clinical Trial/Study Agreement for P11 - 4 Tulane University 1415 Tulane Ave. HC-62 New Orleans LA 70112 Clinical Trial/Study Agreement for P12 - 1 Tulane University Health Sciences Center 1415 Tulane Ave. HC - 62 New Orleans LA 70112 Clinical Trial/Study Agreement for P11 - 4 Tulane University Health Sciences Center 1415 Tulane Ave. HC - 62 New Orleans LA 70112 Clinical Trial/Study Agreement for P10 - 3 Tulane University Hospital & Clinic 1415 TULANE AVE. SL 68 NEW ORLEANS LA 70112 Clinical Trial/Study Agreement UCLA Center for Health Sciences, Rm 66 - 134 10833 Le Conte Ave Los Angeles CA 90095 Clinical Trial/Study Agreement UCLA Institute of Urologic Oncology 10833 Le Conte Avenue Los Angeles CA 900953075 Clinical Trial/Study Agreement for P10 - 3 UCSF Comprehensive Cancer Center 1600 Divisadero St. 3rd Floor San Francisco CA 94115 Clinical Trial/Study Agreement UCSF Comprehensive Cancer Center 1600 Divisadero St. 3rd Floor San Francisco CA 94115 Clinical Trial/Study Agreement for P11 - 3 UMC St Radboud Hospital Geert Grooteplein - Zuid 10 Department of Urology 6525 GA Nijmegen Clinical Trial/Study Agreement for P11 - 1 United BioSource Corporation attn: TVC ACCOUNTS RECEIVABLE 4445 WILLARD AVE, 12th FLOOR CHEVY CHASE MD 20815 CRO Agreement and Amendments Unity Oncology, LLC 62489 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 GPO Agreement and Amendment University Health Network 7 - 504 619 University Ave Toronto ON M5G 2M9 Canada Clinical Trial/Study Agreement University Health Network 7 - 504 619 University Ave Toronto ON M5G 2M9 Canada Clinical Trial/Study Agreement University Hematology Oncology INC 1052 Martin Luther King Drive Suite #2 Centralia IL 62801 Clinical Trial/Study Agreement University of California - San Francisco 500 Parnassus Avenue SAN FRANCISCO CA 94143 Clinical Trial/Study Agreement University of California San Diego - Moores Cancer Clinical Trial/Study Agreement for P07 - 2 Center 3855 Health Sciences Dr. La Jolla CA 92093 University of California San Diego - Moores Cancer Clinical Trial/Study Agreement for P10 - 2 Center 3855 Health Sciences Dr. La Jolla CA 92093 University of California San Diego - Moores Cancer Clinical Trial/Study Agreement for P10 - 3 Center 3855 Health Sciences Dr. La Jolla CA 92093
13 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
University of California San Diego - Moores Cancer Clinical Trial/Study Agreement for P11-3 Center 3855 Health Sciences Dr. La Jolla CA 92093 University of Chicago SONYA BOWEN, FINANCIAL ADMIN 5841 S MARYLAND AVE RMW604 (MC6091) CHICAGO IL 60637 Clinical Trial/Study Agreement University of Chicago SONYA BOWEN, FINANCIAL ADMIN 5841 S MARYLAND AVE RMW604 (MC6091) CHICAGO IL 60637 Leukapheresis Collection Agreement University of Colorado Denver Clinical Trial/Study Agreement Grants and Contracts, Anschutz Medical Center 13001 E. 17th Place, PO Box 6508 Aurora CO 80045 University of Colorado Denver School of Medicine Clinical Trial/Study Agreement for N10-1 12801 East 17th Ave, Room L18-8117 Division of Medical Oncology, Mail Stop 8117 Aurora CO 80045 University of Colorado Denver, Anschutz Medical 1665 Aurora Ct. Room 3200 PO Box 6510, Mail Clinical Trial/Study Agreement for P11 Campus Stop F700 Aurora CO 80045 University of Maryland - Greenebaum Cancer Center Clinical Trial/Study Agreement for P10-3
22 S. Greene St. Baltimore MD 21201
University of Minnesota 420 Delaware St. SE, MMC 394, B-561 Department of Urology Minneapolis MN 55455 Clinical Trial/Study Agreement for N10-1 University of Minnesota 516 Delaware St SE Minneapolis MN 55455 Clinical Trial/Study Agreement for P10-3 University of North Carolina - Lineberger Clinical Trial/Study Agreement for N10-1 Comprehensive Cancer Center 170 Manning Dr. Chapel Hill NC 27599 University of Rochester BOX 270140 518 HYLAN BUILDING ROCHESTER NY 14627 Clinical Trial/Study Agreement University of Rochester Medical Center - James P. Clinical Trial/Study Agreement for P10-3 Wilmot Cancer Center 601 Elmwood Ave., Box 704 Rochester NY 14642 University of Rochester Medical Center - James P. Clinical Trial/Study Agreement for P11 Wilmot Cancer Center 601 Elmwood Ave., Box 704 Rochester NY 146420001 University of Texas Southwestern Medical Center Clinical Trial/Study Agreement ATTN.: LOCKBOX #842265 1950 N. STEMMONS FRWY., STE. 5010 DALLAS TX 75207 University of Virginia Health System, Dept. of Urology Clinical Trial/Study Agreement for P10-3 Hospital Drive, Private Clinics, Room 2570 Charlottesville VA 22908 University of Washington KELLY SALES 825 EASTLAKE AVE EAST/MSG4830 SEATTLE WA 98190 Clinical Trial/Study Agreement University of Washington KELLY SALES 825 EASTLAKE AVE EAST/MSG4830 SEATTLE WA 98190 Clinical Trial/Study Agreement University of Washington KELLY SALES 825 EASTLAKE AVE EAST/MSG4830 SEATTLE WA 98190 Clinical Trial/Study Agreement University of Washington School of Pharmacy Box 357631 Seattle WA 981957631 Clinical Trial/Study Agreement University of Western Ontario WESTERN UNIVERSITY LONDON ON N6A 5B7 CANADA Clinical Trial/Study Agreement University of Wisconsin 21 N Park Street, Suite 6401 Madison WI 537151218 Clinical Trial/Study Agreement
Up Strategies Consulting 15875 BOONES FERRY RD # 2102 LAKE OSWEGO OR 97035 Consulting Services Agreement Uro Partners/ RMD Clinical Research 675 W. North Ave #605 Melrose Park IL 60160 Clinical Trial/Study Agreement for P12-2 UroGPO, LLC 1250 Linda St, Ste 201 Rocky River OH 44116 Pricing/Rebate Agreement Urologic Consultants of SE PA 1 Presidential Blvd., Suites 100 & 115 Bala Cynwyd PA 19004 Clinical Trial/Study Agreement for P11-4 Urologic Consultants of SE PA, LLP 1 PRESIDENTIAL BLVD., SUITE 100 BALA CYNWYD PA 19004 Clinical Trial/Study Agreement Urologic Consultants of Southeastern Pennsylvania Clinical Trial/Study Agreement for P12-1
1 Presidential Blvd., Suites 100 & 115 Bala Cynwyd PA 19004
Urological Associates of Southern Arizona, P.C. 2260 W. Orange Grove Rd. Tucson AZ 85741 Clinical Trial/Study Agreement for N10-1 Urological Associates of Southern Arizona, P.C. 2260 W. Orange Grove Rd. Tucson AZ 85741 Clinical Trial/Study Agreement for P10-3 Urological Associates of Southern Arizona, P.C. 2260 W. Orange Grove Rd. Tucson AZ 85741 Clinical Trial/Study Agreement for P12-2 Urological Associates, Inc. 920 South Hebron Avenue Evansville IN 47714 Clinical Trial/Study Agreement for P10-3 Urological Research Network 2140 W 68th St., Suite 200 Hialeah FL 33016 Clinical Trial/Study Agreement for N10-1 Urological Surgeons of Illinois LTD 375 N. Wall Ste, Ste P530 Kankakee IL 60901 Clinical Trial/Study Agreement Urology Associates 2801 CHARLOTTE AVENUE NASHVILLE TN 37209 Clinical Trial/Study Agreement Urology Associates of San Luis Obispo 1310 Las Tablas Rd. Suite 201 Templeton CA 93465 Clinical Trial/Study Agreement for P12-1 Urology Associates, P.C. 2801 Charlotte Ave. Nashville TN 37209 Clinical Trial/Study Agreement for N10-1 Urology Associates, P.C. 2801 Charlotte Ave. Nashville TN 37209 Clinical Trial/Study Agreement for P11-4 Urology Associates, P.C. 2801 Charlotte Ave. Nashville TN 37209 Clinical Trial/Study Agreement for P12-2 Urology Associates, PC 2801 Charlotte Ave. Nashville TN 37209 Clinical Trial/Study Agreement for P12-1 Urology Center of Alabama, PC 3485 Indpendence Dr. Homewood AL 35209 Clinical Trial/Study Agreement for P10-2 Urology Center of Colorado 2777 MILE HIGH STADIUM CIRCLE DENVER CO 80211 Clinical Trial/Study Agreement for N10-1 Urology Center of Colorado 2777 MILE HIGH STADIUM CIRCLE DENVER CO 80211 Clinical Trial/Study Agreement for P10-3 Urology Center of Spartanburg 391 Serpentine Dr. Ste. 500 Spartanburg SC 29303 Clinical Trial/Study Agreement for P10-3 Urology Center Research Institute 300 Grand Ave, Suite #202 Englewood NJ 7631 Clinical Trial/Study Agreement for P12-1 Urology Clinics of North Texas 8230 Walnut Hill Lane Suite 700 Dallas TX 75231 Clinical Trial/Study Agreement for P12-1 Urology Clinics of North Texas, PLLC 8230 Walnut Hill Lane Suite 700 Dallas TX 75231 Clinical Trial/Study Agreement for P10-3 Urology Group of New Jersey 375 Mt Pleasant Ave West Orange NJ 7052 Clinical Trial/Study Agreement for P10-3 Urology Health Specialists 245 Bryn Mawr Ave. Bryn Mawr PA 19010 Clinical Trial/Study Agreement for P12-1 Urology Health Specialists, LLC 245 Bryn Mawr Ave. Bryn Mawr PA 19010 Clinical Trial/Study Agreement
14 of 16

LOGO

In re Dendreon Corporation Case No. 14-12515
Schedule G - Executory Contracts and Unexpired Leases
Description of Contract or Lease and Nature of Debtor’s Interest. State Whether Lease is for Nonresidential Real Property. State Creditor Name Address1 Address2 City State Zip Country Contract Number of Any Government Contract.
Urology Health Specialists, LLC 245 Bryn Mawr Ave. Bryn Mawr PA 19010 Clinical Trial/Study Agreement Urology Health Specialists, LLC 245 Bryn Mawr Ave. Bryn Mawr PA 19010 Clinical Trial/Study Agreement Urology Health Specialists, LLC 245 Bryn Mawr Ave. Bryn Mawr PA 19010 Clinical Trial/Study Agreement Urology Health Specialists, LLC 245 Bryn Mawr Ave. Bryn Mawr PA 19010 Clinical Trial/Study Agreement for P11 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for N10-1 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P07-2 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P09-1 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P10-2 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P11 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P11-3 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P11-4 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P12-1 Urology of Virginia, PLLC 225 Clearfield Ave. Virginia Beach VA 23462 Clinical Trial/Study Agreement for P12-2 Urology San Antonio Research 7909 Fredericksburg Rd., Suite 200 San Antonio TX 78229 Clinical Trial/Study Agreement for P10-2 Urology San Antonio Research 7909 Fredericksburg Rd., Suite 200 San Antonio TX 78229 Clinical Trial/Study Agreement for P10-3 Urology Specialists of Southern California 16311 Ventura Blvd., Suite 800 Encino CA 914362140 Clinical Trial/Study Agreement for P10-3 Uropartners/RMD Clinical Research 675 W. NORTH AVENUE, SUITE 605 MELROSE PARK IL 60160 Clinical Trial/Study Agreement US Oncology Research, Inc. 2899 PAYSPHERE CIRCLE CHICAGO IL 60674 Clinical Trial/Study Agreement US Oncology, Inc. 2899 PAYSPHERE CIRCLE CHICAGO IL 60674 Clinical Trial/Study Agreement Us TOO International, Inc. 5003 Fairview Avenue Downers Grove IL 605155286 Vendor Agreement USC Care Medical Group, Inc. 1441 Eastlake Avenue, STE. 5409 USC/ Norris Comprehensive Cancer Center Los Angeles CA 90033 Clinical Trial/Study Agreement USC/Norris Comprehensive Cancer Center 1441 Eastlake Ave., Room 3440 Los Angeles CA 90033 Clinical Trial/Study Agreement for N10-1 USC/Norris Comprehensive Cancer Center 1441 Eastlake Ave., Room 3440 Los Angeles CA 90033 Clinical Trial/Study Agreement for P12-2 UT Southwestern 5323 Harry Hines Blvd.m BL 9.100 Dallas TX 753909105 Clinical Trial/Study Agreement UW Oncology Research Fund Cancer Care Alliance 825 Eastlake Ave E, MS: G4830 Seattle WA 981091023
Clinical Trial/Study Agreement Validant Kinsale Holdings Inc 475 Sansome Street, Ste 700 San Francisco CA 94111 Consulting Services Agreement Vanderbilt University Medical Center 1161 21st Ave South, A1302 Medical Center Clinical Trial/Study Agreement for P10-3 North Nashville TN 37232 VC & MA Bvba De Meere 36 2460 Kasterlee Belgium Marketing Services Agreement Veals, Susan 7416 SE 24th Street Mercer Island WA 98040 Service Agreement Veritech 7525 SE 24TH STREET SUITE 360 SCOTT DAVID RAMSEY MERCER ISLAND WA 98040 Vendor Agreement Verizon Wireless PO BOX 660108 DALLAS TX 75266 Vendor Agreement Veteran’s Affairs - Durham 508 Fulton Street Durham NC 27705 Clinical Trial/Study Agreement Veterans Affairs Greater Los Angeles Healthcare Clinical Trial/Study Agreement for P12-1 System Center 10833 Le Conte Ave. Los Angeles CA 90095 Victory Marketing Group Inc. BLDG 5, SUITE 5 678 ROUTE 202/206 NORTH BRIDGEWATER NJ 08807 Commercial Marketing Agreement Vienna Hospital Association Schlossgasse 15/6a 1050 Vienna Austria Clinical Trial/Study Agreement Viewpoint and Associates PO BOX 395 ROCKVILLE CENTRE NY 11571 Service Agreement Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for N10-1 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P07-2 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P09-1 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P10-1 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P10-2 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P10-3 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P11 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P11-3 Virginia Mason Medical Center 1100 9th Ave., Mail Stop C7-URO Seattle WA 98101 Clinical Trial/Study Agreement for P12-2 Virginia Urology 9105 Stony Point Drive Richmond VA 23235 Clinical Trial/Study Agreement for P12-1 Viscira, LLC a California limited liability company 200 VALLEJO STREET SAN FRANCISCO CA 94111 Master Services Agreement Vogel Farina LLC Attn: Diane Newlin 114 Fifth Ave New York NY 10011 Master Services Agreement Vox Medica 2, LLC PO BOX 716, MIDTOWN STATION C/O MERCHANT FINANCIAL CORPORATION NEW YORK NY 10018 Service Agreement VWR International, LLC P.O. BOX 640169 PITTSBURGH PA 15264 Supply Agreement W. Thomas Amick Redacted Employment Agreement Waldron 1100 OLIVE WAY, SUITE 1800 SEATTLE WA 98101 Consulting Services Agreement Walter Reed National Military Medical Center 8901 Wisconsin Ave, Bldg 19, 3rd Floor Bethesda MD 20889 Clinical Trial/Study Agreement for P10-3 Walz, Earl Lawrence MD The Urology Group 2000 Joseph E Sanker Blvd Cincinnati OH 45212 Consulting Services Agreement Watson Clinic 1730 Lakeland Hills Boulevard Lakeland FL 33805 Clinical Trial/Study Agreement for P10-3 WebMD LLC 12186 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 Marketing Services Agreement Weill Cornell Medical College 1305 York Ave., 7th Floor New York NY 10065 Clinical Trial/Study Agreement for N10-1
15 of 16

LOGO

B6H (Official Form 6H) (12/07)
In re Dendreon Corporation Case No. 14-12515 (LSS)
, Debtor
SCHEDULE H—CODEBTORS
Provide the information requested concerning any person or entity, other than a spouse in a joint case, that is also liable on any debts listed by debtor in the schedules of creditors. Include all guarantors and co-signers. If the debtor resides or resided in a community property state, commonwealth, or territory (including Alaska, Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Puerto Rico, Texas, Washington, or Wisconsin) within the eight year period immediately preceding the commencement of the case, identify the name of the debtor’s spouse and of any former spouse who resides or resided with the debtor in the community property state, commonwealth, or territory. Include all names used by the nondebtor spouse during the eight years immediately preceding the commencement of this case. If a minor child is a codebtor or a creditor, state the child’s initials and the name and address of the child’s parent or guardian, such as “A.B., a minor child, by John Doe, guardian.” Do not disclose the child’s name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).
Check this box if debtor has no codebtors.
NAME AND ADDRESS OF CODEBTOR NAME AND ADDRESS OF CREDITOR
0 continuation sheets attached to Schedule of Codebtors

LOGO

B6 Declaration (Official Form 6—Declaration). (12/07)
United States Bankruptcy Court
District of Delaware
In re Dendreon Corporation Case No. 14-12515 (LSS)
Debtor(s) Chapter 11
DECLARATION CONCERNING DEBTOR’S SCHEDULES
DECLARATION UNDER PENALTY OF PERJURY ON BEHALF OF CORPORATION OR PARTNERSHIP
I, the Interim Chief Financial Officer of the corporation named as debtor in this case, declare under penalty of perjury that I have read the foregoing summary and schedules, consisting of 81 sheets, and that they are true and correct to the best of my knowledge, information, and belief.
Date January 9, 2015 Signature /s/ Gregory R. Cox
Gregory R. Cox
Interim Chief Financial Officer
Penalty for making a false statement or concealing property: Fine of up to $500,000 or imprisonment for up to 5 years or both.
18 U.S.C. §§ 152 and 3571.

UNITED STATES BANKRUPTCY COURT

DISTRICT OF DELAWARE


	:
In re	:	Chapter 11
	:
DENDREON CORPORATION, et al.,	:	Case No. 14-12515 (LSS)
	:
Debtors.¹	:
	:	Jointly Administered
	:

SCHEDULE OF ASSETS AND LIABILITIES FOR

DENDREON HOLDINGS, LLC (CASE NO. 14-12516 (LSS))

REFER TO SCHEDULE OF ASSETS AND LIABILITIES FOR

DENDREON CORPORATION (CASE NO. 14-12515 (LSS))

UNITED STATES BANKRUPTCY COURT

DISTRICT OF DELAWARE


	:
In re	:	Chapter 11
	:
DENDREON CORPORATION, et al.,	:	Case No. 14-12515 (LSS)
	:
Debtors.¹	:
	:	Jointly Administered
	:

SCHEDULE OF ASSETS AND LIABILITIES FOR

DENDREON DISTRIBUTION, LLC (CASE NO. 14-12517 (LSS))

REFER TO SCHEDULE OF ASSETS AND LIABILITIES FOR

DENDREON CORPORATION (CASE NO. 14-12515 (LSS))

UNITED STATES BANKRUPTCY COURT

DISTRICT OF DELAWARE


	:
In re	:	Chapter 11
	:
DENDREON CORPORATION, et al.,	:	Case No. 14-12515 (LSS)
	:
Debtors.¹	:
	:	Jointly Administered
	:

SCHEDULE OF ASSETS AND LIABILITIES FOR

DENDREON MANUFACTURING, LLC (CASE NO. 14-12518 (LSS))

REFER TO SCHEDULE OF ASSETS AND LIABILITIES FOR

DENDREON CORPORATION (CASE NO. 14-12515 (LSS))

UNITED STATES BANKRUPTCY COURT

DISTRICT OF DELAWARE


	:
In re	:	Chapter 11
	:
DENDREON CORPORATION, et al.,	:	Case No. 14-12515 (LSS)
	:
Debtors.¹	:
	:	Jointly Administered
	:

STATEMENT OF FINANCIAL AFFAIRS FOR

DENDREON CORPORATION (CASE NO. 14-12515 (LSS))

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE


	x
	:
In re:	:	Chapter 11
	:
DENDREON CORPORATION, et al.,	:	Case No. 14-12515 (LSS)
	:
Debtors.¹	:	Jointly Administered
	:
	:
	x

GLOBAL NOTES, METHODOLOGY AND SPECIFIC

DISCLOSURES REGARDING THE DEBTORS’ SCHEDULES OF

ASSETS AND LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS

Introduction

The Schedules and Statements do not purport to represent financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), nor

Global Notes and Overview of Methodology

elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this or the preceding paragraph.

On November 19, 2014, the United States Trustee for the District of Delaware appointed a statutory committee of unsecured creditors pursuant to Bankruptcy Code section 1102(a)(1). (Docket No. 92).

4. Confidentiality. Due to concerns of confidentiality or concerns for the privacy of an individual, the Debtors have deemed it appropriate and necessary to avoid listing certain names,

addresses and amounts in the Schedules and Statements. Accordingly, there are instances within the Schedules and Statements where names, addresses or amounts have been redacted.

5. Recharacterization. Notwithstanding the Debtors’ reasonable efforts to properly characterize, classify, categorize and designate certain claims, assets, executory contracts, unexpired leases and other items reported in the Schedules and Statements, the Debtors may nevertheless seek to recharacterize, reclassify, recategorize, redesignate, add or delete items. Accordingly, the Debtors reserve all of their rights to recharacterize, reclassify, recategorize, redesignate, add or delete items reported in the Schedules and Statements at a later time as is necessary or appropriate as additional information becomes available, including, without limitation, whether contracts or leases listed in the Schedules and Statements were deemed executory or unexpired as of the Petition Date and remain executory and unexpired postpetition.

6. Liabilities. The Debtors have sought to allocate liabilities between the prepetition and postpetition periods based on the information and research conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available and further research is conducted, the allocation of liabilities between the prepetition and postpetition periods may change. Accordingly, the Debtors reserve all of their rights to amend, supplement or otherwise modify the Schedules and Statements as is necessary or appropriate.

8. Insiders. Solely for purposes of the Schedules and Statements, the Debtors define “insiders” to include the following: (a) members of the board of directors; (b) employees who hold a position on the Executive Committee; (c) shareholders holding in excess of 5% of the voting shares of the Debtors (whether directly or indirectly); (d) relatives of (a) – (c) (to the extent known by the Debtors); and (e) non-Debtor affiliates.

11. Claims Description. Schedules E and F permit the Debtors to designate a claim as “disputed,” “contingent” and/or “unliquidated.” Any failure to designate a claim on a given Schedule as “disputed,” “contingent” or “unliquidated” does not constitute an admission by the Debtors that such amount is not “disputed,” “contingent” or “unliquidated,” or that such claim is not subject to objection. The Debtors reserve all of their rights to dispute, or assert offsets or defenses to, any claim reflected on their Schedules on any grounds, including, but not limited to amount, liability, validity, priority or classification. Additionally, the Debtors expressly reserve all of their rights to subsequently designate such claims as “disputed,” “contingent” or “unliquidated.” Moreover, listing a claim does not constitute an admission of liability by the Debtors.

12. Causes of Action. Despite their reasonable efforts to identify all known assets, the Debtors may not have identified and/or listed as assets in the Schedules and Statements all of their causes of action or potential causes of action against third-parties (and in particular have not identified or listed causes of action arising under the provisions of chapter 5 of the Bankruptcy Code and any other relevant non-bankruptcy laws to recover assets or avoid transfers). The Debtors reserve all of their rights with respect to any cause of action (including avoidance actions), controversy, right of setoff, cross-claim, counterclaim or recoupment; any claim on a contract or for breach of duty imposed by law or in equity; and any demand, right, action, lien, indemnity, guaranty, suit, obligation, liability, damage, judgment, account, defense, power, privilege, license or franchise, in each case of any kind or character whatsoever, known or unknown, fixed or contingent, matured or unmatured, suspected or unsuspected, liquidated or unliquidated, disputed or undisputed, secured or unsecured, assertable directly or derivatively, whether arising before, on, or after the Petition Date, in contract or in tort, in law or in equity, or pursuant to any other theory of law (collectively, “Causes of Action”) they may have, and neither the Global Notes nor the Schedules and Statements shall be deemed a waiver of any claims or Causes of Action or in any way prejudice or impair the assertion of such claims or Causes of Action.

13. Summary of Significant Reporting Policies. The following is a summary of significant reporting policies:

Currency. Unless otherwise indicated, all amounts are reflected in U.S. dollars.

Undetermined Amounts. The description of an amount as “unknown,” “TBD” or “undetermined” is not intended to reflect upon the materiality of such amount.

Liens. Property and equipment listed in the Schedules and Statements are presented without consideration of any liens that may attach (or have attached) to such property and equipment.

16. Totals. The asset totals listed on Schedule B represent all known amounts included in the Debtors’ books and records as of October 31, 2014. The liability totals listed on Schedule F, however, reflect postpetition payments on prepetition claims made pursuant to First-Day Orders, as noted above. To the extent there are unknown or undetermined amounts, the actual total may be different than the listed total. Also as noted above, certain liabilities reflected in the books and records in accordance with GAAP, but which would not represent a claim against the Debtors, are not reflected on Schedule F.